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Abstract 
Phenotyping of human muscle based on its profile of myosin heavy chain isoforms is 
commonly used to help understand changes in muscle function. However, in many 
instances, measureable changes in force output or contractility occur in the absence 
of any change in myosin heavy chain profile. Therefore, more sophisticated analysis 
is required. Proteomic techniques including 2-dimensional gel electrophoresis, high-
performance liquid chromatography and peptide mass spectrometry can be used to 
investigate changes in the abundance of hundreds of proteins simultaneously. To 
date, such techniques have not been used to specifically characterise the human 
myofibrillar proteome, or study how the myofibrillar proteome relates to muscle 
outputs such as peak isometric force or the velocity of contraction. This thesis 
presents a series of studies that develop proteomic techniques for the analysis of 
myofibrillar proteins as well as optimisation of techniques for measuring the range of 
muscle output from isometric through to velocity maximum of the human knee 
extensor muscles in vivo. After optimisation, the proteomic and muscle function 
measurement were employed to study diurnal variation. Time-of-day differences in 
sports performance and muscle function are widely reported, and typically, 
performance is ~10 % greater in the evening compared to the morning. This is 
consistent with our result in Chapter 3; we investigated this chapter by conducting a 
battery of muscle performance tests in a population of well-familiarised participants. 
Our data show that RFD exhibits the greatest diurnal variation (18 %) followed by 
isometric force (10.2 %). The diurnal variation in IKD data was less robust (range 
8.1 - 9.8 %), which may have been due to the lesser precision of this technique 
compared to MVC and RFD. Therefore MVC and RFD were used in the final study. 
In final study, this thesis reports significantly (P<0.05) greater peak isometric force 
(11 %) and rate of force development (16 %) of knee extensor muscles of young 
strength-trained males in the evening compared to morning. Proteomic analysis of 
biopsy samples of the vastus lateralis profiled more than 100 myofibrillar protein 
species and detected 8 significant differences in protein abundance between morning 
and evening samples. The greatest difference was in the abundance of the slow 
isoform of myosin binding protein C (MyBPC1), which is known to modulate the 
activity of actin-bound myosin ATPases. MyBPC1 was resolved to 6 species; 
therefore the difference in abundance of one species reported here likely represents a 
change in post-translational modification. Therefore, this thesis provides 
associational evidence that post-translational modification of MyBPC1 contributes to 
the diurnal variation in muscle function. 
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INTRODUCTION TO THESIS 
This thesis aims to combine new techniques in muscle proteomics with optimised 
measures of human muscle force production in vivo and use diurnal variation as a 
model. In doing so, we hope to bring new understanding regarding the role of muscle 
proteins in underpinning muscle force production.  
 
Proteomics is the study of proteins using high-throughput techniques and relies on a 
combination of genomics, mass spectrometry and protein biochemistry. The human 
genome contains of approximately 20,000 genes that are transcribed into mRNA and 
then can be translated in to proteins. Researchers can test hypotheses regarding 
individual mRNA or proteins using techniques such as Northern blots (for mRNA 
expression) or Western blots (for protein abundance) (Wackerhage, 2014). This 
‘reductionist’ approach, where biology is reduced to individual questions, has been 
the mainstay of biological research. However, data arising from hypothesis-led 
studies clearly indicates that biology is not organised or controlled by isolated events. 
Rather, biological systems are organised as complex networks and multiple 
interactions occur to bring about physiological changes. Therefore, more 
comprehensive (e.g. ‘-omic’) analysis techniques are required in order to advance 
our understanding of biological systems.  
 
The proteome is cell-specific and dynamic, responding on a minute-by-minute basis 
to changes in cell environment. Consequently, the proteome reflects the particular 
stage of development and current environmental condition the cell finds itself 
3 
 
experiencing. With regard exercise proteomics, Burniston and Hoffman, (2011) 
report proteomic studies have mostly focused on striated muscle responses to 
endurance training, which are associated with health benefits underpinned by 
improvements in aerobic capacity. However, few studies have specifically used 
proteomic techniques to investigate the human myofibrillar sub-proteome, which 
will be the main focus of the work conducted in this thesis. Although limited in 
number of proteins, the myofibrillar sub-proteome is complex because each 
myofibrillar protein can be expressed as different isoforms and splice-variants, and 
many also undergo post-translational modifications, such as phosphorylation. 
Therefore, this thesis investigates different proteomic approaches for capturing this 
complex information so that it can be correlated with changes in muscle function. 
 
Traditionally, the functional characteristics of a muscle have been related to the size 
and composition of its myofibres. Human muscle consists of 3 principal fibre types, 
type I, type IIa and type IIx and studies on the contractile properties of single human 
muscle fibres in vitro demonstrate each fibre type exhibits a different force-velocity 
profile (Larsson et al., 1997). While the peak isometric force produced by each fibre 
type is relatively similar, the maximal velocity of shortening differs markedly; the 
maximum velocity of shortening of IIa fibres is ~4-times greater than slow type I 
fibres, and the maximal velocity of shortening of IIx fibres is approximately double 
that of fibres that express myosin heavy chain IIa. Therefore, differences in the 
relative proportions of each fibre type can alter the gross force-velocity profile of the 
muscle. This has direct consequences on power output and athletic performance, but 
many fibres are hybrids of two fibre types and so attempts to explain changes in 
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muscle function based on changes to the proportion of type I, type IIa and type IIx 
fibres becomes difficult.  
 
Muscle fibres are designated as begin type I, IIa or IIx based on their whether the 
express myosin heavy chain (MyHC) isoform I (protein code MYH7), MyHC IIa 
(protein code MYH2) or MyHC IIx (protein code MYH1). Each myofibre nucleus 
(i.e. myonucleus) contains the entire genetic information for Type I, IIa and IIx as 
well as all other related proteins, but the myofibrillar genes are selectively expressed 
based on the activity pattern of muscle use. Typically muscle of untrained 
individuals exhibits relative proportions of 40 % type I, 45 % type IIa and 15 % type 
IIx (e.g. Holloway et al., 2009). Resistance exercise training is associated with 
hypertrophy of each myofibre type and, in addition, results in a shift toward greater 
number of IIa fibres such that the contribution of type IIa fibres to gross muscle 
performance becomes greater (Widrick et al., 2002). In contrast, endurance training 
is associated with selective hypertrophy of type I fibres (Gollnick et al., 1973).  
 
Phenotyping of muscle based on its relative expression of MyHC isoforms has 
provided important insights regarding muscle function and plasticity, but such 
characterisation is relatively simplistic. Skeletal muscle peak force is proportional to 
physiological cross sectional area (CSA) and myosin heavy chain isoform (Pearson 
et al., 2006), but muscle power output is a complex variable that may be influenced 
by numerous qualitative changes in other myofibrillar proteins. It is important to 
appreciate the diverse heterogeneity of human muscle fibres, which comprise 
different myosin heavy chains, as well as many other ancillary proteins (Schiaffino 
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& Reggiani, 1996). Indeed, studies (Cristea et al., 2008; McGuigan et al., 2003) 
report significant changes in muscle function induced by squat jumping (Malisoux et 
al., 2006) and sprint training (Holloway et al., 2009) in the absence of changes in 
MyHC content. Changes in isoform expression, splice variation or post-translational 
modification (PTM) of MyHC and other myofibrillar proteins, such as troponins and 
myosin light chains (MyLC), can alter contractile characteristics in the absence of 
changes in MyHC. Therefore, it is important to investigate the entire myofibrillar 
sub-proteome in order to gain further understanding of the proteins that dictate 
muscle function. 
 
Recent technological developments including robust two-dimensional gel 
electrophoresis (2DGE), high-performance liquid chromatography (HPLC) and mass 
spectrometry (MS) enable comprehensive investigations and inductive ‘discovery 
science’ approaches at the protein level and have recently been applied to questions 
of muscle adaptation. This thesis begins by investigating the type of proteomic 
technique that is best suited to analysis of myofibrillar proteins. Specifically our aim 
was to advance the study of changes in myofibrillar proteins beyond MyHC in order 
to more accurately understand the mechanisms that underpin the force-velocity (f-v) 
characteristics of human muscle. After investigating different proteomic techniques 
our next aim was to establish techniques for robust measurement of human muscle 
performance in vivo. Finally, we attempted to bring these two areas of research (i.e. 
muscle proteomics and muscle function) together to investigate proteins that 
correlate with diurnal changes in muscle force production.  
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The power output of human muscle and human sports performance exhibit diurnal 
variation (Drust et al., 2005; Reilly and Waterhouse, 2009). Diurnal variation in 
muscle force and sports performance in young healthy individuals is widely reported 
but the mechanism underpinning this phenomenon are not yet understood. Muscle 
force production is least between the hours of 06.00 – 08.00 in the morning and 
greatest from 16.00 – 18.00 in the afternoon. Table 1 summaries research studies that 
have investigated the effects of diurnal variation on muscle performance (see Table 
1). Regardless of the dependant variable measured (e.g. maximum isometric force, 
peak torque etc.) muscle performance is consistently better during the evening as 
opposed to the morning. The magnitude of the change in muscle output from 
morning to evening is reported to range between 5-20%. The underlying cause of 
this variation has been attributed to variations in metabolism, circulating levels of 
hormones, and differences in core or local muscle temperature, all of which have 
shown patterns of circadian rhythms and may therefore affect performance (Araujo 
et al., 2011; Racinais & Oksa, 2010). 
Table 1. Studies reporting diurnal variation in muscle output 
Test Author Difference (%) 
MVC   
 Martin et.al (1999) 8.9% 
 Racinais et al. (2005) 9.2% 
 Reilly (2007). 9.0% 
 Edwards et al. (2013) 12.6% 
IKD   
60 Reilly (2007). 6.2% 
90  4.6% 
180  8.2% 
60 Edwards et al. (2013) 9.6% 
240  10.6% 
Anaerobic   
Broad jump Reilly (2007). 3.4% 
Stair run  2.1% 
Flight time  2.4% 
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Fluctuations in force production co-occur alongside biological rhythms in core 
temperature but we have found diurnal variation in muscle performance is not 
entirely explained by differences in muscle temperature. For example, passive 
heating in the morning to stimulate the warmer afternoon muscle temperature did not 
bring about similar elevation in muscle performance. Similarly, passive cooling in 
the afternoon to replicate the cooler muscle temperature of the morning was not 
associated with the decrease in performance. Thus intrinsic differences occur in the 
ability of skeletal muscle to produce force during the course of the day. The 
parameters of muscle performance (i.e. maximum force and maximum speed) are 
determined by collections of contractile proteins. Differences in genetic background, 
habitual activity or training status affect the relative amounts of each muscle protein 
and are one of the main reasons for the broadly different physique and physical 
performance of sprinters compared to marathon runners. The same contractile 
proteins can also be rapidly modified to cope with short-term changes in demand. 
This latter mechanism contributes to the positive effect of warming up prior to 
strenuous exercise, and similar mechanisms could able responsible for the greater 
output of skeletal muscle in the afternoon compared to the morning. Therefore 
further investigation involving proteomic analysis of muscle biopsies needs to be 
done. 
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Aim and objectives of the thesis 
The overall aim of this thesis was to combine proteomic analysis of muscle biopsy 
samples with measurements of muscle performance in humans. Because the 
proteome is what defines a cell (or tissue) and dictates its functional properties we 
reasoned that changes in muscle function must be underpinned by changes in the 
muscle proteome. More specifically, changes in muscle force production will be 
underpinned by changes to the myofibrillar proteins and we used diurnal variation as 
a model. To achieve our overall aim we conducted a series of experiments to 
establish and optimise techniques for proteomic analysis of muscle biopsy samples 
and techniques for the analysis of human muscle function in vivo. The purpose of 
this chapter is to summarise the findings from each of the foregoing experimental 
chapters and detail how the main aims of this thesis were met. A secondary purpose 
of this chapter is to provide recommendations for further research based upon this 
body of work. 
 
 The specific aims of this thesis were:  
1. To establish new proteomic techniques for the analysis of the myofibrillar 
sub-proteome of human muscle  
2. i) To investigate whether measurements of isolated knee extension can be 
used to predict performance during more complex sport-related movements (i.e. 
vertical jump performance) 
ii) To investigate the reliability of isolated knee extension measurements 
encompassing the entire range of the human force-velocity relationship in vivo 
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4. To determine which method of measurement or which feature of knee 
extensor performance exhibits the greatest diurnal variation   
5. To discover diurnal differences in the myofibrillar sub-proteome of human 
vastus lateralis and investigate whether these correlate with differences in muscle 
function. 
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Chapter 1 
Analysis of Animal and Human Skeletal Muscle Using Traditional 
and Proteomic Analysis 
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1.1 INTRODUCTION 
Chapter background 
Skeletal muscle 
Skeletal muscle represents ~40 % of body weight in healthy adults and is important 
in metabolism, thermogenesis and locomotion. The ability of muscle to produce 
force underpins all sporting performance. Individual skeletal muscle fibres have two 
main protein structures that make up the myofilament and incorporate actin (thin 
filament) and myosin (thick filament). These proteins are assembled in a specific 
manner to form the basic repeating functional unit of a myofibril – the sarcomere. 
The sarcomere consists of thick myosin filaments that are anchored to a protein sheet 
(the M-band) and overlap with the thin actin filaments. This arrangement gives the 
skeletal muscle its characteristic striated appearance. The sarcomeres (Figure 1) are 
arranged in sequence along the myofibrils, and it is the interaction between actin and 
myosin within each sarcomere that enables a muscle to contract.  
 
Figure 1. Figure of sarcomere component. 
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The myosin molecule is made up of 6 polypeptides – 2 heavy chains and 4 light 
chains. The myosin heavy chain contains a myosin head that binds to the actin 
molecule and forms the basis for muscle contraction. The myosin head region serves 
as the binding site for adenosine triphospate (ATP) and contains the enzyme 
adenosine triphosphatase (ATPase), which enables the hydrolysis of ATP into 
adenosine diphosphate (ADP) and inorganic phosphate (Pi), thus providing the 
energy for muscle contraction (Scott et al. 2001). The thin actin filament consists of 
2 regulatory proteins – troponin and tropomyosin. Under resting conditions, 
tropomyosin binds to the active sites on actin, and prevents actin and myosin from 
binding together.  
 
The stimulus for muscle contraction is an action potential, which is conducted along 
the sarcolemma. Depolarisation of the fibre leads to the release of calcium from the 
sarcoplasmic reticulum and the activation of the cross bridge cycle that results is 
muscle contraction and force generation. Cross-bridge cycling continues as long as 
calcium and ATP are available, although the speed at which this occurs is mainly 
determined by the rate at which the myosin head ATPase can hydrolyse ATP.  
 
Skeletal muscle comprises a heterogeneous mixture of myofibres, in human muscle 3 
fibre subtypes are recognized based on their contractile and metabolic properties 
(Schiaffino, 2010). Fast-twitch fatigable fibres rely predominantly on glycolytic 
metabolism and are designated FG (fast glycolytic), whereas, fast-twitch fatigue-
resistant and slow-twitch fibres have relatively greater mitochondrial content and are 
designated FOG (fast oxidative glycolytic) and SO (slow oxidative), respectively. 
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The fibretype-specific differences in contractile function are due to differential 
expression of a diverse range of isoforms of each myofibrillar protein (Schiaffino & 
Reggiani, 1996). Myosin heavy chain (MyHC) isoforms are intimately associated 
with myofibre contractile and energetic properties and are commonly used molecular 
markers: FG fibres express MyHC IIx/d, FOG fibres express MyHC IIa and SO 
fibres express MyHC I, which is also the predominant isoform in adult human 
myocardium. Phenotyping of muscle based on its profile of FG, FOG and SO fibres 
or relative expression of MyHC isoforms has provided important insights regarding 
muscle function and plasticity, but such characterization is relatively simplistic. For 
example, changes in isoform expression splice variation or post-translational 
modification of other myofibrillar proteins, such as troponins and myosin light 
chains, can alter contractile characteristics in the absence of changes in MyHC. 
Moreover, each myofibre type is metabolically heterogeneous and can exhibit a 
broad spectrum of different metabolic enzyme concentrations that determine 
substrate utilisation and resistance to fatigue (Pette 1985). Proteomics affords the 
capability to analyse large numbers of contractile and metabolic proteins 
simultaneously and, therefore, could be used to develop a more sophisticated 
understanding of muscle diversity and plasticity. 
 
Proteomics 
The terms ‘proteomic’ and ‘proteome’ were coined by Mark Wilkin at the Siena 
Conference in 1994 (Wasinger, 1995). These ‘-omic’ terms symbolize a redefinition 
of how we think about biology and the workings of living systems. The proteome is 
the cell-specific protein complement of the genome, and the proteins expressed 
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within a cell are what define that cell and dictate its functional characteristics. 
Anderson & Anderson (2002) stated that a proteome contains a wide diversity of 
unique proteins ranging in physical and chemical properties and are present over a 
large dynamic range in abundance. In muscle, the top 10 myofibrillar proteins (e.g 
myosin, actin, troponin, tropomyosin etc.) account for ~50 % of the total protein 
content (Geiger et al., 2013). An important characteristic of the muscle proteome is 
that each myofibrillar protein can be expressed as different isoforms and splice-
variants. The high abundance of these proteins means that subtle changes in isoform 
expression have overt effects on muscle function. However, presently the majority of 
our knowledge relates to the effects of different myosin heavy chain (MyHC) 
isoforms only. Sub-proteome analysis of myofibrillar proteins could greatly advance 
muscle phenotyping by enabling measurement of changes in isoform expression, 
splice variation or post-translational modification of myofibrillar proteins, and 
correlate these to changes in muscle function. For example, in adult skeletal muscle, 
troponin T is expressed as fast and slow isoforms and each isoform can undergo 
numerous splice variations and post-translational modifications. Proteomic 
techniques can study each of these different troponin T species (Holloway et al., 
2009), whereas immunological techniques differentiate fast and slow isoforms only 
(e.g. Malisoux et al., 2006).  
 
Proteomics studies include the characterization of the proteome in terms of protein 
structure, function and expression level under particular biological conditions 
(James, 1997). Recent technological developments including robust of two-
dimensional (2-D) gel electrophoresis, high-performance liquid chromatography 
(HPLC) and mass spectrometry (MS) enable comprehensive investigations and 
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inductive ‘discovery science’ approaches at the protein level. Proteomics can provide 
useful information about the mechanism of human diseases and developing 
improved methods for disease diagnosis and treatment. Central to this ability is the 
‘open’ or non-targeted nature of proteomic experiments. The areas of study are fairly 
diverse in scope, for example, considering protein structure, function, protein-protein 
interactions, in addition to the role of proteins in metabolic or signal pathways and 
their contribution to biological processes (Marcotte et al., 1999; Schwikowski et al., 
2000). Furthermore, biomarker discovery can be achieved by using expression 
proteomics (differential profiling) to identify change in protein abundance that 
correlates with the physiological state of the organism as tissue.  
 
The proteome presents a difficult analytical challenge because not all proteins are 
amenable to separation or analysis using a single technique (e.g. hydrophobic vs 
hydrophilic proteins). Santoni et al., (2000) report hydrophobic proteins are critical 
components of cellular membranes, and are more difficult to manipulate in solution 
due to their poor solubility in water. To date, attempts to study changes in the 
skeletal myofibrillar proteome beyond MyHC (e.g. Malisoux et al., 2006) have been 
largely unsuccessful due to the complexity of different protein species and 
limitations of immunological techniques, i.e. their in ability to distinguish between 
isoforms or variants. Therefore, it is necessary to establish the most suitable 
techniques for analysis of the myofibrillar sub-proteome.  
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Proteomic techniques 
Considering the complexity of the proteome, improving the methods of analysis is an 
important objective. The methodologies employed in proteomics vary depending on 
the objectives of the experiment. Proteome mining experiments aim to catalogue all 
detectable proteins within a sample. This is important work because unlike of levels 
of analysis such as genomics or transcriptomics, the entire complement of protein 
species within a sample is not known and cannot be predicted. Expression 
proteomics, or differential protein profiling, entails the determination of relative 
protein abundance in a comparative scheme for example comparing the proteome of 
a tissue under two physiological conditions. Regardless of the overall objective (i.e. 
mining or profiling) proteomic analysis schemes incorporate at least two stages: (i) 
protein separation and (ii) protein identification by mass spectrometry. 
 
Protein separation 
The analysis scheme used to study the proteome is referred to as the proteomics 
workflow. Several workflows have been devised for conducting differential 
expression analysis or proteomic profiling. Usually the workflow uses a ‘Top-down’ 
gel-based approach or bottom-up solution-based approach. The gel-based approach 
involves multidimensional separation of proteins through two-dimensional (2D) 
polyacrylamide gel electrophoresis (PAGE), which is often abbreviated to 2D gel 
electrophoresis (2DGE). Bottom-up, in-solution analysis, typically uses high-
performance liquid chromatography (HPLC) of tryptic peptide digests of the protein 
samples.   
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The majority of previous studies have used 2DGE as it affords high-resolution 
separation of proteins (Ofarrell, 1975; Gorg et al., 2000). Frequently sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is used as stand-alone 
method of protein separation as known as 1D-PAGE (de Godoy et al., 2008) but the 
2D-PAGE technique combines isoelectric focusing (IEF), as a first dimension 
separation, and SDS-PAGE as a second dimension. The IEF first dimension involves 
the extraction and solubilisation of proteins using a buffer containing a variety of 
protease inhibitors non-ionic detergent and solubilizing agents (Ofarrell, 1975; Gorg 
et al., 2000). Proteins are then loaded onto a polyacrylamide or agrose gel strip, 
containing an immobilized pH gradient (IPG) (Bjellqvist et al., 1982; Gorg et al., 
1988). After the sample has been absorbed on to the strip, an electric field is applied 
across the gel strip causing proteins to migrate in a direction based on their charge 
until they reach their isoelectric point (pI) on the pH gradient. Prior to the SDS-
PAGE second dimension, proteins are denatured using the anionic surfactant sodium 
dodecyl sulfate (SDS). In 2D-PAGE, the focused IPG strip is first equilibrated with 
an SDS solution, using dithiothreitol (DTT) and iodoacetamide (IAA), respectively, 
which cleave disulfide bonds and prevent disulfide bond reformation. This improves 
digestion of cysteine-containing proteins and detection of cysteine-containing 
peptides. Then the strip is placed onto an SDS gel slab. An electric field is applied 
with the positive electrode at the bottom and the negative at the top and SDS bound-
proteins (i.e. negatively charged) migrate through the gel dependent upon their 
relative molecular mass. The larger proteins travelling a much smaller distance than 
the smaller proteins. After that, the gels are digitised scanned and saved in grayscale 
tiff format to capture both the area and density of each spot. Digitised scanned 
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images of stained gels are then measured for the concentration of each band or spot 
by densitometry and can be used to interpret relative protein abundance.  
 
Importantly, at this stage differences in abundance of proteins between the study 
groups is known but the identity of these proteins is not known. This is fundamental 
to the non-targeted/unbiased nature of proteomics experiments and enables new 
discoveries to be made.   
 
In contrast to gel-based workflow, the other workflow employs a solution-based, 
peptide level analysis which involves the enzymatic digestion of the proteome prior 
to multidimensional liquid chromatography separations and MS peptide sequencing. 
High-Performance Liquid Chromatography (HPLC) is highly applicable as an initial 
step to fractionate protein mixtures and the advantages of HPLC is the diversity of 
separation modes available (Lieber, 2002), but typically reverse phase is used to 
separate peptides based on their hydrophobicity. Peptides can be separated by 
running a linear gradient of the organic solvent. Molecules are bound to the 
hydrophobic matrix in an aqueous buffer (polar) and eluted from the matrix using a 
gradient of organic solvent (non-polar). The matrix usually consists of spherical 
silica beads (3-5 micron) which have linear octadecane groups (C18) attached to the 
surface via co-valent bonds. These beads are usually porous in order to increase the 
surface area of the beads available for binding. There are three common stationary 
phase chain lengths, C4, C8, and C18.  C4 is generally used for intact proteins and C18 
is generally used to capture peptides or small molecules.  The idea here is that the 
larger protein molecule will likely have more hydrophobic moieties to interact with 
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the column and thus a shorter chain length is more appropriate.  Peptides are smaller 
and need the more hydrophobic longer chain lengths to be captured, so C8 and C18 
are used for peptides or small molecules.   
 
Mass Spectrometry 
Non-targeted proteomic analyses are made possible by mass spectrometry (MS) 
which is used to identify proteins against genome databases.  MS relies on separating 
charged peptide ions by their mass-to-charge ratio (m/z). It became an ideal tool for 
high-throughput analysis of large numbers of proteins from complex mixtures when 
its speed and sensitivity were capable of analysing proteins on HPLC timescale (i.e. 
peptides elute within a 1 min window). Generally a mass spectrometer can be broken 
down into three parts: an ion source, an m/z analyser and a detector.  
 
Ion Sources 
The first stage of the MS instrument is the ion source and it serves two main 
purposes. First, it brings molecules into the gas phase and secondly the molecules are 
ionized so that they can be manipulated by electric fields within the mass analyser. 
The development of the soft ionization methods for MS analyses of biological 
macromolecules were contributed by Fenn et al. (1989) with the technique of 
electrospray ionization (ESI) and the other technique of matrix-assisted laser 
desorption/ionization (MALDI) by Karas & Hillenkamp (1988), which was 
subsequently applied to whole protein analysis by Tanaka et.al (1988). Fenn's 
contributions specifically related to the development of electrospray ionization and 
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earned a share of the Nobel Prize in Chemistry in 2002. In MALDI source, the 
sample to be analysed is mixed with a chemical matrix, which contains organic 
molecules that donate protons to the sample when energised by the laser. The 
admixture of sample and matrix is then spotted onto a small plate or slide and then 
allowed to evaporate in air. The co-crystallization of small organic molecules with 
the protein sample from a solid allows ionization through the use of a laser, resulting 
in desorption and ionization of the protein or peptide. However, one of the 
disadvantages of MALDI compared to LC-ESI is it considered to be more difficult to 
couple MALDI to separation platforms such as LC, although this is possible, i.e LC-
MALDI (Burniston & Connolly, 2010; Holloway et al., 2009). LC-MALDI is 
considered as a very powerful technique but it is very time consuming because it is 
not ‘online’.   
 
Meanwhile ESI which was used in the current thesis is a relatively simple ion source 
which permits the direct coupling of liquid samples to MS. Fragmentation of peptide 
ions is favoured by positive charges on the peptide ions and the HPLC 
chromatographic characteristic of peptides are improved at acidic pH values. 
Therefore analysis is performed against a background of 0.1% formic acid (FA). The 
mechanics of ESI source are relatively simple. The sample enters the source through 
a flow stream and passes through a fine bore fused silica capillary held at high 
voltage. As the flow exits the tip of capillary, it sprays out in a fine mist of droplets 
which contain peptide ions. Peptide ions are separated from the solvent components 
and transferred to the mass analyser through a process of evaporation.  
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The Mass Analyser  
The mass analyser is the heart of a mass spectrometer and is responsible for 
resolving peptides ions. Ion separation is achieved by taking advantage of the 
differences in behaviour between ions of different mass to charge ratio (m/z) within 
an electric and/or magnetic field. The four analysers in common use on MS 
nowadays are time of flight (TOF), quadrupole, ion trap and Fourier transform ion 
cyclotron resonance (FTICR) analysers. Time-of-flight (TOF), quadrupole and ion 
trap analysers use electric fields while the latter group comprises magnetic sector and 
ion cyclotron analysers. The analysers used in the work will be discussed in detail. 
 
The instrument employed in studies presented in this thesis was the quadrupole-high 
capacity ion-trap (HCT Ultra ETD II; Bruker Daltonics, Bremen, Germany). The ion 
trap mass analyser is a popular instrument for proteomic analysis (March, 1996; 
Jonscher, 1997). It comes in two different varieties: the 3D trap / Paul traps, and the 
2D trap / quadrupole or linear ion trap (LIT). In each design, ions are retained, or 
trapped, within the mass analyser by use of alternating electric field with radio 
frequency and a direct current electric field. An ion trap consists of three electrodes: 
two capping electrodes at each end of the ion trap and a ring electrode that surrounds 
the trap chamber. The ion trap mass analyser is particularly popular for proteomic 
analysis due to its improved sensitivity over quadrupole instruments and its ability to 
perform several stages of tandem MS. That is measurement of peptide ions (i.e. MS) 
fragment ions (i.e. MS/MS) and selected ions from peptide fragments (i.e. 
MS/MS/MS; or MS
n
) 
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The Detector 
The last part is the detector, which detects the ions resolved by the mass analyser. 
The detector used in the current work was an electron multiplier (EM) design 
consisting of a series of dynodes held at a high negative potential. When the 
positively charged peptide/fragment ions hit the detector secondary particles are 
released, including electrons. The electrons are amplified through a series of dynodes 
to create a current that is equivalent to number of peptide/fragment ions that entered 
the detector. In this way, the intensity or abundance of each ion is recorded. 
 
In short, the MS converts components of a mixture to ions and then separates them 
on the basis of their mass-to-charge ratio (m/z). The data are automatically recorded 
by the instrument and can then be retrieved for manual or computer-assisted 
interpretation.   
 
A short history of muscle phenotyping 
Muscle fibres contain the entire genetic complement of the organism but only 
specific genes and isoforms are selectively expressed based on the activity pattern 
and muscle use. As early as the 1800s, Ranvier observed that the gross appearance of 
muscle fiber ranged from white to deep red, reflecting the amount of myoglobin 
content (Kernell, 2006). In the early 1970’s, studies using animal models reported 
white muscles had relatively high peak tension and contractile velocities but were 
easily fatigued, whereas red muscle exhibited slow contractile properties and a high 
resistance to fatigue (Burke et al., 1973). In 1985, Pette & Vrbova used microscopy 
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and histochemical techniques in rat and human muscle; these techniques rely on 
chemical staining using the myosin ATPase within each muscle fibre after 
selectively denaturing myosin isoform using different pH pre-incubations. They 
discovered the importance of activity in the control of gene expression of the 
mammalian muscle fibre. Much later, Kosek et al., (2006) used sophisticated co-
immunohistochemistry of MyHC isoforms to investigate the effects of resistance 
training on myofibres in the muscle of young and elderly individuals. Muscle 
phenotype can also be determined biochemically using analysis of relative 
abundances of each MyHC isoform. One dimensional denaturing sodium dodecyl 
sulphate (SDS) - PAGE is a simple and inexpensive method for resolving proteins in 
complex mixtures. The most commonly used methods are derived from the 
discontinuous SDS-PAGE system first described by Laemmli (1970). Betto et al., 
(1986) first reported the separation distinct polypeptides corresponding to type I, IIa 
and IIb MyHC isoforms using SDS-PAGE. Following these pioneering studies, 
many studies (e.g. Hori et al., 1989; Kobayashi et al., 1990) focused on describing 
MyHC isoform profile in muscular dystrophies compared to normal controls using 
this technique. Baumann et al., (1987) used the SDS-PAGE in their study on 
exercise training and report changes in protein expression of the contractile 
apparatus associated with fibre type inter conversion within the established sequence 
of types IIb > IIa > IIc > I. These and many other studies conducted during this 
period represent muscle protein biochemistry. The advance of muscle proteomics 
was made possible by the introduction of mass spectrometry protein identification, 
which enables non-targeted analysis of proteins and the generation of new 
hypotheses.   
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A short history of muscle proteomics 
In theory, proteomics techniques should be able to characterise and measure the 
relative abundance of each myofibrillar protein species (i.e. encompassing isoforms, 
splice-variants and post-translational states) simultaneously. This more 
comprehensive analysis circumvents the need to reduce the description of muscle to 
its relative proportion of 3 fibre types and we hope our work will demonstrate that 
whole muscle function can be more thoroughly understood by relating changes in 
muscle performance to the entire myofibrillar proteome. 
 
The first study to report proteomic analysis of skeletal muscle was Isfort et al., 2000 
and reported the effects of atrophy in rat slow twitch muscle. Since this initial 
publication there have been many studies in skeletal muscle – a summary of 
proteomic studies investigating muscle of laboratory animals is presented in this 
chapter (Table 2), whereas a more specific list of studies reporting proteomic 
analysis of human muscle is presented in Chapter 4 (Table 21). In particular 2DGE 
has been used to catalogue the proteins expressed in striated muscle. Early 
investigations produced 2D gel maps of mouse mixed-fibre gastrocnemius muscle 
(Sanchez et al., 2001), and compared archetypal muscles such as rat extensor 
digitorum longus (EDL) and soleus that comprise predominantly fast- or slow-twitch 
fibres, respectively (eg. Bozzo et al., 2005). Meanwhile Hojlund et al., (2003) used 
2DGE of human vastus lateralis to observe proteins with potential roles in type 2 
diabetes. Furthermore 2DGE of human samples has been used to provide more 
detailed information regarding proteome changes due to aging (Gelfi et al., 2006), 
obesity (Hittel et al, 2005) and exercise training (Holloway et al., 2009; Egan et al, 
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2011). Gelfi et al. (2003) in their study of 2D gel map of human vastus lateralis 
muscle provide a valuable resource for the definition of functional properties of 
muscle fibres. These and other proteome mining works provide important catalogues 
of accessible muscle proteins and extend earlier biochemical and histochemical 
studies describing muscle diversity.  
 
Table 2. Summary of proteomic studies on animal skeletal muscle 
Author, Year Sample Technique 
Isfort et al., 2000 Rat soleus denervation 2DGE, MALDI-TOF 
Sanchez et al., 2001 Mouse skeletal muscle 2DGE, MALDI-TOF 
Yan et al., 2001  Rat skeletal muscle 2DGE, MALDI-TOF 
Le Bihan et al., 2004 Mouse skeletal muscle  SELDI-TOF 
Donoghue et al., 
2005  
Rabbit skeletal muscle electro-
stimulation 
2DGE, MALDI-TOF 
Piec et al., 2005 Rat skeletal muscle ageing 2DGE, MALDI-TOF 
Okumura et al., 
2005  
Rat skeletal muscle SDS-PAGE, 2DGE, 
MALDI-TOF 
Gelfi et al., 2006  Rat soleus & gastrocnemius 
ageing 
2-DGE, LC-ESI-
MS/MS. 
Guelfi et al., 2006 Rat skeletal muscle acute 
exercise 
2DGE, LC-ESI-MS/MS 
O'Connell et al., 
2007  
Rat skeletal muscle ageing 2DGE, MALDI-TOF 
De Palma et al, 2007 Rat skeletal muscle hypoxia 2D DIGE, LC-ESI-
MS/MS 
Donoghue et al. 
2007 
Rabbit tibialis anterior electro-
stimulation 
2DGE, MALDI-TOF 
Burniston 2008 Rat Plantaris exercise  2DGE, MALDI-
TOF/TOF 
Doran et al., 2008 Rat skeletal muscle ageing 2D DIGE, MALDI-TOF 
O'Connell et al., 
2008  
Rat gastrocnemius ageing 2DGE, MALDI-TOF 
Moriggi et al. 2008 Rat skeletal muscle dytrophy 2D DIGE, MALDI-TOF  
Gannon et al. 2008 Rat gastrocnemius ageing 2DGE, MALDI-TOF 
Gannon et al., 2009 Rat gastrocnemius ageing 2DGE, MALDI-TOF 
Donoghue et al. 
(2010)  
Rat skeletal muscle ageing 2DGE, MALDI-TOF, 
LC-ESI-MS/MS 
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Two-dimensional gel electrophoresis (2DGE), Matrix-assisted laser desorption 
ionisation (MALDI), Surface-enhanced laser desorption ionisation (SELDI), Time of 
flight (TOF), Tandem time of flight (TOF/TOF), Liquid chromatography (LC), 
Electrospray ionisation (ESI), Mass spectrometry (MS, Tandem mass spectrometry 
(MS/MS), Difference in-gel electrophoresis (DIGE), Selective reaction monitoring 
(SRM). 
 
The use of 2DGE offers robust comparative analysis of protein species, which 
represent different post-translational states of a protein (Jungblut et al., 2008). 
However, 2DGE requires a significant level of skill is laborious and has a number of 
technical limitations, including difficulties in resolving proteins at the extremes of 
the mass and pH scales, and a limited dynamic range. Therefore, there is currently a 
drive to move away from 2DGE and develop simpler (SDS-PAGE) or more 
automated HPLC workflows. In muscle proteomics, the time efficiency of 
orthogonal SDS-PAGE and HPLC separations has been investigated (Parker et al., 
2009). The combination of SDS-PAGE with HPLC coupled directly to electrospray 
ionisation (ESI) tandem mass spectrometry (MS/MS), known as GeLC-MS/MS is of 
particular utility in skeletal muscle protein identification (Hojlund et al., 2008). 
Several studies have applied the GeLC-MS/MS technique in proteomic research, Yi 
et al., (2008) used GeLC-MS/MS and reported combination of proteomic and 
transcriptomic analyses. In 2008, Hojlund and colleagues catalogued almost 1,000 
proteins in the human skeletal muscle proteome using GeLC-MS/MS and Norheim 
Lewis & Ohlendieck 
2010 
Mouse skeletal muscle 
dystrophy 
2DGE , LC-ESI-MS/MS 
Mullen & 
Ohlendieck 2010 
Rats gastrocnemius diabetes 2DGE, LC-ESI-MS/MS  
Mullen & 
Ohlendieck 2011 
Rat gastrocnemius diabetes 2DGE, LC-ESI-MS/MS 
Macedo et al. 2012  Mouse skeletal muscle MALDI-TOF/TOF 
Malik et al., 2013  Rats soleus & Human vastus 
lateralis 
LC-ESI-MS profiling, 
LC-ESI-MS/MS, SRM 
Burniston et al., 
2014 
Rat soleus, artificial selection 2D DIGE, LC-ESI-
MS/MS 
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et al., (2011) used this method for identification of proteins secreted by skeletal 
muscle cells in vitro. 
 
Work in our laboratory has pioneered the application of proteomic techniques to 
investigate cardiac and skeletal muscle responses to endurance exercise (summarised 
in Burniston & Hoffman, 2011). Further to standard proteomic techniques using 
2DGE (e.g. Burniston, 2008), we have developed specific methods for analysing 
muscle proteins (e.g. Burniston & Hoffman, 2011; Burniston & Connolly, 2010; 
Holloway et al., 2009) using sub-fractionation and solution-based protein separations 
(i.e. 1D HPLC). The current thesis further develops this workflow by specifically 
investigating the myofibrillar sub-proteome using liquid chromatography separation 
of proteins with real-time tandem mass spectrometry. Our aim is to create a more 
robust analysis platform for measuring differences in the abundance of dozens of 
important myofibrillar proteins based on quantitative label-free mass spectrometry 
techniques. The main proteins of interest (in addition to myosin heavy chain 
{MyHC} isoforms) will be the isoform, splice variant and post-translational sub-
species of regulatory and essential myosin light chains, tropomyosins and troponins, 
which may also modulate muscle contractile characteristics.  
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Rational of this study 
Proteomics is at the heart of our understanding of the effects of exercise in skeletal 
muscle. Recent developments in the field of proteomics have led to a renewed 
interest in muscle fibre phenotyping. The percentage of different types of muscle 
fibres affects muscle performance. The myofibrillar proteome determines the muscle 
function and there are more proteins than just MyHC for example troponins, MyLC 
etc. that contribute to the contractile properties of muscle. Therefore proteomic 
techniques are needed to capture more comprehensive information.  The principal 
separation approaches used with intact proteins are 1D- and 2D-SDSPAGE, 
preparative isoelectric focusing (IEF) and HPLC (Liebler, 2002). In most of the 
current literature two-dimensional gel electrophoresis is used to resolve proteins, 
with mass-spectrometry employed to identify the protein for example, muscle 
proteins were successful analysed using 2-DE and MyHC isoforms using 1-DE 
(Holloway et al., 2009). However, 2D gel electrophoresis is laborious and presents 
challenges to resolve proteins at larger mass and pH ranges. Therefore, differential 
analysis using high-performance liquid chromatography online mass-spectrometry is 
used to overcome this resolution problem and as this approach is mostly an 
automated analysis, it should have less human error associated.  
 
Skeletal muscle may be ideal for LC-MS profiling because the abundance of 
metabolic enzymes and myofibrillar proteins is high. Most analytical proteomics 
problems begin with a protein mixture that contains varying molecular weights, 
solubility and modifications. In order to prepare sample for MS analysis, the 
complex mixtures of proteins or peptides must be separate into somewhat less 
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complex mixture and the intact proteins must be cleaved to peptides. Consequently, 
we used different type of skeletal muscle such as rat muscle and human muscle on 
various analytical techniques investigate whether LC-MS could provide a rapid 
automated method for profiling the major metabolic proteins in skeletal muscle and 
therefore lead to a step increment in level of sophistication of current muscle 
phenotyping techniques. In addition, the advanced technique of selective reaction 
monitoring (SRM) was used to verify differences in the abundance of protein 
detected by LC-MS profiling. Selective/multiple reaction monitoring (S)/MRM 
assays are an attractive option for biomarker development because they enhance the 
sensitivity, selectivity and speed of the assay (Han & Higgs, 2008) but as yet these 
approaches have not been applied to the skeletal myofibrillar proteome. 
 
In summary, the literature clearly shows that most differential proteomic 
experiments have used 2DGE for expression profiling. Secondly, proteome mining 
studies have commonly used GeLC-MS/MS. Therefore, our first task was to 
investigate whether direct LC-MS profiling would work on skeletal muscle. This 
cannot be taken for granted because muscle is made of a small number of 
myofibrillar protein isoforms, which have large amounts of sequence homology. 
Therefore, we first performed LC-MS of soluble proteins because this could provide 
profiling based on metabolic properties. Secondly, we used LC-MS profiling of 
human myofibrillar proteins, which is more challenging than the soluble protein 
fraction. And third, we used SRM/MRM assays in an attempt to overcome the 
problems due to the large amount of sequence homology the myofibrillar proteome. 
To do this, we used SRM/ MRM assays to target peptides that are isoform specific, 
similar to previous work cardiac muscle reported in Burniston & Connolly (2010). 
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Aim of this study 
In order to develop a robust and automated technique it is necessary to perform 
measurements using several methods and utilising different analytical approaches. 
To achieve the aims of this chapter we used existing rat and human muscle samples 
from experiments where it was reasonable to expect that overt difference in the 
muscle proteome exist. Specifically, we tested label-free LC-MS profiling on soleus 
muscle from rats artificially selected as either high- or low-capacity runners (HCR 
LCR, respectively) that exhibit a greater than 5-fold difference in aerobic capacity. 
Our hypothesis being that LC-MS analysis of soluble protein provides ‘metabolic 
profiling’ that explain the difference in aerobic capacity. Secondly, techniques for 
the analysis of the human myofibrillar proteome were investigated using samples 
were provided from a recent study (Cobley et al., 2012) from vastus lateralis of 
young and elderly participants that were designated as being either trained or 
untrained. 
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1.2 METHODS 
Analysis of soluble muscle proteins 
1.2.1  Animal model of high- and low-capacity runners 
The inception of high-capacity runner (HCR) low-capacity runner (LCR) strains 
from a founder population of genetically heterogeneous N:NIH rats has been 
described in detail (Koch & Britton, 2001). Ten male HCR/LCR rats (n = 5, in each 
group) from generation 25 (12-13 weeks old) were imported from the University of 
Michigan. The transfer of animals to the UK and subsequent procedures were 
conducted under the British Home Office Animals (Scientific Procedures) Act 1986 
and according to UK Home Office Guidelines. Rats were housed in a conventional 
facility and the environmental conditions controlled at 20 ± 2 ºC, 45-50 % relative 
humidity with a 12 h light (0600-1800) and dark cycle. Food and water were 
available ad libitum during a 14-day acclimatization period. After an overnight fast 
(~10 h), animals were asphyxiated with CO2 and killed by cervical dislocation. 
Skeletal muscles and other organs were isolated and cleaned of fat and connective 
tissue before being weighed and frozen in liquid nitrogen. This part of the 
experiment was performed by my supervisor, Dr Jatin Burniston. 
 
1.2.2  Muscle processing 
Soleus muscles were pulverised in liquid nitrogen then homogenised on ice in 8 
volumes of 1 % (v/v) Triton X-100, 50 mM Tris pH 7.4 containing Complete™ 
protease inhibitor (Roche Diagnostics, Lewes, UK). Samples were incubated on ice 
for 15 min then centrifuged at 1,000 xg, 4 ºC for 5 min. Supernates were precipitated 
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in acetone and resuspended in Lysis Buffer: 7 M urea, 2 M thiourea, 4 % (w/v) 
CHAPS, 30 mM Tris, containing Complete™ protease inhibitor (Roche Diagnostics, 
Lewes, UK). After clearing by centrifugation (12,000 g, 4 ºC for 45 min) protein 
concentrations were measured using the Bradford assay (Sigma, Poole, Dorset, UK) 
and each sample adjusted to 5 μg μl-1. Aliquots containing 100 μg proteins were 
precipitated in 5 volumes of acetone for 1 h at -20 ºC. Pellets were resuspended in 
0.1 % (w/v) Rapigest SF (Waters; Milford, MA) in 50 mM ammonium bicarbonate 
and incubated at 80 ºC for 15 min. Dithiothreitol (DTT) was added (final 
concentration 1 mM) and incubated at 60 ºC for 15 min followed by incubation 
whilst protected from light in the presence of 5 mM iodoacetamide (IAA) at 4 ºC. 
Sequencing grade trypsin (Promega; Madison, WI) was added at a protein ratio of 
1:50 and digestion allowed to proceed at 37 ºC overnight. Digestion was terminated 
by the addition of 2 μL concentrated trifluoroacetic acid (TFA) and peptide solutions 
were cleared by centrifugation at 13 000 g for 5 min. 
 
1.2.3  Liquid chromatography-mass spectrometry 
Label-free liquid chromatography-mass spectrometry (LC-MS) analysis was 
performed using a quadrupole-high capacity ion-trap (HCT Ultra ETD II; Bruker 
Daltonics, Bremen, Germany) coupled online via an electrospray ionisation source to 
a nano-flow HPLC system (Ultimate 3000; Dionex, Sunnyvale, CA). Tryptic digests 
(0.8 μg/ μl) were diluted 1:10 with aqueous 0.1 % FA and 5 μl loaded via a Zorbax 
300SB C18 5 μm, 5 x 300 μm pre-column (Agilent Technologies Ltd). Peptides were 
separated using a Zorbax 300SB C18 3.5 μm, 15 cm x 75 μm analytical reverse 
phase column (Agilent Technologies Ltd) at a flow rate of 300 ml min
-1
 using a non-
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linear gradient rising to 40 % acetonitrile 0.1 % FA over 160 min. Mass spectra for 
LC-MS profiling were recorded between 200 m/z and 2500 m/z using Standard 
Enhanced mode (8100 (m/z)/s). In addition, equivalent data-dependent tandem mass 
spectrometry (MS/MS) spectra were collected from triplicate analysis of a pooled 
standard comprising each HCR and LCR sample. MS/MS spectra of collision-
induced dissociation fragment ions were recorded for the 5 most abundant precursors 
from each survey scan (350 m/z to 1600 m/z). 
 
1.2.4  Progenesis LC-MS protein profiling 
Both MS and MS/MS spectra were aligned using Progenesis LC-MS software 
(Nonlinear Dynamics, Newcastle, UK). Prominent ion features (mean ± SD per 
chromatogram: 455 ± 42) were used as vectors to warp each dataset to a common 
reference chromatogram. An analysis window of 15 min - 145 min and 200 m/z - 
1800 m/z was selected, which encompassed a total of 32,824 features with charge 
states of +2, +3 or +4. Log transformed MS data were normalised by intersample 
abundance ratio and used to investigate differences in expression between LCR and 
HCR groups by one-way analysis of variance. MS/MS spectra (16, 872 queries) 
were exported in Mascot generic format and searched against the Swiss-Prot 
database (2011.6) restricted to ‘Rattus’ (7617 proteins) using a locally implemented 
Mascot (www.matrixscience.com) server (version 2.2.03). The enzyme specificity 
was trypsin allowing 1 missed cleavage, carbamidomethyl modification of cysteine 
(fixed), deamidation of asparagine and glutamine (variable), oxidation of methionine 
(variable) and an m/z error of ± 0.5 Da. The Mascot output (xml format), restricted 
to nonhomologous protein identifications was recombined with MS profile data in 
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Progenesis LC-MS. Peptide features with MOWSE scores <10 (MudPIT scoring) 
were excluded and potential conflicts in peptide assignments were resolved manually. 
Functional annotation was conducted using the Database for Annotation, 
Visualization and Integrated Discovery [DAVID; (Huang et al., 2009)]. Over-
representation of gene ontology (GO) classes: cellular component (CC), biological 
process (BP) and molecular function (MF) was investigated. Association of proteins 
with pathways of the Kyoto Encyclopedia of Genes and Genomes [KEGG; http:// 
www.genome.jp/kegg/, (Kanehisa & Goto, 2000)] was also assessed. 
 
1.2.5  Selective reaction monitoring (SRM) of heart-type fatty acid binding 
protein 
Selective reaction monitoring (SRM) was used to verify differences in the abundance 
of heart-type fatty acid binding protein (HFABP) detected by LC-MS profiling. 
HFABP exhibited the greatest fold difference between HCR and LCR muscles, and 
SRM of serum HFABP levels has previously been reported (Zhen et al., 2007) SRM 
was performed using similar instrument settings described in section 1.2.4 but 
samples were separated using a linear chromatographic gradient rising to 40 % 
acetonitrile 0.1 % FA in 15 min, rather than 160 min used during LC-MS profiling. 
Samples were analysed in duplicate and in a randomised order. A single transition 
454-551 was monitored, which represents the y5 ion (551.21 m/z) of the doubly 
charged peptide SLGVGFATR (2+ 454.19 m/z) of residues 23-31 of HFABP.  
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Figure 2. Selective reaction monitoring of FABPH. Annotated MS/MS spectra of the doubly-charged precursor, 454.19 m/z (A) of residues 23–
31 (SLGVGFATR) of FABPH and (B) monitoring of the selected fragment ion (551.21 m/z).
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Traditional biochemical analysis of muscle fibre type (Human sample) 
The profile myosin heavy chain (MyHC) isoform in muscle is an important 
determinant its contractile and metabolic properties. Research in this area typically 
uses traditional biochemical analysis of muscle fibre type by 1-dimensional sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (1DE; SDS-PAGE). SDS-
PAGE separates proteins according to their size and no other physical feature, the 
difference in mass of the 3 human MyHC isoforms is type I (223,097 Da), type IIa 
(223,044 Da) and type IIx (223,145 Da) which is relatively minor and so resolving 
the protein isoforms can be challenging. Nonetheless we used this traditional 
analysis methods as a basis from which to develop more sophisticated analytical 
techniques.  
 
1.2.6  Human samples 
In the current work samples were provided from a recent study (Cobley et al., 2012) 
that collected biopsy sample from vastus lateralis of young and elderly participants 
that were designated as being either trained or untrained (n = 24). Hence, there were 
4 groups young trained, young untrained, old trained and old untrained. Trained 
participants were competitive amateur cyclists that habitually completed at least five 
endurance sessions per week. Older trained participants were required to have 
adopted such a regimen for minimum ten years. Untrained participants did not 
partake in endurance-based training and completed < 3 exercise sessions per week. 
These individuals exhibited marked difference in age and training status which are 
expected to affect muscle phenotype. Therefore these samples provide ideal substrate 
for establishing the biochemical analysis techniques.  
37 
 
1.2.7  Muscle processing  
Muscle samples were ground using a pestle and mortar, under liquid nitrogen. The 
powder was accurately weighed (20 mg) and homogenised on ice in 10 volumes of 
lysis buffer, using a glass-teflon homogeniser. The Lysis and solubilising buffer 
consisted of 1 % (v/v) Triton X-100,  40 mM Tris, phosphatase inhibitor and 
complete protease inhibitor cocktail (Roche, Indianapolis, USA). Homogenates were 
centrifuged at 1,000 xg, 4 °C for 10 min and the supernatant was decanted and stored 
in 200 µl aliquots at -80 °C. The current thesis reports analysis of the pellet that 
contains myofibrillar protein was resuspensed in 1 % SDS buffer and boiled (95°C) 
for 5 minutes in preparation for one-dimensional gel electrophoresis. 
 
A Bradford Assay (Bradford 1976) was performed to ascertain the protein 
concentration in each sample. Bovine serum albumin (BSA) standards (from 0.2 mg 
ml
-1
 to 1.0 mg.ml
-1
 in 0.2 mg.ml
-1 
increments) were prepared from a commercial 
stock solution (1.0 mg.ml
-1
; Sigma-Aldrich, Poole, Dorset) and pipetted in triplicate 
(5 µl per well) onto microtitre plate. Muscle supernatants were diluted 1:10 to bring 
them within the standard range and pipetted (5 µg per well) in duplicate. Bradford 
reagent (Sigma) was added (250 µl per well) and the mixtures incubated at room 
temperature for 5 minutes, before reading at a wavelength of 595 nm (Tecan GmbH, 
Austria). Interpolation from the BSA standard curve was used to determine the 
protein concentration in each muscle supernatant sample. For subsequent loading 
onto the gels, samples were normalised to 5 µg or 0.5 µg/µl in Laemmili buffer 
(Laemmli, 1970) and boiled for 5 min. For experiments using a ‘pooled standard’ a 
sample was created by combining an aliquot of 10 µg protein from each individual. 
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1.2.8  1DE SDS-PAGE (8 % for MyHC) 
MyHC isoforms were separated according to molecular weight by 8 % denaturing 
SDS-PAGE as described previously (Talmadge & Roy, 1993). Mini-slab gels of 
dimensions 11 x 8.5 x 0.75 cm were prepared according to the manufacturer’s 
instruction (Mini-VE system, GE Healthcare, Sweden). Glass plates were cleaned 
with 70 % ethanol to ensure all traces of protein were removed. Cassettes were 
formed (8 x 10.5 cm) by two glass plates separated by spacers of the required 
thickness (1.0 mm) placed at the sides. The stacking gels consisted of (final 
concentration): 30 % (v/v) glycerol, 4 % (v/v) acrylamide-N,N’–methylene–bis-
acrylamide bis (50:1), 70 mM Tris (pH 6.7), 4 mM EDTA, and 0.4 % (w/v) SDS. 
The separating gels were composed of 30 % (v/v) glycerol, 8 % (v/v) acrylamide-bis 
(50:1), 0.2 M Tris (pH 8.8), 0.1 M glycine, 0.4 % (w/v) SDS polymerisation was 
initiated with 0.05 % (v/v) N, N, N’,N’ –tetramethylethylenediamine (TEMED) and 
0.1 % (v/v) ammonium persulfate (APS). A 10-well comb was inserted during 
polymerisation (RT for 1 h) of the stacking gel. Combs were removed and the wells 
washed with running buffer: 0.3 % (w/v) SDS, 3.6 % (w/v) Tris and 3.4 % (w/v) 
glycine to remove unpolymerised acrylamide. According to Bamman et al. (1999), 
the lower electrode buffer for human muscle was a dilution of 250 ml upper 
electrode buffer diluted with 1250 ml dH2O. Ten microliters of each sample equal to 
5 µg of protein were loaded equivalently into each lane and electrophoresed on ice 
through the stacking gel at 280 V for 15 hours. Following the process, the gel was 
removed from the glass plates and washed 3 times in ddH2O, with each wash taking 
~5 minutes. The ddH2O was poured off and then the gels were stained in 100 ml of 
colloidal Coomassie blue (Bio-safe, Bio-rad laboratories, Hercules, USA) for 1 hour 
before being de-stained overnight in ddH2O. 
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1.2.9  1DE SDS-PAGE (15% for low molecular weight (LMW) myofibrillar 
proteins) 
Low molecular weight (i.e 50 - 15 kDa) myofibrillar proteins were separated by 15 % 
denaturing SDS-PAGE. Mini-slab gels of dimensions 11 x 8.5 x 0.75 cm were 
prepared as described in previous section.  The stacking gels consisted of (final 
concentration): 5 % RTU bis-acrylamide solution, 1.0 M Tris-HCl (pH 6.8), and 0.4 % 
(w/v) SDS, 0.1 % bromophenol blue, ddH2O polymerisation was initiated with 
TEMED and 10 % APS. The separating gels were composed of 15% RTU Bis-
acrylamide solution, 1.5 M Tris-HCl (pH 8.8), 0.4 % (w/v) SDS, ddH2O 
polymerisation was initiated with TEMED and 10 % APS. A 10-well comb was 
inserted during polymerisation (RT for 1 h) of the stacking gel. Combs were 
removed and the wells washed with running buffer: 0.1 % (w/v) SDS, 0.3 % (w/v) 
Tris and 1.4 % (w/v) glycine to remove unpolymerised acrylamide. Ten microlitres 
of each sample equal to 50 µg of protein of muscle homogenates were loaded 
equivalently into each lane and electrophoresed through the stacking gel at 100 V for 
30 min then increased to 200V and continue until tracking dye reached the bottom 
edge of the resolving gel (~1 hour 30 min). Following the process, the gel was 
removed from the glass plates and washed and stained as described previously in 
1.2.8. 
 
1.2.10 Image Analysis using Progenesis  
Digitalised scanned images (16-bit greyscale, 300 dpi, ~85 µm pixel size) of stained 
gels were analysed using T120 software (Total Lab, Newcastle UK). Gels were 
scanned and saved in tiff format. T120 software enables the measurement of the 
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protein content with each band by densitometry and can be used to interpret the 
percentage distribution of MyHC isoforms. Lanes were detected on an image by 
selecting the ‘Create Lanes’ icon from the Lane Creation Toolbar. There are several 
different algorithms for determining the background values. The algorithms were 
tested by clicking on the ‘Subtract Background’, and the rolling ball method was 
chosen (Figure 3). Quality was checked using Profile Deconvolution, which is the 
process of separating a lane profile into a series of individual curves, each 
representing a single band.  The bands were detected using automatic or fixed width 
edge detection and band volume measurement occurs automatically when the ‘Detect 
Bands’ icon is pressed. Following the process, the bands volume data was exported 
from the measurement window for data analysis. 
 
 
 
Figure 3: The process of subtracting the background using the rolling ball method. 
Green line represents the staining density of each protein band (1, 2, 3) of myosin 
heavy chain isoforms and the red line represents the gel background. 
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Data for ‘pooled standard’ and individual samples were extracted by T120 software 
that enables measurement of the concentration of each band by densitometry and can 
be used to calculate the relative percentage of each MyHC isoform to investigate 
differences in expression between groups. The data for grouping were analysed using 
Statistical Package for Social Sciences (SPSS) version 17.0 software (SPSS v.17, 
SPSS Inc, Chicago). Volume measurements from each detected band (Total lab TL 
120) were exported into Microsoft Excel and entered manually in SPSS. A two-way 
between participants ANOVA was employed to analyse the influence of training 
status (e.g. trained vs. untrained) and age (e.g. young vs. old). Significance level was 
set at <0.05, and all data were presented as mean ±SD. 
 
Two-Dimension Gel Electrophoresis of Myofibrillar fraction 
It is likely each 1DE band contains several proteins, therefore two dimension gel 
electrophoresis (2DGE) was used to discover which myofibrillar proteins were 
resolved in to multiple species. 2DGE was performed using similar sample and 
muscle processing described in sections 1.2.7. However, the samples need to be 
diluted in non-ionic lysis buffer (7 M urea, 2 M thiourea and 4 % CHAPS) in order 
to maintain protein change states for isoelectric focusing (IEF). A pooled sample was 
made and precipitated with 5 volumes of acetone. Buffer was prepared by adding 2.8 
mg DTT, 5µl IPG buffer pH 3-10 to 1 ml of rehydration buffer containing 8 M urea, 
2 % (w/v) CHAPS, 20 mM dithiothreitol, and 0.5% (v/v) ampholytes.   
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1.2.11  2DGE  
Muscle homogenates were prepared for 2D electrophoresis by centrifugation at 
8,000 rpm for 2 min. An aliquot of the pooled myofibrillar fraction, containing 125 
µg of protein was loaded onto 7-cm immobilized pH gradient (IPG) strips (pH 3–10; 
GE Healthcare, Little Chalfont, UK) overnight. Isoelectric focusing was conducted 
as follows: 50 V for 15 min, 250 V for 15 min, linear gradient to 4,000 V over 2 h 
and 4,000 for 2 h.  The IPG strips were then equilibrated in 50 mM Tris-HCl (pH 
8.8), containing 6 M urea, 30 % (v/v) glycerol, 2 % (w/v) sodium dodecylsulfate, 
and a trace of bromophenol blue. Proteins were electrophoresed through a linear 12 % 
polyacrylamide gel at 20 °C; initially at a constant current of 15 mA per gel for 30 
min and then at 30 mA per gel. After electrophoresis, the gel was removed from the 
glass plates and washed 3 times in ddH2O, with each wash taking ~5 minutes. The 
ddH2O was poured off and then the gels were stained in 100ml of colloidal 
Coomassie blue (Bio-safe, Bio-rad laboratories, Hercules, USA) for 1 hour before 
being de-stained overnight in ddH2O. 
 
1.2.12 Image Analysis using Progenesis  
Digitalised scanned images (16-bit greyscale, 300 dpi, ~85 µm pixel size) of stained 
gels were scanned and saved in tiff format. Clear spots were selected and numbered 
to identify the related proteins. 
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1.2.13  In-gel digestion and LC-MS 
In-gel digestion was performed to prepare proteins separated by gel electrophoresis 
for identification by mass spectrometry. Gel spots were cut using a glass pipette and 
dispensed into clean labelled plastic tubes. One hundred microliters of 50:50 
acetonitrile (ACN)/50 mM Ambic was added to each tube and the gel plugs 
incubated for 10 min at 37º C. This step is done to de-stain the gel plug and remove 
the Colloidal Coomassie Blue. Then the de-stain solution was removed using a gel-
loading tip. This de-staining process was repeated at least 3 times or until no more 
blue colour could be seen. Samples were incubated in 50 µl absolute ACN for 10 
mins at 37 °C. Then ACN was removed by using a gel-loading tip and the gel dried 
by incubating for 15 mins at 37 °C. Sequence grade trypsin was prepared and 20 µl 
of diluted trypsin stock was added to the dehydrated gel plug and incubated at 37 °C 
for 1 hour. After 1 h 10 µl of 50mM Ambic was added to each tube and incubated 
overnight at 37 °C. The reaction was stopped by addition of 2 µl of 2.6 M formic 
acid. This method was modified slightly for 1D gel pieces. After de-staining, DTT 
was added (150 µl, 9.8 mM in 50 mM Ambic) and incubated at 37 ºC for 30 min 
followed by incubation whilst protected from light in the presence of 5 mM 
iodoacetamide in 50 mM Ambic at 4 ºC for 30 min. Then the solution was removed 
using a gel-loading tip. 75 µl absolute ACN was added and incubated at 37ºC for 10 
min until the gel plug dehydrated and became white. Sequencing grade trypsin 
(Promega; V5113) was added at a protein and digestion allowed to proceed at 37 ºC 
overnight. Digestion was terminated by the addition of 3 μL concentrated TFA and 
peptide solutions were cleared by centrifugation at 13400 xg for 1 min.    
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Protein identification 
Label-free liquid chromatography-mass spectrometry (LC-MS) analysis was 
performed using a quadrupole-high capacity ion-trap (HCT Ultra ETD II; Bruker 
Daltonics, Bremen, Germany) coupled online via an electrospray ionisation source to 
a nano-flow HPLC system (Ultimate 3000; Dionex, Sunnyvale, CA). MS/MS spectra 
were exported in Mascot generic format and searched against the Swiss-Prot 
database (2011.6) restricted to ‘Rattus’ (7921 entires) using a locally implemented 
Mascot (www.matrixscience.com) server (version 2.2.03). The enzyme specificity 
was trypsin allowing 1 missed cleavage, carbamidomethyl modification of cysteine 
(fixed), deamidation of asparagine and glutamine (variable), oxidation of methionine 
(variable) and an m/z error of ± 0.5 Da.  
 
Solution-based analysis of human myofibrillar proteins (Human) 
1.2.14  Sample and muscle processing 
This technique was performed using muscle samples from Cobley et al., 2012, 
processed in section 1.2.7. An aliquot of the myofibrillar fraction of human muscle 
was prepared for in-solution digest, by precipitating supernates in 5 volumes of 
acetone and resuspended in Lysis Buffer: 7 M urea, 2 M thiourea, 4 % (w/v) CHAPS, 
30 mM Tris, containing Complete™ protease inhibitor (Roche Diagnostics, Lewes, 
UK). After clearing by centrifugation (12,000 xg, 4 ºC for 45 min) protein 
concentrations were measured using the Bradford assay (Sigma, Poole, Dorset, UK) 
and each sample adjusted to 5 μg μl-1. Aliquots containing 100 μg protein were 
precipitated in 5 volumes of acetone for 1 h at -20 ºC. Pellets were resuspended in 
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0.1% (w/v) Rapigest SF (Waters; Milford, MA) in 50 mM ammonium bicarbonate 
and incubated at 80 ºC for 15 min. DTT was added (final concentration 1 mM) and 
incubated at 60 ºC for 15 min followed by incubation whilst protected from light in 
the presence of 5 mM iodoacetamide at 4 ºC. Sequencing grade trypsin (Promega; 
Madison, WI) was added at a protein ratio of 1:50 and digestion allowed to proceed 
at 37 ºC overnight. Digestion was terminated by the addition of 2 μL concentrated 
TFA and peptide solutions were cleared by centrifugation at 13 000 xg for 5 min.  
 
1.2.15  Liquid chromatography-mass spectrometry 
Label-free liquid chromatography-mass spectrometry (LC-MS) analysis for human 
sample was performed similar process described in section 1.2.3, which includes MS 
for profiling and MS/MS for protein identification. The MS only data were exported 
to Profile Analysis (Bruker Daltonics, version 2.0) for quantitative analyses. The 
group was defined into two attributes (age and training status) and the Profile 
Analysis project was saved. Then peptides were assigned to ‘buckets’ which 
represent time and MS space, e.g. elution time 10 min and the mass-to-charge 600 
m/z, then the peptides regulation ratios were calculated and peptides that were 
significantly different between samples with different group attributes were 
determined. The results of the calculation were saved and inspected in the Bucket 
Table and the T-Test result Table; then the quantitative results were exported to 
SPSS. A two-way between participants ANOVA was employed to analyse the 
influence of training status (e.g. trained vs. untrained) and age (e.g. young vs. old). 
Significance level was set at <0.05, and all data were presented as mean ±SD. 
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After MS/MS data were imported into ProteinScape (Bruker Daltonics, version 2.0), 
all LC-MS/MS were combined in to a single database search. After that a Mascot 
protein database search was performed on the combined MS/MS data set. Peptides 
identifications were linked to the peptide regulation ratios determined in Profile 
Analysis and protein regulation ratios were calculated from peptide regulation ratios. 
Finally a PDF report was generated by selecting the Mascot search result entry. 
 
1.2.16  Multiple reaction monitoring (MRM) of myosin light chain protein 
Multiple reaction monitoring (MRM) was used to verify differences in the 
abundance of myosin light chain protein (MyLC) detected by LC-MS profiling. 
MyLC exhibited the greatest fold difference between either significant main effect 
for age or training status or significant interaction. MRM was performed using 
similar instrument settings described in section 1.2.4 but samples were separated 
using a linear chromatographic gradient rising to 40 % acetonitrile 0.1 % FA in 15 
min, rather than 160 min used during LC-MS profiling. Samples were analysed in 
duplicate and in a randomised order. A transition 498-759 was monitored for MYL3, 
771-835 and 600-658 for MYL1, 660-735 and 762-780 for MLRS. Abundance data 
(MRM Transition) were exported to SPSS for 2-way ANOVA (Table 12 and Table 
13). 
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1.3 RESULTS 
Analysis of soluble muscle proteins from HCR/LCR rats 
1.3.1 Physical and Physiological Characteristics of HCR and LCR Rats 
The body weight of LCR (460 ± 40 g) was 1.38-fold greater (p < 0.0001) than HCR 
(334 ± 36 g) and there was a 6.44-fold difference (p < 0.0001) difference in running 
capacity (1,625 ± 112 m vs. 252 ± 43 m) between HCR and LCR strains (Figure 4).  
 
Figure 4. Physical characteristics of high-(HCR) and low-capacity runner (LCR) 
rats. Furthest distance (m) completed during a standardised treadmill test of LCR and 
HCR rats at approximately 10 weeks of age (A). Body weight of LCR and HCR rats 
prior to tissue harvesting at approximately 14 weeks of age (B). Data are expressed 
as Mean ± SD (n = 5, in each group), * p < 0.05. 
 
In total 207 protein entries (2,999 peptides) mapped to features in progenesis LC-MS 
and were used for quantitative analysis. Log transformed MS data were normalised 
by inter-sample abundance ratio and used to investigate differences in expression 
between LCR and HCR groups by one-way analysis of variance. Proteins more 
abundant in HCR muscle were associated with aerobic metabolism and hierarchal 
clustering highlighted two prominent groups of proteins (respiratory chain and fatty 
acid metabolism) that shared patterns of expression across the biological replicates. 
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1.3.2 Liquid chromatography-mass spectrometry (Rat soleus muscle) 
Differential analysis of HCR and LCR samples highlighted 16 proteins (Table 3) that 
were more abundant (p < 0.05) in HCR soleus. No proteins were found to be 
significantly more abundant in LCR muscle. 
Table 3. Differences in protein abundance between LCR and HCR soleus muscle.  
Description  Database 
ID  
MOWSE 
(peptides)  
Fold 
Diff.  
p 
value   
Cytochrome b-c1 complex subunit 
1  
QCR1  322 (11)  1.10  0.0274  
Cytochrome b-c1 complex subunit 
2  
QCR2  459 (15)  1.09  0.0290  
Cytochrome c oxidase subunit 2  COX2  111 (4)  1.14  0.0458  
Cytochrome c oxidase subunit 4 
isoform 1  
COX41  159 (5)  1.15  0.0206  
ATP synthase subunit beta  ATPB  1185 (21)  1.14  0.0326  
ATP synthase subunit d  ATP5H  64 (2)  1.16  0.0081  
ADP/ATP translocase 1  ADT1  562 (10)  1.16  0.0232  
Voltage-dependent anion-selective 
channel protein 1  
VDAC1  412 (12)  1.12  0.0111  
Voltage-dependent anion selective 
channel protein 3  
VDAC3  53 (4)  1.16  0.0137  
Electron transfer flavoprotein 
subunit beta  
ETFB  279 (8)  1.13  1.13  
Fatty acid-binding protein, heart  FABPH  349 (7)  1.54  0.0064  
Fatty acid-binding protein, 
adipocyte  
FABP4  95 (4)  1.15  0.0426  
Methylmalonate-semialdehyde 
dehydrogenase  
MMSA  115 (5)  1.05  0.0235  
Dihydrolipoyl dehydrogenase  DLDH  184 (6)  1.15  0.0077  
3-Ketoacyl-CoA thiolase  THIM  396 (7)  1.25  0.0071  
Enoyl-CoA hydratase  ECHM  76 (3)  1.19  0.0245  
Description and Database ID relate to the protein name and accession number 
identified from Mascot searches of the UniProt Rattus database. Protein abundance 
relative differences (fold difference) in HCR compared to LCR are reported for 
proteins exhibiting significant (p < 0.05) differences in abundance at a FDR of 
<10%. 
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1.3.3 SRM Verification of FABPH 
LC-MS profiling found FABPH exhibited the greatest difference (1.54-fold, p = 
0.0064) in abundance between HCR and LCR muscle. SRM verified this finding and 
measured a 2.84-fold greater (p = 0.0095) abundance in HCR soleus (Figure 5). The 
reproducibility of the SRM method was assessed using technical replicates of HCR 
and LCR samples. The assay exhibited no significant systematic bias in retention 
time or area under the curve of the ion chromatogram, which was used to estimate 
abundance. The average retention time was 21 ± 0.2 min (coefficient of variation 
0.4%) and the coefficient of variation of measures of FABPH abundance was 20%.  
 
 
Figure 5. Selective reaction monitoring chromatograms of the 454.19 m/z to 551.21 
m/z transition in HCR and LCR soleus. The red shaded area represents a HCR 
sample and the blue area represents a LCR sample. The histograms represent the ion 
abundance of the areas under the chromatogram curves for the respective groups. 
Data are presented as means ± SD (n = 5, in each group), * p < 0.05. 
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Gel-based analysis of human myofibrillar proteins  
1.3.4 Characteristics of human muscles samples  
Analysis was performed on human muscles samples collected by percutaneous 
needle biopsy during a previous study (Cobley et al., 2012). Samples were collected 
from vastus lateralis of 12 young and 12 older participants that had different habitual 
training status: Young trained (YT n = 6), young untrained (YU n = 6), old trained 
(OT n = 6) and old untrained (OU n = 6). Baseline participant characteristics are 
displayed in table 4. 
Table 4. Baseline participant characteristics, values presented as mean ± SD 
Parameter YT YU OT OU 
Age (years) 24.2 ± 3.6* 22.1 ± 3.4* 64.5 ± 5.5
# 
63.8 ± 3.0
# 
Weight (kg) 66.2 ± 10.0 84.5 ± 10.8 71.8 ± 7.8 95.5 ± 24.8*
# 
Height (cm) 176.6 ± 8.6 181.6 ± 6.5 174.6 ± 6.8 174.8 ± 9.3 
Data are from Cobley et al., (2012) are presented as mean ± SD for young trained 
(YT), young untrained (YU), old trained (OT) and old untrained (OU). * P<0.05 
significantly different from OT. 
# 
P<0.05 significantly different from YT. 
 
 
1.3.5 Traditional muscle phenotyping: Analysis of Myosin heavy chain isoforms 
by SDS-PAGE.  
Analysis of ‘pooled standard’ 
The electrophoresis conditions were optimised using a ‘pooled standard’ that was 
created by combining an aliquot (10 µg protein from each individual). The running 
conditions were optimised until the MyHC isoforms were clearly resolved mid – 
way through the minigel (Figure 6).  Figure 6 shows representative images and 
analysis of MyHC band volumes. Using this method we were able to separate MyHC 
51 
 
isoforms into 2 distinct band (IIa/x, I). The average percentages of MyHC I (52.4%) 
and MyHC IIa/x (47.6%), found in the ‘pooled standard’ of vastus lateralis 
homogenates by this minigel protocol (Table 5).  
 
Individual samples from each group  
Individual samples from young trained (YT; n = 6), young untrained (YU; n = 6), old 
trained (OT; n = 6), and old untrained (OU; n = 6) were separated using the 
optimised method (Figure 7). MyHC IIx was less than 10 % from samples of young 
trained, untrained and trained elderly individuals whereas young untrained exhibited 
the highest abundance of the MyHC IIa/x isoform. The elderly trained result also 
found the MyHC I (78.1 %) was significantly (P<0.05) greater than MyHC IIa 
(21.7 %) (Table 6). 
 
 
Figure 6. Separation of MyHC isoforms by SDS-PAGE. (A) Representative image 
of gel lanes showing separation of MyHC isoforms. (B) Density plot showing area of 
interest,   into two distinct bands (IIa/x and I) based in differences in migration 
(Pooled standard sample from all participants). (C) Images of lanes aligned with the 
area of interest. 
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Table 5. Duplicate analysis of ‘pooled standard’. Volume and percentage for each 
band from pooled standard sample in two different lanes. 
Band 
Lane 1 
(Volume) % 
Lane 2 
 (Volume) % 
Volume  
mean ± SD 
% 
mean± SD 
% 
CV 
IIa/x 1323 46.3 1603 48.8 1429 ± 241.1 47.6 ± 3.9 3.6 
I 1528 53.7 1690 51.2 1609 ± 114.6 52.4 ± 1.7 1.2 
Data represented ‘pooled standard’ proteins were identified by T120 software which 
enables the concentration of each band to be measured by densitometry and can be 
used to calculate the relative percentage of each MyHC isoform. 
 
 
Figure 7. Separation of myofibrillar isoforms by SDS-PAGE. Representative image 
of gel lanes from young trained (YT), young untrained (YU), old trained (OT) and 
old untrained (OU) individuals showing separation of MyHC isoforms into distinct 
bands (IIa/x, I) based in differences in migration of four different group samples. 
 
 
Table 6. Volume and percentage for each band from four different group sample. 
Band YT YU OT OU 
IIa/x(%) 44.6 ± 14.2 64 ± 15.1 21.9 ± 13.8* 39.5 ± 20.7 
I(%) 55.4 ± 27.8 36 ± 12.1 78.1 ± 14.2* 60.5 ± 30.1 
Data are from Cobley et al., (2012) are presented as mean ± SD for young trained 
(YT), young untrained (YU), old trained (OT) and old untrained (OU). Each group 
proteins were identified by T120 software which enables to measure the 
concentration of each band by densitometry and can be used to interpret percentage 
of MyHC isoforms. *
 
P<0.05 significantly different from YU. 
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1.3.6 Analysis of low molecular weight (LMW) myofibrillar proteins  
In total 12 bands could be reliably separated in human muscle (Figure 8). Band 
densities spanned one order of magnitude i.e. ranged from 6900 to 71000 (Table 7).  
The molecular weight range of proteins was separated using 15% gels was (6- to 90-
kDa).  LC-MS/MS of in gel tryplic digests was used to identify the proteins present 
in each band. Protein identification focused on a range from 45 to 15 kDa consistent 
with optimum resolution for 15% gels. Figure 8 represent the bands detected using 
automatic fixed width edge detection and band volume measurement.  
 
Figure 8. Optical density plot of myofibrillar bands in human muscle vastus 
lateralis. (A) Peaks are labelled corresponding to band number (1-12) and density 
plot showing area of interest. (B) Images of lanes aligned with the area of interest. 
 
Individual samples from four different groups (n = 24) were separated using the 
optimised method (Figure 8) and the bands identified by T120 software which 
enables to measure the concentration of each band by densitometry and investigate 
differences in expression between groups by one-way analysis of variance. One 
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statistically significant difference was detected. Band 8 was 42 % more abundant in 
the young untrained, interaction was p = 0.029. Proteins identified within each band 
by mass spectrometry and database searches, were categorised further and ranked by 
MOWSE score to determine the primary protein typically found in each band (Table 
8).   
 
Myofibrillar Proteins 
Table 7. Protein expression of 1-DE gel bands (bands 1-12 in Figure 8). 
Band YT YU OT OU 
1 67243±8735 64735±11595 70248±16665 61158±14620 
2 15637±6576 18445±8069 17286±5878 14137±6637 
3 18437±2410 21044±9215 26920±12653 21739±7969 
4 18435±5130 18798±5023 15944±2935 19584±5843 
5 9912±2583 9866±5523 10023±4387 8980±7092 
6 27235±2157 32333±9400 33644±9901 29128±8493 
7 10191±2942 9229±4860 15489±6931 9836±2700 
8* 11807±4674 21005±5631 10785±3137 10997±3835 
9 11005±3463 12372±7708 13493±10147 8946±7833 
10 10098±6137 6942±3458 6942±3473 7382±6326 
11 14910±6682 10236±6370 14137±8278 14346±14554 
12 16432±7402 13009±7210 15100±9291 15146±13225 
Data is presented as mean ± SEM. * Significant difference between training status 
and age. Data represented each group proteins were identified by T120 software 
which enables to measure the concentration of each band by densitometry. There is 
only significant difference was evident in band 8 (p < 0.05) where the volume of 
MyLC2/Troponin C protein was higher in trained and young participants.  
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Table 8. Proteins detected in each band (bands 1 to 12) of myofibrillar bands in 
human muscle vastus lateralis. 
 
Band Protein description MW (kDa) Score 
1 Actin, alpha skeletal muscle 42 789.2 
 Creatine kinase M-type 43.1 705.5 
 Fructose-bisphosphate aldolase 39.4 124.1 
 PDZ and LIM domain protein 3 39.2 53.8 
    
2 Tropomyosin beta chain 32.8 879 
 Tropomyosin alpha-1 chain 32.7 683.8 
 Tropomyosin alpha-3 chain 32.8 553.4 
 Glyceraldehyde-3-phosphate dehydrogenase 36 403.8 
 Troponin T, fast skeletal muscle 31.8 225.6 
 Troponin T, slow skeletal muscle 32.9 67.9 
 Glycerol-3-phosphate dehydrogenase [NAD+], cytoplasmic 37.5 52.2 
    
3 Tropomyosin alpha-3 chain 32.8 764.3 
 Tropomyosin beta chain 32.8 731.7 
 Troponin T, slow skeletal muscle 32.9 649 
 Tropomyosin alpha-1 chain 32.7 644.3 
 Troponin T, fast skeletal muscle 31.8 354 
    
4 Tropomyosin alpha-1 chain 32.7 962.9 
 Tropomyosin alpha-3 chain 32.8 767 
 Tropomyosin beta chain 32.8 465.5 
 Myozenin 31.7 484.8 
 Troponin T, fast skeletal muscle 31.8 279.6 
 Troponin T, slow skeletal muscle 32.9 129.5 
    
5 Trypsin-1 26.5 57.5 
    
6 Myosin light chain 1/3, skeletal muscle isoform 21.1 700 
 Myosin light chain 3 21.9 683.4 
 Troponin I, slow skeletal muscle 21.7 238.3 
 Troponin I, fast skeletal muscle 21.3 218.3 
    
7 
Myosin regulatory light chain 2, ventricular/cardiac muscle 
isoform 18.8 710 
 Myosin light chain 1/3, skeletal muscle isoform 21.1 218.3 
    
8 Myosin regulatory light chain 2, skeletal muscle isoform 19 619 
 Troponin C, skeletal muscle 18.1 383.1 
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9 Troponin C, slow skeletal and cardiac muscles 18.4 502 
 Myoglobin 17.2 411.5 
 Hemoglobin subunit beta 16 85.5 
    
10 Hemoglobin subunit beta 16 425 
 Myoglobin 17.2 137.4 
 Hemoglobin subunit alpha 15.2 96.3 
    
11 Hemoglobin subunit beta 16 537.5 
 Hemoglobin subunit delta 16 535.2 
 Cytochrome c 11.7 174.1 
 Fatty acid-binding protein, heart 14.8 129 
    
12 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 5 13.5 66.1 
Data represent proteins were identified by mass spectrometry and database searches, 
these were categorised further and ranked by score to determine the primary protein 
typically found in each band. Proteins are ranked by score, highest to lowest. 
 
Band 8 showed significant differences contain Myosin regulatory light chain and 
troponin C. The protein here similar weight (i.e. 18, 19 kDa) but the predict pH are 
different. So 2D gel is required to determine which of these proteins is different in 
this group.  
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1.3.7 Two-dimensional gel electrophoresis.  
Two-dimensional gel electrophoresis was used to resolve proteins species within 
each 1DE and mass-spectrometry was employed to identify the proteins within each 
spot. Small format 2D gel was used because sample was limited and the myofibrillar 
fraction was not expected to be too complex. To ascertain the resolution of this 
technique a pooled sample was used. All samples were combined to create a 
consistent ‘pooled standard’ sample and the molecules were separated according to 
their isoelectric point using isoelectric focusing (IEF) and molecular weight (SDS-
PAGE). Selected gel spots were cut and from the gel and processed by manual in-gel 
tryplic digestion in preparation for LC-MS/MS analysis. Figure 8 indicated that 
using this method we were able to separate the myofibrillar isoforms by SDS-PAGE 
into more diverse proteins and 91 spots were resolved, cut and digested. Only 59 
spots were successfully identified (Table 8). Each spot identified by protein name, 
score, number of peptides, sequence percentage, MW and pI. From 59 spots there 
were 26 unique proteins. 
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Figure 9. Separation of myofibrillar isoforms by 2DE SDS-PAGE. Distinct spots 
separated based in differences in pH and migration (Pooled standard sample from all 
participants). 26 proteins were successfully identified. 
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Table 9. Proteins detected in 2D gel spots. 
# Accession Protein name Score SC 
(%) 
Peptides MW pI 
48 LDB3 LIM domain-binding 
protein 3 
438 18 8 77.
1 
9.4 
81 ALBU Serum albumin precursor 923 37 23 69 5.9 
83 ALBU Serum albumin precursor 1160 50 25 69 5.9 
69 K2C1 Keratin, type II cytoskeletal 
1 
310 11 6 66 8.8 
70 K2C1 Keratin, type II cytoskeletal 
1 
319 12 7 66 8.8 
66 ATPA ATP synthase subunit alpha, 
mitochondrial precursor 
610 32 16 59.
7 
9.6 
34 FIBB Fibrinogen beta chain 475 34 11 55.
9 
9.3 
35 FIBB Fibrinogen beta chain 909 54 19 55.
9 
9.3 
36 FIBB Fibrinogen beta chain 886 55 21 55.
9 
9.3 
78 FIBG Fibrinogen gamma chain 
precursor 
384 40 14 51.
5 
5.3 
65 ENOB Beta-enolase 504 35 10 46.
9 
8.6 
37 KCRM Creatine kinase M-type 631 38 12 43.
1 
6.9 
38 KCRM Creatine kinase M-type 454 38 12 43.
1 
6.9 
39 KCRM Creatine kinase M-type 715 38 15 43.
1 
6.9 
63 KCRM Creatine kinase M-type 465 38 10 43.
1 
6.9 
40 KCRM Creatine kinase M-type 674 46 18 43.
1 
6.9 
73 ACTS Actin, alpha skeletal muscle 1381 61 22 42 5.1 
89 ACTS Actin, alpha skeletal muscle 713 50 17 42 5.1 
74 ACTS Actin, alpha skeletal muscle 1149 54 20 42 5.1 
61 ALDOA Fructose-biphosphate 
aldolase 
284 29 7 39.
4 
9.2 
62 ALDOA Fructose-biphosphate 
aldolase 
392 31 9 39.
4 
9.2 
45 G3P Glyceraldehyde-3-
phosphate dehydrogenase 
325 31 6 36 9.3 
21 TNNT1 Troponin T, slow skeletal 
muscle 
520 29 15 32.
9 
5.8 
22 TNNT1 Troponin T, slow skeletal 
muscle 
727 35 15 32.
9 
5.8 
68 TPM2 Tropomyosin beta chain 1598 38 16 32.
8 
4.5 
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20 TPM3 Tropomyosin alpha-3 chain 186 21 7 32.
8 
4.5 
52 TPM3 Tropomyosin alpha-3 chain 1880 53 22 32.
8 
4.5 
67 TPM1 Tropomyosin alpha-1 chain 1488 49 19 32.
7 
4.5 
25 TNNT3 Troponin T, fast skeletal 
muscle 
244 25 6 31.
8 
5.6 
26 TNNT3 Troponin T, fast skeletal 
muscle 
209 25 7 31.
8 
5.6 
42 TNNT3 Troponin T, fast skeletal 
muscle 
183 14 3 31.
8 
5.6 
27 TNNT3 Troponin T, fast skeletal 
muscle 
268 30 8 31.
8 
5.6 
43 TNNT3 Troponin T, fast skeletal 
muscle 
191 19 5 31.
8 
5.6 
28 TNNT3 Troponin T, fast skeletal 
muscle 
290 25 8 31.
8 
5.6 
29 TNNT3 Troponin T, fast skeletal 
muscle 
146 25 7 31.
8 
5.6 
30 TNNT3 Troponin T, fast skeletal 
muscle 
254 26 7 31.
8 
5.6 
31 TNNT3 Troponin T, fast skeletal 
muscle 
201 25 5 31.
8 
5.6 
32 TNNT3 Troponin T, fast skeletal 
muscle 
246 25 8 31.
8 
5.6 
41 MYOZ1 Myozenin-1 342 38 7 31.
7 
9.3 
44 MYOZ1 Myozenin-1 334 48 10 31.
7 
9.3 
49 CAH3 Carbonic anhydrase 3 260 32 7 29.
5 
7.1 
59 CAH3 Carbonic anhydrase 3 352 39 8 29.
5 
7.1 
51 CAH1 Carbonic anhydrase 1 516 45 9 28.
9 
6.7 
53 MYL6B Myosin light chain 6B 364 47 11 22.
7 
5.5 
54 MYL6B Myosin light chain 6B 380 51 12 22.
7 
5.5 
17 MYL1 Myosin light chain 1/3, 
skeletal muscle 
1451 89 18 21.
1 
4.8 
18 MYL1 Myosin light chain 1/3, 
skeletal muscle 
1689 74 17 21.
1 
4.8 
10 MLRS Myosin regulatory light 
chain 2 
833 88 17 19 4.7 
11 MLRS Myosin regulatory light 
chain 2 
804 78 12 19 4.7 
12 MLRS Myosin regulatory light 
chain 2 
608 54 7 19 4.7 
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13 MLRV Myosin regulatory light 
chain 2, venticular/cardiac 
muscle 
655 74 17 18.
8 
4.7 
14 MLRV Myosin regulatory light 
chain 2, venticular/cardiac 
muscle 
642 72 15 18.
8 
4.7 
15 MLRV Myosin regulatory light 
chain 2, venticular/cardiac 
muscle 
1098 90 20 18.
8 
4.7 
9 TNNC2 Troponin C, skeletal muscle 777 54 11 18.
1 
3.9 
5 MYG Myoglobin 624 55 9 17.
2 
7.9 
2 HBB Haemoglobin subunit beta 686 75 11 16 6.9 
3 HBB Haemoglobin subunit beta 3235 83 12 16 6.9 
4 HBB Haemoglobin subunit beta 1321 82 11 16 6.9 
1 HBA Haemoglobin subunit alpha 846 70 8 15.
2 
9.4 
Data represent proteins which were identified by mass spectrometry and database 
searches, these were categorised further and ranked by score to determine the 
primary protein typically found in each spot.  
 
In-solution analysis of human myofibrillar proteins  
1.3.8 Liquid chromatography-mass spectrometry (Human - YOTU) 
Two-dimensional gel electrophoresis resolved Band 8 but it did not resolve all 
expected abundant myofibrillar proteins for example MyHC, Myosin binding protein 
C, alpha actinin-2 were missing from table 8. Therefore, differential analysis using 
high-performance liquid chromatography online mass-spectrometry was investigated 
to see if it could overcome this resolution problem. In total 49 protein entries (484 
peptides) were consistently detected and used for label-free quantitative analysis. 
This number of identified proteins is more than the number identified by 2D gel. 
Table 10 details the entire list of Mascot protein identifications and normalised 
abundance of each protein. Based on MOWSE score the most robust identification 
were type IIa myosin heavy chain (MYH2) and type I myosin heavy chain (MYH7). 
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The lowest scoring proteins detected were myomesin-2, keratin and fructose-
biphosphate aldolase.  
 
Table 10. List of Mascot protein identifications. 
Accession Protein name Score SC 
(%) 
Peptide
s 
Obs. 
MW 
Obs
. pI 
MYH3 Myosin-3 1299
7 
20 1 223.
8 
5.5 
MYH13 Myosin-13 5824 14 1 223.
5 
5.4 
MYH7 Myosin-7  3107
3 
52 71 223 5.5 
MYH1 Myosin-1  2777
7 
41 11 223 5.5 
MYH2 Myosin-2  3667
6 
51 94 222.
9 
5.5 
MYH4 Myosin-4 1837
9 
28 1 222.
9 
5.6 
MYOM2 Myomesin-2 116 9 5 164.
8 
5.8 
MYPC1 Myosin-binding protein C, 
slow type 
763 17 14 128.
2 
5.7 
ACTN2 Alpha-actinin-2 5705 45 31 103.
8 
5.2 
LDB3 LIM domain-binding 
protein 3 
1259 18 9 77.1 9.4 
ALBU Serum albumin precursor 1689 41 20 69.3 5.9 
K2C1 Keratin, type II 
cytoskeletal 1 
171 10 6 66 8.8 
PDLI5 PDZ and LIM domain 
protein 5 
135 15 4 63.9 9.6 
K1C10 Keratin, type I cytoskeletal 116 6 3 58.8 5 
ATPB ATP synthase subunit beta, 
mitochondrial  
261 21 6 56.5 5.1 
DESM Desmin  1778 39 15 53.5 5.1 
VIME Vimentin 424 14 2 52.6 4.9 
ENOB Beta-enolase 324 47 4 46.9 8.6 
CASQ1 Calsequestrin-1 1718 11 2 44.5 3.9 
KCRM Creatine kinase M-type 5182 43 1 43.1 6.9 
ACTS Actin, alpha skeletal 
muscle 
1239
0 
63 23 42 5.1 
ACTB Actin, cytoplasmic 1 6353 30 1 41.7 5.2 
ALDOA Fructose-bisphosphate 1159 41.8 9 39.4 9.2 
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aldolase A OS 
ALDOC Fructose-biphosphate 
aldolase C 
102 18 1 39.4 6.5 
FHL1 Four and a half LIM 
domains protein 1 
398 14 3 36.2 10.
5 
G3P Glyceraldehyde-3-
phosphate dehydrogenase 
599 38 7 36 9.3 
TNNT1 Troponin T, slow skeletal 
muscle 
1119 26 6 32.9 5.8 
TPM2 Tropomyosin beta- chain  7878 38 13 32.8 4.5 
TPM3 Tropomyosin alpha-3 
chain 
6338 44 7 32.8 4.5 
TPM1 Tropomyosin alpha- 1 
chain  
7298 44 11 32.7 4.5 
TNNT3 Troponin T, fast skeletal 
muscle 
1262 24 6 31.8 5.6 
MYOZ1 Myozenin-1 599 51 7 31.7 9.3 
CAH3 Carbonic anhydrase 3 760 38 6 29.5 7.1 
MYL6B Myosin light chain 6B 152 15 1 22.7 5.5 
MYL3 Myosin light chain 3  4390 68 10 21.9 4.9 
TNNI1 Troponin I, slow skeletal 
muscle 
1043 29 5 21.7 10.
3 
TNNI2 Troponin I, fast skeletal 
muscle 
901 14 3 21.3 9.6 
MYL1 Myosin light chain 1/3, 
skeletal muscle isoform  
8270 8 15 21.1 4.8 
MLRS Myosin regulatory light 
chain 2, skeletal muscle 
isoform  
7121 72 2 19 4.7 
MLRV Myosin regulatory light 
chain 2, venticular/cardiac 
muscle 
3186 72 11 18.8 4.7 
TNNC1 Troponin C, slow skeletal 
and cardiac muscles 
261 9 2 18.4 3.9 
TNNC2 Troponin C, skeletal 
muscle 
2162 33 4 18.1 3.9 
MYG Myoglobin 3163 55 8 17.2 7.9 
MYL6 Myosin light polypeptide 6 1402 30 2 16.9 4.4 
HBB  Haemoglobin subunit beta 1140
3 
88 12 16 6.9 
HBD Haemaglobin subunit delta 4206 69 2 16 9.1 
HBA Haemoglobin subunit 
alpha 
2586 53 6 15.2 9.4 
Data represent proteins were identified by mass spectrometry and database searches, 
these were categorised further and ranked by score to determine the primary protein 
typically found in each spot.  
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Profile Analysis 
Table 10 reports Profile Analysis data aligned with mascot protein ID i.e. label-free 
profiling.  Using profile analysis 265 buckets were resolved and exported to SPSS 
for two-way ANOVA. Forty buckets had significant differences but only 19 
identified when aligned with mascot protein identification (Table 11).  
Table 11. Differences in protein abundance in vastus lateralis muscle by profile 
analysis aligned with mascot protein identification. Red highlight represent myosin 
light chain group were selected for MRM analysis. 
Accession & 
Protein name 
 p value  
min : bucket Age Training Age * 
Training 
Sequence 
ACTS_HUMAN 
Actin 
  
  
  
 
MLRS_HUMAN 
Myosin regulatory light 
chain 2, skeletal muscle 
 
  
 
MYH_HUMAN 
Myosin 
 
  
  
  
  
  
  
 
MYL1_HUMAN 
Myosin light chain 1/3, 
skeletal muscle 
MYL3_HUMAN 
Myosin light chain 3  
TPM_HUMAN 
Tropomyosin  
40.1min : 
644.31m/z 
0.552 0.289 0.02 GILTLK 
98.9min : 
895.86m/z 
0.024 0.315 0.336 SYELPDGQVITIG
NER 
44.7min : 
1162.47m/z 
0.043 0.537 0.678 EITALAPSTMK 
83.4min : 
652.64m/z 
0.159 0.029 0.05 VAPEEHPTLLTE
APLNPK 
 
103.8min : 
1524.61m/z 
 
0.117 
 
0.03 
 
0.2 
 
FLEELLTTQCDR 
32.1min : 
1173.43m/z 
0.06 0.026 0.399 DGIIDKEDLR 
104.4min : 
1319.51m/z 
0.045 0.046 0.465 GADPEDVITGAF
K 
 
117.6min : 
895.91m/z 
 
0.026 
 
0.096 
 
0.211 
 
NAYEESLDQLET
LK 
21.9min : 
1004.37m/z 
0.268 0.348 0.041 ELEEISER 
144.6min : 
1893.88m/z 
0.004 0.051 0.051 LLSTLFANYAGA
DAPIEK 
67.1min : 
1507.59m/z 
0.015 0.275 0.302 LTYTQQLEDLKR 
21.5min : 
1272.36m/z 
0.015 0.51 0.87 TLEDQMNEHR 
20.0min : 
1411.48m/z 
0.876 0.832 0.027 ELTYQTEEDRK 
17.8min : 
1482.51m/z 
0.108 0.555 0.033 KVQHELDEAEER 
 
119.4min : 
1010.42m/z 
 
0.508 
 
0.022 
 
0.444 
 
EAFLLFDR 
116.4min : 
1542.60m/z 
0.001 0.841 0.798 DQATYEDFVEGL
R 
 
22.9min : 
1524.60m/z 
 
0.03 
 
0.917 
 
0.662 
 
AAPAPAPPPEPER
PK 
 
68.8min : 
1243.50m/z 
 
0.04 
 
0.574 
 
0.63 
 
IQLVEEELDR 
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Differentially abundant protein included α-actin, MyHC, MyLC and tropomyosin. 
The majority of these proteins had multiple peptides assigned to them but cases (e.g. 
α-actin and MyHC). The peptides assigned to a protein each exhibited different 
patterns of differences in abundance, i.e. demonstrating either significant main effect 
for age or training status or significant interaction. This is likely due to high degree 
of homology across isoforms of these proteins. Therefore, α-actin, MyHC and 
tropomyosin were excluded from the follow up analyses. Tropomyosin was also 
excluded because this was based on single peptide. Proteins taken forward for 
confirmatory analysis were MLRS, MyLC 1 and 3.  
 
Label-free profiling is a non-targeted discovery technique and is susceptible errors in 
the alignment of MS spectra. Therefore best practice is to perform confirmatory 
analysis using a targeted technique such as western blotting or selective reaction 
monitoring. In this case selective reaction monitoring (SRM) was used to verify 
differences in the abundance of proteins detected by LC-MS profiling. 
 
1.3.9  Selective reaction monitoring (SRM)  
SRM involves programming the mass spectrometer to detect pairs of peptide ions 
and fragment ions that are specific to the protein of interest. In skeletal muscle it is 
particularly important to select targets that use isoform-specific peptides. This 
removes ambiguity but the number of isoform-specific peptides represents a small 
proportion of the overall protein sequence, which makes this analysis challenging. 
Samples were analysed in duplicate and in a randomised order. Figure 10 show an 
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example of proteins identified in human samples, a single transition 600–658 was 
monitored, which represents the y5 ion (600.82 m/z) of the doubly charged peptide 
K.ITLSQVGDVLR.A of MYL1_HUMAN.  
 
 
Figure 10. Selective reaction monitoring of MYL1. Annotated MS/MS spectra of 
the doubly-charged precursor, (A) of residues K.ITLSQVGDVLR.A of 
MYL1_HUMAN and (B) monitoring of the selected fragment ion (600.82 m/z). 
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1.3.10  Multiple reaction monitoring (MRM) Verification  
Multiple reaction monitoring (MRM) using mass spectrometry is a highly sensitive 
highly selective (targeted), allowing us to fine tune an instrument to specifically look 
for peptides, or protein fragments, of interest. The MRM platform technology allows 
for targeted analysis of multiple selective reactions for proteins of interest for 
example like listed in table 12 and table 13.  
 
MRM based on the result from age group on Profile Analysis 
Table 12. Area coverage in protein between elderly and young vastus lateralis 
muscle. 
Data is presented as mean ± SD. * Significant difference from YU group. Data 
represented each group proteins were identified by LC-MS which enables to measure 
the area coverage of each protein. There is significant difference was evident 
between YU and OT in all listed protein and between YU and OU in MYL1 (771.76 
– 835.42) transition and MYL1 average. 
 
 
 
 
 YT YU OT OU 
MYL1 
(771.76 – 835.42) 
1034397.9 
±482407.6 
1779223.6 
±672895.4 
703544.3* 
±181593.3 
907659.8* 
±356365.7 
 
MYL1 
(600.8 – 658.3) 
5777961.7 
±2532524.8 
5707742.4 
±7583675.2 
5457556.3* 
±5430854.3 
8436602.7 
±8908408.7 
 
MYL3 
(498.21 – 759.44) 
4529903.6 
±1478327.4 
2438270.8 
±1166681.2 
7233900* 
±3889691.5 
5296113.1 
±2556299.8 
 
MYL1 
(Average) 
1568154.8 
±801499.4 
2698360.8 
±845963.9 
1062304.8* 
±186342.6 
1451987.4* 
±600787.3 
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MRM based on the result from training group on Profile Analysis 
Table 13.  Area coverage in protein between trained and untrained vastus lateralis 
muscle. 
Data is presented as mean ± SD. * (p<0.05) Significant difference from YU group 
and # (p=0.05) with YU group. Data represented each group proteins were identified 
by LC-MS which enables to measure the area coverage of each protein. There is 
significant difference was evident between YU and OT in MLRS (762.81 – 780.27) 
transition, MYL1 (505.7 – 550.22) transition and MLRS average. Meanwhile MLRS 
(660.27 – 735.42) transition the p-value equal to 0.05 between YU and OT group. 
 
 
  
 YT YU OT OU 
MLRS 
(660.27 – 735.42) 
829855.6 
±450898.4 
1229365.2 
±345497.1 
573957# 
±273417.4 
939341.5 
±463042.3 
 
MLRS 
(762.81 – 780.27) 
1632432.8 
±1160794.7 
2571437.4 
±980082.3 
869758.7* 
±321700.3 
1675950.5 
±1081564.5 
 
MYL1 
(505.7 – 550.22) 
2829422.5 
±1822148.7 
4829979.3 
±2072181.3 
1199865.5* 
±373670.5 
2441917.1 
±1515769.9 
 
MLRS 
(Average) 
1231144.2 
±794307.8 
1900401.3 
±658755.7 
721857.8* 
±295366.2 
1307646 
±730069.8 
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1.4 DISCUSSION 
Label-free profiling of soluble proteins from HCR/LCR rats 
The current work reports a time- and sample-efficient method of profiling the 
expression of the major metabolic enzymes in skeletal muscle. Using a simple LC-
MS approach we surveyed more than 200 proteins, including almost all enzymes of 
the major metabolic pathways (i.e., glycolysis, fatty acid β-oxidation, the 
tricarboxylic acid cycle and some components of the respiratory chain). Recently 
(Hussey et al., 2012), spectral counting was successfully combined with GeLC-
MS/MS to perform differential analysis of 438 proteins in human skeletal muscle. 
However, that relatively broad coverage of the muscle proteome was achieved at the 
expense of substantially greater machine time and sample usage. Hussey et al. (2012) 
separated 60 μg aliquots of muscle homogenate in to 20 molecular weight fractions, 
which were analysed by LC-MS/MS over 90 min periods. This equates to roughly 
1,800 min machine time per sample (biological replicate). In the current work, 
approximately 50 ng of tryptic peptides from each biological replicate was resolved 
by LC-MS of 180 min duration. This represents a 10-fold improvement in time 
efficiency and a greater than 100-fold increase in sample efficiency; albeit at the 
expense of a 2-fold decrease in the number of proteins detected. We believe the 
current approach represents a useful compromise that may lead to more widespread 
application of LC-MS profiling as a semi-automated and efficient means of 
phenotyping skeletal muscle. 
 
Here, we applied LC-MS profiling to muscle of HCR and LCR rats that exhibit 
differences in exercise capacity, cardiometabolic disease risk and life expectancy 
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(Koch et al, 2011). Deterioration in the metabolic flexibility of skeletal muscle is 
associated with insulin resistance, which is a cardinal feature of human metabolic 
syndrome, and also accompanies natural ageing. Metabolic dysfunction and 
insensitivity to insulin are also evident as correlated traits of selection on low 
running capacity. For example, in the basal (fasted) state LCR muscle has lesser 
uptake and oxidation of fatty acids and, when stimulated by insulin, glucose uptake 
of LCR hindlimb muscles is significantly less than HCR (Rivas et al., 2011). 
Transcriptome profiling (Kivela et al., 2010) reports enrichment of gene-sets, 
including oxidative phosphorylation, fatty acid metabolism and PPAR signalling, 
correlate with the differences in running activity of LCR and HCR animals. However, 
such differences between HCR and LCR are generally more pronounced in 
predominantly fast- compared to slow-twitch muscles. The proportion of type IIa 
MyHC (42 ± 16% versus 22 ± 14%) was significantly greater in HCR gastrocnemius 
used for transcriptome analysis, which may have contributed to some of the 
differences observed in metabolic markers. To obviate effects due to myofibre 
profile, we performed proteomic analysis of slow-twitch soleus muscle that has 
consistent myofibre proportions (~80% type I, ~20% type IIa) in HCR and LCR rats 
(Kivela et al., 2010). 
 
LC-MS profiling detected 16 significant differences between HCR and LCR soleus 
muscles. Consistent with the selection paradigm and earlier reported by Kivela et al. 
(2010), the differences in soleus mitochondrial content, the majority of proteins were 
more abundant in HCR muscle (Table 3) and were associated with the mitochondrial 
respiratory chain. Specifically, HCR soleus had greater abundance of cytochrome b-
c1 complex subunit 1 and cytochrome c oxidase subunit 4, isoform 1, which were 
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included in the oxidative phosphorylation gene-set enriched in HCR gastrocnemius 
muscle. In addition, 3-ketoacyl-CoA thiolase (THIM) and enoyl-CoA hydratase 
(ECHM) included in the HCR gastrocnemius gene-set “Fatty acid oxidation” were 
also more abundant in HCR soleus (Table 3).  
 
FABPH exhibited the most prominent difference between HCR and LCR muscles, 
and we used selective reaction monitoring (SRM) to verify this initial discovery. 
SRM assays afford greater selectivity and sensitivity than LC-MS profiling and can 
often be performed more rapidly. During LC-MS profiling relative quantification is 
achieved by monitoring the intensity of parent-ion masses but this may be 
susceptible to interference from unrelated peptides of similar mass-to-charge ratio. In 
contrast, SRM analysis monitors the intensity of a known product-ion mass during 
fragmentation of a selected parent ion (known as a transition) and this additional 
level of filtering affords greater selectivity and sensitivity. SRM analysis of FABPH 
in rat serum has previously been reported by Zhen et al., (2007) and we report an 
identical parent/fragment ion transition can be used in rat skeletal muscle with good 
reliability (i.e., 20% coefficient of variation). Our method development was also 
aided by use of the same MS platform for both LC-MS profiling and SRM (Han & 
Higgs, 2008) and we were able to shorten analysis time per sample by a factor of 10. 
SRM confirmed our discovery by LC-MS profiling that FABPH is significantly 
more abundant in HCR muscle (Figure 6). FABPH binds long-chain fatty acids in 
the sarcoplasm and the abundance of this protein is tightly associated with the 
capacity of muscle to take up fatty acids (Binas & Erol, 2007). Thus the lesser 
FABPH content of LCR muscle is likely to be a key factor contributing to the lesser 
uptake of FA in LCR muscle (e.g., Rivas et al., 2011) under basal conditions. In 
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addition FABPH is also known to have reciprocal effects on the utilisation of 
glucose and long-chain fatty acids during exercise (Shearer et al., 2005). Therefore 
the lesser abundance of FABPH in LCR muscle may also play a role in the relative 
poor running capacity of these animals. Paradoxically, FABPH is less abundant in 
muscle of normal-weight individuals compared to obese and morbidly obese patients 
(Hittel et al., 2005), which may be expected to have relatively poorer exercise 
capacity. This phenomenon is likely to be connected with the elevated storage of 
intramuscular triacylglycerides, which occurs in both obese individuals and 
endurance-trained athletes (Shaw et al., 2010).  
 
Proteomic analysis of human myofibrillar proteins 
In the present study the results show the separation of human MyHC isoforms in 
mini-format SDS-PAGE stained with Coomassie colloidal blue. The average 
percentages were MyHC I (52.4%), MyHC IIa (38.4%), and MyHC IIx (9.2%) in the 
vastus lateralis homogenates (Figure 6). This demonstrates that we were able to use 
the traditional biochemical analysis as a point of comparison for developing 
proteomic techniques in human muscle samples. Consistent with previous studies 
relating to aging, we report differences in MyHC isoform profile exhibiting a loss of 
type IIx fibres and increase in the abundance of type I and type IIa fibres in older 
compared to young adults. Similarly, Andersen et al., (1999) reported that MyHC I 
and MyHC IIa were significantly greater in elderly participants compared to younger 
participants. The effect of increasing age on the human skeletal muscle may also 
influence fibre size and fibre number, mostly of type 2 fibres has also been reported 
(Lexxel et al., 1988) but our biochemical techniques are not able report data on these 
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variables. Many studies regarding MyHC report that participants undergoing 
resistance training have the ability to produce a shift from MyHC IIx to IIa (Adams 
et al., 1993; Carroll et al., 1998; Jurimae et al., 1996). Andersen et al., (1999) 
reported that there were small percentages of the MyHC IIx isoform in young trained 
participants but MyHC I and MyHC IIa were significantly greater in elderly 
participants compared to younger participants. In the present study (Figure 6) the 
result showed a similar outcome where the young and elderly trained had less MyHC 
IIx and a greater abundance of MyHC IIa. Williamson et al., (2000), reported there 
were significantly increase in the expression of MyHC I (pre 50.4 ± 6.7 and post 
51.9 ± 7.9 %) as a result from low intensity training. In the study reported here that 
both untrained and trained elderly showed 0 % of MyHC IIx. This is supported by 
Sharman et al., (2001) reporting that MyHC expression with aging is not associated 
with increases in MyHC IIb/x isoform. The elderly trained had the greatest 
abundance MyHC I (89.2 %), which may be due to the combined effects of ageing 
and endurance training. 
 
The results using SDS-PAGE 15% for low molecular weight (LMW) myofibrillar 
proteins also suggests training status alters the expression of the myofibrillar 
proteome. However the only significant difference was evident in band 8 where the 
volume of MLRS protein was highest in YU group and lowest at OT group. MLRS 
is the skeletal muscle isoform of myosin regulatory light chain 2 and is 
predominantly found in fast-twitch skeletal muscle. This finding is consistent with 
our preliminary results of myosin heavy chain profile that show in YU group they 
have 47.6% type II fibre and in OT group they have only 10.8% type II fibre. This is 
consistent with the selective atrophy in type II fibres with increasing age (Lexell & 
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Taylor, 1991). Proteomic analyses of human muscle samples also provided further 
information on ageing induced decline in myofibrillar isoforms, with young males 
showing higher band volume than older. However, 1-DE combined with MS 
analyses identified multiple proteins within each band making it difficult to 
determine specific changes in individual proteins, supporting a need for more 
thorough protocol such as 2-DE. 
 
There were many studies conducted using the two dimension electrophoresis method 
in proteomics using human muscle samples (Hojlund et al., 2003; Capitanio et al., 
2005; Holloway et al., 2009; Hody et al., 2011; Hartwig et al., 2014;  Conti et al., 
2014).  Previous work in our lab (Holloway et al., 2009) used large format 2D (13cm) 
gel and resolved 256 spots, and paired t-tests identified 20 significant differences in 
expression (false discovery rate less than 10%). The differences in spot expression 
represent changes in post-transcriptional or post-translational processing. 
Furthermore studies using larger format 2D (18cm) gel, resolved more than 500 
protein spots on each gel were detected by silver staining, of which 150 were excised, 
digested in-gel with trypsin and characterized by matrix assisted laser desorption 
ionization-mass spectrometry and tandem electrospray mass spectrometry (MALDI-
MS/MS). Using these techniques, 124 spots including contractile proteins and 
metabolic enzymes were identified. Our current work used small format 2D gel 
because the myofibrillar fraction was expected to be less complex and using this 
method we were able to separate the myofibrillar isoforms into 91 spots (Figure 9). 
Gel spots were cut and processed by manual in-gel tryplic digestion in preparation 
for LC-MS/MS analysis. In total, 59 spots were successfully identified (Table 9). 
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From 59 spots there were 26 unique proteins were discovered in multiple spots, 
which may represent different splice variants or post-translational modification. 
 
2D gel electrophoresis did not resolve all of the expected abundant myofibrillar 
proteins for example MyHC, Myosin binding protein C, alpha actinin-2 were 
missing. Therefore, differential analysis using high-performance liquid 
chromatography online mass-spectrometry was used to overcome this resolution 
problem. Yi et al., (2008) used HPLC-ESI-MS/MS analysis and managed to identify 
507 proteins and the majority of the proteins identified by mass spectrometry also 
had their corresponding transcripts detected by microarray analysis, although 73 
proteins were only identified in the proteomic analysis. In addition, the combination 
of 1D gel electrophoresis and HPLC electrospray ionization tandem mass 
spectrometry, managed to identify 954 different proteins in human vastus lateralis 
muscle obtained from three healthy participants (Hojlund et al., 2008). In the current 
work a total of 49 unique protein entries (484 peptides) mapped to features in 
progenesis LC-MS and were used for quantitative analysis. This number of proteins 
is greater than number of protein by 2D gels, and includes protein such as MyHC, 
Myosin binding protein C and alpha actinin-2 not detected by 2D gel electrophoresis. 
 
LC-MS profiling was conducted to investigate whether this proteomic technique 
could provide a more automated method for muscle phenotyping. Myofibrillar 
proteins were identified by mass spectrometry and database searches were checked 
for the existence of expected myofibrillar proteins listed by Schiaffino & Reggiani 
(2011) (Table 14). The listed proteins were grouped according to the main structural 
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components of the sarcomere (Figure 11). All proteins of the thin filament and most 
of the thick filament were detected. However, relatively few proteins of the Z-Disk 
and M-Band were detected, which may be due to their relatively low abundance 
compared to the main myofibrillar proteins. 
Table 14. List of Mascot protein identifications with the main components of the 
striated muscle.  
Schiaffino (2011) 
Accession 
Proteinscape Protein name 
# of 
spots 
Z-DISC       
α-actinin-slow       
α-actinin-fast ACTN2_HUMAN Alpha-actinin-2 73 
FATZ-2 (calsarcin-1)      
FATZ-1 (calsarcin-2)      
FATZ-3 (calsarcin-3)      
ZASP      
Myotilin, palladin, 
myopalladin      
FHL1 (SLIM1)      
αB-crystallin      
Muscle LIM protein LDB3_HUMAN LIM domain-binding protein 3 48 
THIN FILAMENT      
Actin  ACTS_HUMAN Actin, alpha skeletal muscle 74 
Tropomyosin-α-fast TPM3_HUMAN Tropomyosin alpha-3 chain 20 
Tropomyosin-α-slow TPM1_HUMAN Tropomyosin alpha- 1 chain  67 
Tropomyosin-β TPM2_HUMAN Tropomyosin beta- chain  68 
TnC-fast TNNC2_HUMAN Troponin C, skeletal muscle  
TnC-slow TNNC1_HUMAN 
Troponin C, slow skeletal and 
cardiac muscles  
TnI-fast TNNI2_HUMAN Troponin I, fast skeletal muscle  
TnI-slow TNNI1_HUMAN Troponin I, slow skeletal muscle  
TnT-fast (splicing TNNT3_HUMAN Troponin T, fast skeletal muscle 43 
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var) 
TnT-slow (splicing 
var) TNNT1_HUMAN 
Troponin T, slow skeletal 
muscle 21 
M-BAND      
Myomesin-1      
Myomesin-1 EH 
variant     
 
Myomesin-2 
(Mprotein) MYOM2_HUMAN Myomesin-2 
 
Myomesin-3      
THICK FILAMENT      
MyHC-1 or β/slow MYH7_HUMAN Myosin-7   
MyHC-2A MYH2_HUMAN Myosin-2   
MyHC-2X MYH1_HUMAN Myosin-1   
MyHC-2B MYH4_HUMAN Myosin-4  
MyHC-eo MYH13_HUMAN Myosin-13  
MyHC-emb MYH3_HUMAN Myosin-3  
MyLC-1s MYL1_HUMAN 
Myosin light chain 1/3, skeletal 
muscle isoform  
17 
MyLC-1f/3f MYL3_HUMAN Myosin light chain 3   
MyLC-2f MLRS_HUMAN 
Myosin regulatory light chain 2, 
skeletal muscle isoform  
11 
MyLC-2s MLRV_HUMAN 
Myosin regulatory light chain 2, 
venticular/cardiac muscle 
13 
MBP-C-slow MYPC1_HUMAN 
Myosin binding protein C, slow 
type  
  
MBP-C-fast       
Titin long isoforms       
Titin short isoforms       
The list showing the main components of the striated muscle sarcomere (Schiaffino 
& Reggiani, 2011) and the mutual list of proteins identified in Mascot proteinscape. 
All proteins detected as Schiaffino list in thin filament and most in thick filament. 
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Difference in protein abundance were calculated by linking the regulation ratios 
determined in Profile Analysis for each of the identified peptides from the parent 
protein. In total, the current study resolved 265 peptide features (termed ‘buckets’), 
which were exported to SPSS for statistical analysis. Two-way ANOVA revealed 40 
of these features exhibited statistically significant differences but just 19 of these 
were identified when aligned with the Mascot protein identifications. There were 
significant differences in the abundance of peptides from myofibrillar proteins such 
as MyHC, actin, MyLC and troponin. However, while we saw numerous peptides 
identified as MyHC it was not possible to determine the specific isoform (e.g. 
MYH7, MYH1 etc.) because these peptides originated from regions of the protein 
that are identical across all isoforms. In contrast, several isoform-specific peptides 
were identified for the essential and regulatory MyLC. The profiling data suggested 
that the fast skeletal muscle isoform of regulatory myosin light chain (MLRS) was 
more abundant in the muscle of young untrained people, whereas the fast isoform of 
myosin essential light chain (MYL1) was significantly less abundant in muscle of 
elderly compared to young adults. 
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Figure 11. Illustration of the structure of thin filament and thick filament; and its 
main protein components that are known to exist as multiple isoforms. Protein 
identifiers and descriptions are from the Swiss-Prot database. The MOWSE score 
and sequence coverage for each protein are also reported from the database searches. 
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During LC-MS profiling relative quantification is achieved by monitoring the 
intensity of parent-ion masses but this may be susceptible to interference from 
unrelated peptides of similar mass-to-charge ratio. Therefore we checked our data by 
performing MRM assays for MYL1, MYL3 and MLRS peptides. SRM assays afford 
greater selectivity and sensitivity than LC-MS profiling because the analysis 
monitors the intensity of a known product-ion mass during fragmentation of a 
selected parent ion (known as a transition). This additional level of filtering affords 
greater selectivity and sensitivity and using this approach we were able to 
independently confirm our profiling data. 
 
Our findings are consistent with other biochemical and proteomic studies of muscle 
exercise and ageing. A study conducted by Larsson et al. (1997) reports the effects of 
aging on shortening velocity of single human muscle fibres and used SDS-PAGE to 
measure the composition of MyHC and MyLC. Similar to our experience, they were 
unable to clearly resolve myosin light chains because of the uncertainties due to co-
migration of other myofibrillar proteins such as troponins. Nonetheless, Baumman et 
al. (1987) reports high-intensity endurance training increases the abundance of the 
slow ventricular isoform of regulatory myosin light chain. Similarly, a more recent 
study by Reidy et al., (2014) reports the fast regulator isoform (MLRS) was less 
abundant in competitive compared to recreational runners. Gelfi et al., (2006) reports 
2DGE analysis of age-related differences in human muscle proteins, including a 
relatively lesser abundance of the fast skeletal muscle regulatory light chain in 
muscle of elders compared to young individuals. Because Gelfi et al., (2006) and our 
current work are each cross-sectional studies, it is important to note the difference in 
our findings may be related to differences in the myofibre profiles of either the 
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young or elderly populations. Because Gelfi et al., (2006) did not report 
physiological data regarding their participants it is not possible to compare their 
exercise capacity with the participants used in Cobley et al., (2012), which were the 
substrate for the current work.   
 
 
  
82 
 
1.5 CONCLUSION 
 
This study investigated whether it was feasible to use proteomic techniques to 
perform muscle phenotyping. Both traditional biochemical analysis (e.g. SDS-PAGE) 
and advanced proteome techniques (e.g. multiple reaction monitoring) were 
investigated. We report SDS-PAGE can be used to analyse MyHC isoforms but this 
technique does not offer sufficient resolution of low molecular-weight myofibrillar 
proteins. Indeed, MS analysis and 2DGE separation each showed that the majority of 
SDS-PAGE protein bands contain numerous myofibrillar proteins. Simple LC-MS 
profiling was able to identify almost all expected myofibrillar proteins and detect 
some significant differences between samples from young and elderly, trained and 
untrained individuals that supported the differences in muscle MyHC fibre profile. 
Nonetheless, relatively few of the identified proteins could be quantified. On balance, 
we find ‘bottom-up’ analysis is best suited to mining of the myofibrillar proteome, 
whereas ‘top-down’ analysis using 2DGE is better suited to differential profiling of 
the myofibrillar proteome. 
 
The proteomic techniques development for automated analysis of myofibrillar 
proteins enhanced the level of sophistication of human myofibre phenotyping. To 
date attempts to study the myofibrillar sub-proteome in human muscle have been 
largely incomplete, therefore study of changes in myofibrillar proteins beyond 
MyHC are needed to more accurately understand the mechanisms that underpin the 
f-v characteristics of human muscle that will be discussed in next chapter.   
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Chapter 2 
Measurement of the Force-Velocity Profile of Human Skeletal 
Muscle 
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Chart to contextualise Chapter 2 
 
In this chapter, the study progression is quite complex so Figure 12 is included to 
guide the reader through this multi-component chapter.   
 
Figure 12. Chart to contextualise the chapter and help to see more clear progression 
and development of Chapter 2. 
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2.1 INTRODUCTION 
Chapter background 
Muscle power output 
Muscle power output is a key determinate of success in many sports, in particular 
those involving jumping, sprinting and rapid changes in direction. The power output 
of a muscle is a function of its ability to produce force while shortening rapidly 
(power being the product of force*velocity). Many sports require forceful high-
velocity movements but the force-velocity relationship of skeletal muscle (Figure 13) 
dictates that the force produced by a muscle decreases as the velocity of the 
contraction increases. The force-velocity relationship was first described by Hill 
(1938) and Katz (1939) and later summarized by Hill in 1970 as a rectangular 
hyperbolic equation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. An illustration of the force-velocity relationship of skeletal muscle. 
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Skeletal muscles are velocity- and length-dependent force producers. Because of this 
velocity- and length-dependence, movement necessarily alters the force produced by 
a muscle.  Hakkinen et al. (1985) state that only the motor units that are recruited in 
a specific exercise will produce force and will therefore respond and adapt to a 
resistance stimulus. However, the force-velocity characteristic of skeletal muscle is 
actually a fundamental property of the cross bridge cycle rather than motor unit 
recruitment (Duchateau et al., 2006). Specifically, the force-velocity relationship is 
underpinned by the cross bridge cycle and the number of myosin heads that are able 
to contribute to force output during a contraction. Therefore, the profile of myosin 
heavy chain isoforms has a major influence of force-velocity curve.  These aspects of 
muscle physiology have been studied in animal models to understand the 
relationship between skeletal muscle design and performance. However, measuring 
muscle performance in humans in vivo is more difficult because of voluntary 
activation and the effects of synergist and antagonist muscle groups. Nonetheless, it 
is important to try to measure human muscle outputs because animal models cannot 
be used to study complex sport-related movements.  
 
Single fibre measurements have been used to investigate the effects of sport-related 
movements or sports training in humans. Analysis of the force-velocity profile of 
single muscle fibres in vitro reveals plyometric jump training increases the maximal 
shortening velocity of myofibres to a greater extent than the increases in cross 
sectional area and peak isometric force (Malisoux et al., 2006). This may be due to 
changes in the calcium sensitivity of human single muscle fibres following 
plyometric training as Malisoux et al., (2006) reported increased calcium sensitivity 
especially in type I fibres. This is suggests that velocity profile of a particular muscle 
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fibre type can be changed without altering its MyHC content. These measurements 
performed on skinned fibres in the absence of neural input provide clear evidence 
that jump training is able to alter the fundamental properties of skeletal muscle and 
affect the curvature of the force-velocity relationship. However, traditional 
biochemical analysis was not able to define the exact protein modification that was 
responsible for this effect. 
 
We will attempt to explain differences in human muscle performance in vivo by 
proteomic analysis. Proteomics will provide more comprehensive analysis can be 
conducted in an ‘unbiased’ non-targeted manner to discover new information. 
However, relatively large amounts of muscle are required to develop this method so 
whole samples of muscle needle biopsies (i.e. ~50 mg) of muscle are required, rather 
than single fibres. Therefore, we were keen to find the most robust or precise 
measurements of isolated limb movements so that changes in muscle performance 
could be correlated with the muscle proteome. Moreover, we sought to find a 
selection of techniques that were capable of analysing the entire force-velocity range 
of muscle. This is particularly important because changes in maximum force are 
likely to be explained by myofibre hypertrophy whereas changes in the make-up of 
the muscle myofibrillar proteome are likely to affect the native of the force-velocity 
curve and perhaps modulate velocity to a greater extent than force. Lastly, we were 
interested in relating our findings to sporting movements so we chose to use isolated 
knee extension as our model of muscle function.  
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Biopsy samples can be taken from the quadriceps muscles responsible for knee 
extension and we also hypothesised that the force output of the knee extensors could 
be correlated with power output during a squat jump, which is a sport-related 
movement. Analysis of squat jumps has been used to detect significant differences in 
force-velocity and power-velocity profiles either across different training 
backgrounds (e.g. Cormie et al., 2009 ; Cormie et al., 2010) or responses to different 
training interventions (Cormie et al., 2010a). Moreover, squat jump power-output is 
commonly used as a screening tool or performance indicator in athletic populations. 
Previous work by Iossifidou et al., (2005) has reported a correlation of power 
generation between knee extension IKD and the squat vertical jump performance. 
Iossifidou et al., (2005) measured knee joint power generation during a concentric 
knee extension isokinetic test and a squat vertical jump and they found a stronger 
correlation at the highest velocities (300˚.s-1). However, there is a large difference in 
knee angular velocity and peak power between squat vertical jump which typically > 
450˚.s-1 and knee extension at 300˚.s-1 IKD. For example, significant differences 
were found between knee joint power in the two tests performed by Iossifidou et al., 
(2005) to trained basketball player and track and field athletes (squat vertical jump: 
2255 ± 434 W; isokinetic knee extension: 771 ± 81 W).   
 
Several studies (Aragon & Gross, 1997 ; Bobbert et al., 1986) investigating joint 
kinematics during jumping state that knee angular velocity during vertical jump is 
approximately 15 rad.s
-1, which is equal to 860˚.s-1. However, in interpreting the 
relationships, the squat vertical jump involves both legs and is also influenced by the 
action of the bi-articular muscles and there is a combined transfer of energy between 
joints. So the velocity during isolated knee extension is likely to be less.  
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Techniques for investigating the force-velocity profile of the knee extensors 
There are various techniques that can be implement to test the muscles capability to 
produce force with difference speed of contraction. Isokinetic testing can be used to 
investigate power output and also differences in the force-velocity profile of muscle 
groups. Isokinetic dynamometers control the velocity of joint flexion or extension by 
applying variable resistance throughout the range of motion. Therefore the velocity 
of joint rotation is constant, excluding acceleration to and deceleration from the 
designated velocity and the force is dependent on how hard the individual pushes 
against the load cell (Huang et al., 2003). IKD can be used at low, moderate and high 
velocities depending on the different evaluations or programs and provides reliable 
data. Data acquisition and analysis have been improved by using computer systems 
interfaced to isokinetic dynamometers. Recently developed computer systems 
provide correction for gravitational and inertial errors, accurate computation of 
isokinetic parameters and real-time display of the torque output.  
 
Kanehisa & Fukunaga (1999) reported isokinetic muscle contractions at velocities of 
60, 180 and 300 deg/s and investigated difference in force output of weight lifters 
compared to untrained participants. This study was designed to determine velocity-
specific isokinetic forces and cross sectional areas of reciprocal muscle groups 
measured by B-mode ultrasonic apparatus in weight lifters (n = 34) and untrained 
male participants (n = 31). Force declined at higher velocity movements (as expected 
from muscle force-velocity curve) in both sedentary individuals and Olympic weight 
lifters. However, this effect was less pronounced in Olympic weight lifters and this 
trend may be due to adaptations induced by their training regimen, which places 
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emphasis on high velocity movements. These findings suggest isokinetic 
dynamometry could be used to study the force velocity profile of human muscle 
groups in vivo but first we wanted to confirm that a commercial isokinetic 
dynamometer was able to measure the entire range of velocities produced during 
knee extension.  
 
2.2 Pilot Studies 
Pilot study I 
The aim of this pilot work was to establish a simple technique for measuring peak 
angular velocity of knee extension during unloaded kicking and to determine the 
maximum angular velocity of the knee during unloaded. An appropriately positioned 
linear encoder (Figure 14) may be used to calculate knee angular velocity during 
unloaded kicking. Therefore we investigated the correlation between linear encoder 
and kinematic measurement of angular velocity using a camera system during 
unloaded kicking. If successful, this technique could provide a simple measurement 
of maximum velocity. 
 
One healthy male participant volunteered to participate in the study and performed 
10   unloaded kicks (knee extension) at different velocities in order to determine 
maximum angular velocity at knee extension. Angular velocity, acceleration, 
moment of force, and power development during maximal unloaded knee extension 
were determined using ProReflex Motion Capture System (Qualisys, Sweden) 
(Figure 14). Ten maximal unloaded knee extensions were performed at varying 
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velocities separated by rest periods of 30 s. Trials with a visible countermovement 
were discarded. A cuff was strapped around the lower leg, approximately 2 cm 
above the medial malleoli and connected to a linear velocity encoder (MuscleLab 
Ergotest version 4010, Norway). Average velocity (AV) was recorded during each 
kick. The lower leg is allowed to move freely. The participant was instructed to 
extend their right knee “as fast as possible” into a kicking pad (Figure 14). The 
movement range was from 90° knee flexion, which is the relaxed starting position, to 
~5–10° from full extension. During the test sessions, three-dimensional motion 
analysis was performed with an Oqus Motion Capture System (Qualisys, Sweden). 
Twelve markers were used in total for dynamic trials (Iliac crest, knee medial 
epicondyle, knee lateral epicondyle, upper leg proximal anterior and posterior, upper 
leg distal anterior and posterior, lower leg proximal anterior and posterior, lower leg 
distal anterior and posterior, maleolus lateral) and attached on the right side. Data 
were transferred to Windows-based data acquisition software (Qualisys Track 
Manager). This system includes an advanced optoelectronic camera system that 
produces clean and accurate 3D data and also recording velocity. All modelling and 
analysis was undertaken in visual D (v.4.83, C-Motion, Germantown, MD, USA) 
using geometric volumes to represent segments (Hanavan, 1964) based on cadaver 
segmental data (Dempster, 1955). 
 
Data from the linear encoder (MuscleLab) were record as meter per second linear 
velocity, therefore, to compare between the camera systems, which give angular 
velocity, the MuscleLab data must be converted into angular velocity (Table 15). 
Angular velocity is equal to theta (degree/one radian=57.2958) multiplied by 
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distance (length in metres) from participant’s knee to the attachment of the linear 
encoder at their ankle.  
 
A 
 
B 
 
Figure 14.  Apparatus for measuring maximum velocity of unloaded knee extension 
(A) Leg in rest position and (B) Leg extended to kicking pad. 
 
 
Table 15. Conversion of MuscleLab data to angular velocity.  
Velocity (m/s) (/)ℓ In 
meter 
ω (sec x 57.2958) Peak angular velocity 
(degree/sec) 
1.46 0.36 4.06 232.4 
1.27 0.36 3.53 202.1 
0.95 0.36 2.64 151.2 
0.94 0.36 2.61 149.6 
1.29 0.36 3.58 205.3 
1.59 0.36 4.42 253.1 
1.79 0.36 4.97 284.9 
1.81 0.36 5.03 288.1 
1.70 0.36 4.72 270.6 
1.91 0.36 5.31 304.1 
Equating angular velocity, v=ωxℓ. Equating velocity on linear speed, v=m/s where 
v=velocity, m=meter, s=second, ω=angular speed, ℓ=length (participant’s leg) Each 
one of the degree represent one kick or attempt. 
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The correlation between the velocity of unloaded kicks measured by the Qualisys 
Track Manager and calculated from the linear encoder is shown in Figure 15. 
Correlation coefficients measure the strength of association between two variables, 
and we found a strong positive relationship 0.9382 between the two measurement 
techniques.   
 
 
ML 232.4 202.1 151.2 149.6 205.3 253.1 284.9 288.1 270.6 304.1 
QTM 384.6 310.3 280.2 280.9 336.4 425.4 475.5 438.1 438.1 528.9 
 
Figure 15. Correlation between ML and QTM. 
Angular velocity is reported in degrees per second (Ω) measured by the Qualisys 
Track Manager (QTM) camera system or calculated from the MuscleLab (ML) 
linear encoder. 
 
We conclude that measurement of linear displacement using MuscleLab can be used 
to measure angular velocity at knee during maximum unloaded kicking. However, 
the average maximum angular velocity of knee extension measured using the QTM 
system was 362˚.s-1, and the highest value was 528˚.s-1. This contrasts with Andersen 
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et al., (2005) that reports changes in the human muscle force velocity relationship 
during training and detraining, and found peak unloaded kicking angular velocity 
after detraining was ~800˚.s-1 measured by flexible goniometer. This maybe due to 
differences in the methods or participants of the two studies. We recruited a 
recreationally active person, whereas Andersen et al., (2005) studied trained athletes. 
Nonetheless, this range of velocities is close to the range (0-500 ˚.s-1) that can be 
measured by the Biodex 3 isokinetic dynamometer (Multi-Joint System 3 Pro; 
Biodex Medical Systems, New York, USA). Therefore a further study was 
conducted to investigate whether IKD was capable of measuring the entire range of 
velocities in an untrained population.  
 
Pilot study II 
Five healthy sedentary male volunteered to participate in the high velocity isokinetic 
dynamometry study. The mean (± SD) age, height, body mass were 25 ± 2.5 years, 
179.4 ± 8.6 cm and 79.4 ± 8.8 kg, respectively. Consistent with Drouin et.al (2004) 
the biodex was set to 500˚.s-1 and knee extension and flexion performance was 
measured according to standard protocols using an isokinetic dynamometer. Strict 
adherence to the guidelines of the Biodex isokinetic dynamometer operations manual 
was followed. Participants were familiarized with use of the dynamometer and 
testing procedures prior to the measurements. Each participant completed a warm-up 
protocol prior to muscular performance. The warm-up session included 5 minutes 
cycling at 150 W on a cycle ergometer (Monark Ergomedic 824E) and a 
standardised routine of quadriceps and hamstrings stretching exercises. Then 3 to 5 
specific warm-up trials (50 % effort) were conducted on the isokinetic dynamometer 
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prior to completing 5 maximal velocity attempts. We found none of the participants 
were capable at achieving the maximum 500˚.s-1 angular velocity. Because the 
Biodex software only measures power when the prescribed velocity is reached, force 
and power data are not reported for these experiments. We conclude that the 
maximum pre-selected angular velocity for future work should be 450˚.s-1 because 
participants can achieve that speed and power data will be recorded.  
 
In summary, our pilot findings suggest isokinetic dynamometry can be used to 
investigate the entire range of velocities (i.e. from isometric to velocity maximum) of 
knee extension in normal human participants. Therefore it is not necessary use a 
separate analysis technique (unloaded kicking). However, it was still necessary to 
prove that IKD is a reliable measurement tool across this range of velocities because 
few other studies report IKD at velocities > 300˚.s-1. Also it was still unknown 
whether there is a correlation between IKD knee extension and Max power (or 
similar) during vertical jumping, i.e. external validity. 
 
Therefore, the information that we gathered from pilot studies will be applied in the 
main study of this chapter (i) to investigate the feasibility of using isolated knee 
performance to measure the force-velocity profile of human muscle in vivo and (ii) 
to test the reliability by using standard isometric and IKD in analyses of isolated 
knee exercise. 
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Rational of this study 
Previously, analysis of squat jumps has been used to detect significant differences in 
force-velocity and power-velocity profiles either across different training 
backgrounds (e.g. Cormie et al, 2009 ; Cormie et al, 2010) or responses to different 
training interventions (Cormie et al., 2010a). The squat jump technique is used 
extensively to assess the performance of athletes but it encompasses simultaneous 
extension of ankle, knee and hip joints and delineating links between this complex 
movement and the myofibrillar proteome of a specific muscle would be challenging. 
To overcome this difficulty we will investigate the feasibility of using isolated knee 
performance to measure the force-velocity profile of human muscle in vivo.  
 
Aim of this study 
We will conduct force-velocity and power-velocity analyses of isolated knee 
exercise using standard isometric and IKD and test the reliability at these 
measurements. If these are found to be reliable we will use this protocol as the main 
physiological assessment in our subsequent studies. A further aim of this study was 
to investigate the reliability of jump analysis by force platform and investigate 
whether isolated knee extension data can be correlated with indices of jump 
performance. 
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2.3 METHODS 
Measurement on force platform and isokinetic dynamometry  
2.3.1  Participants 
Eleven male participants with different sporting backgrounds (e.g sprinter, rugby 
player, footballer etc.) participated in this study, which was approved by LJMU 
ethics committee reference number 12/SPS/013. The mean (± SD) age, height, body 
mass were 24.9 ± 3.1 years, 176.2 ± 7.1 cm and 80.2 ± 10.1 kg, respectively. 
Participants were questioned on their training history and the Physical Readiness 
Questionnaire (PAR-Q; Thomas et al., 1992) was used as a screening tool to assess 
each volunteer’s level of physical fitness and ability to engage in physical activity. 
Each participant was required to perform 4 sessions (1 introductory session and 3 
repeated experiment sessions). Briefly, the sessions consisted of squat jumps on a 
force platform and then isokinetic dynamometry of knee extension movement at 5 
different velocities. All measurements were performed at the same time of day for 
each participant to limit diurnal variation (Reilly and Waterhouse, 2009). 
 
2.3.2 Force platform 
Jump performance was assessed in order to investigate whether a correlation exists 
between isolated knee performance measured by IKD and whole body jump 
performance. Performance during jump squat was measured by force platform and 
linear encoder (Muscle Lab, version 4010, Norway). Objective of this testing was to 
investigate the correlation of average velocity data collected by linear encoder and 
force platform. Each participant performed an extensive dynamic warm-up 
(consisting of squat, lunge and jump squats), which was standardised and repeated 
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before each session. After completing the warm-up, each participant performed a 
countermovement jump for three repetitions. Participants held a 0.4-kg rigid plastic 
pole across their shoulders. The linear encoder was attached at the pole via a fine 
string. The linear encoder was placed directly under the axis of travel.  
 
During each jump, participants were instructed to step on the force platform and 
stand still while the force platform offset was zeroed. They were then instructed to 
jump as high as possible, using a single countermovement jump. The basic 
description process was STEP ON, JUMP and then STEP OFF. Only trials in which 
participant reached a relative knee angle (i.e., angle between the midline of the lower 
leg and the midline of the thigh) <90° of flexion were considered successful. 
Participants were reminded to squat as low as they can during the jumping phase.  
 
Acknowledge software (FPL-960.acq file) was used to display the force data from 
analogue signals collected from the floor-mounted force platform (Kistler, UK). 
MuscleLab software (Ergotest, Norway) of the linear encoder made simultaneous 
measurements during each jump. To provide a comparison between force platform 
data and the linear encoder output data were extracted from force platform analysis 
and used to calculate average power force and velocity. Force and time data were 
extracted from the point of transition between counter movement and jump. 
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2.3.3 Isokinetic dynamometry 
 IKD was performed at different velocities to investigate the reliability of data across 
f-v curve. Knee extension and flexion performance was measured according to 
standard protocols using an isokinetic dynamometer (Multi-Joint System 3 Pro; 
Biodex Medical Systems, New York, USA). Strict adherence to the guidelines of the 
Biodex isokinetic dynamometer operations manual was followed. Participants were 
familiarized with use of the dynamometer and testing procedures prior to the 
baseline measurements to reduce possible influences of test habituation on muscular 
performance. Each participant completed a warm-up protocol prior to analysis of 
their muscular performance. The warm-up session include 5 minutes cycling on a 
cycle ergometer (Monark Ergomedic 824E) set with 150 W resistance and a 
standardise routine of quadriceps and hamstrings stretching exercises. After a 5 
minutes rest on completion of the warm-up, the participants were instructed to 
continue with the testing procedure. 
 
The participant was seated; leaning against a backrest inclined at 16˚ from vertical 
and with the seat inclined 6˚ from horizontal. The axis of the knee was aligned with 
the axis of the Biodex dynamometer exercise arm. The accuracy of alignment was 
checked by allowing the participant to extend the leg while pushing against the shin 
pad that was positioned over the lower third of the leg. If the pad did not move up or 
down the leg over the range of motion to be tested, the knee was considered to be 
aligned with the axis of the lever arm.  
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The participant’s position was secured using thigh, pelvic and torso straps in order to 
minimize body movements during the test procedure. Shoulder straps were applied 
diagonally across the chest with the participant’s arms crossed and their palms on 
opposite shoulders to minimize excessive upper body movement and muscular 
substitution. The lateral femoral epicondyle was used as a bony landmark for 
matching the axis rotation of the knee joint and the axis rotation of the dynamometer 
shaft. 
 
Each participant used the same radius for each test but the angular velocities were 
tested in a different order for each session using balanced Latin Square design. Test 
angular velocities were set at 60˚.s-1, 120˚.s-1, 240˚.s-1 and 450˚.s-1. Participants were 
asked to do 3 repetitions of extension and flexion for each angular velocity. One 
minute rest was given between each angular velocity. Peak torque (PT) and average 
power (AV) were recorded and exported as an excel file for further analysis through 
the report after the testing. 
 
After completing the isokinetic test, participants were asked to remain at the same 
position and rest for 5 minutes. Meanwhile the protocol was changed to isometric 
mode. The participants performed isometric contractions at a static knee joint angle 
at 60°. They were instructed to extend their knee “as fast and hard as possible” and 
sustain the maximal voluntary isometric contraction for two seconds. The 
participants were asked to do 3 repetitions with 60 seconds rest between each 
attempt. 
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2.3.8 Data analysis  
The data were analysed using Statistical Package for Social Sciences (SPSS) version 
17.0 software (SPAA v.17, SPSS Inc, Chicago). To assess reliability across the three 
testing, one way ANOVA analysis repeated measures was used to analyse the main 
effects of time. Bonferroni test for multiple comparisons was used to determine the 
differences when one way ANOVA repeated measure showed a significant effect of 
time. Significance level was set at <0.05, and all data were presented as mean + SD. 
Furthermore we look at the reproducibility. Typically reproducibility is expressed as 
a coefficient variation (CV) relative to measurement value. There are various 
methods of calculating CV, the simplest method is with data from repeated 
measurements on a single case, where the standard deviation (SD) of the error is 
divided by the total mean and multiplied by 100 (Sale, 1991). 
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2.4 RESULTS 
Force platform and isokinetic dynamometry 
Eleven participants completed each of the 3 repeated trials according to the protocol 
design and were included the analysis. The average jump height across the 3 trials 
was 0.334 ± 0.07 m and the peak ground reaction force and power output were 
1739.82 ± 212.86N and 4.54 ± 0.90W/kg respectively. Average velocity measured 
by MuscleLab was 1.73 ± 0.14 m/s, data were also extracted from force platform and 
average velocity was calculated during the jump phase D – F in figure 16. 
 
 
Figure 16. Typical output from force platform jump analysis. 
Force (N) was recorded during CMJ using AcqKnowledge 3.9 software. A. Standing 
phase. B. Initial momentum phase. C. Start of amortization. D. Peak plyometric 
force. E. Final momentum phase. F. Take off. G. Flight phase. H. Peak plyometric 
force upon landing. 
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This phase relates to the dynamic concentric phase of the jumping movement. When 
calculated from force plot data the average take off velocity was more (2.442 ± 0.312 
m/s) than that recorded by MuscleLab system. Moreover there was no correlation (R² 
= 0.3677) between the data recorded using the force platform and linear encoder 
(MuscleLab system). This demonstrates that ground reaction force is a poor indicator 
of vertical acceleration measured at the shoulder (i.e. bar across shoulder). 
 
 
 
Figure 17. Correlation of jump velocity measured by MuscleLab and take-off 
velocity measured by Force platform. 
Correlation of jump velocity and take-off jump velocity (m/s) measured by two 
different methods. The correlation coefficient at r
2
 = 0.3677. 
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 Isokinetic dynamometry devices control the velocity of limb movement by applying 
variable resistance throughout the range of motion. Thus, excluding acceleration and 
deceleration phase outside of when the velocity of joint rotation is constant and the 
force (N.m) measured is dependent on the maximum strength of the individual at that 
velocity of movement. As such IKD applied over a series of velocities is able to 
provide information relating to the f-v profile of the major muscles contributing to 
the movement. Moreover, because force is recorded at a known velocity of 
movement muscle power output can also be derived from IKD data. Figure 18 shows 
an example trace of IKD data during knee extension-flexion movements. 
 
 
Figure 18. Example torque output during knee extension-flexion movements. 
Torque (N.m) was recorded during 3 isokinetic knee extension (A) and flexion (B) 
movement at angular velocity of 60˚.s-1. 
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Peak torque during knee extension at velocities of 0˚.s-1, 60˚.s-1, 120˚.s-1, 240˚.s-1 and 
450˚.s-1 is shown in Figure 19. Consistent with force-velocity characteristics of 
skeletal muscle, peak torque was greatest during isometric contraction and declined 
as the velocity of contraction increased.   
 
 
 
Figure 19. Knee extension torque-velocity relationship measured using isokinetic 
dynamometry.  
Peak torque data are presented as mean ± SD across 3 repeated trials (n = 11, in each 
trial). Peak torque (Nm) was recorded during isokinetic knee extension at angular 
velocities of 0 (isometric), 60˚.s-1, 120˚.s-1, 240˚.s-1 and 450˚.s-1.  
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Figure 20 reports average power output measured during 3 repeated trials of the 11 
participants. Average power at 60˚.s-1 was 149.87 ± 32.44 W whereas the greatest 
power output (357.03 ± 83.72W) was recorded during knee extension at 450˚.s-1. 
Therefore peak power output occurs with low load and high movement velocity.  
 
Power output at 60˚.s-1 was 42 % of power output, developed at 450˚.s-1 and was 
significantly (p<0.05) different from all other velocities investigated. Power output 
120˚.s-1 was also significant difference from 240˚.s-1 and 450˚.s-1. However there was 
no significant difference between 240˚.s-1 and 450˚.s-1(p=0.11). 
 
Figure 20. Knee extension power-velocity relationship measured using isokinetic 
dynamometry.  
Average power data are presented as mean ± SD across 3 repeated trials (n = 11, in 
each trial). Average power (W) was recorded during isokinetic knee extension at 
angular velocities of 60˚.s-1, 120˚.s-1, 240˚.s-1 and 450˚.s-1.  
* p<0.05 significant different from 120, 240 and 450˚.s-1. 
# p<0.05 significant different from 240 and 450˚.s-1. 
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To investigate this further angular acceleration during knee extension at 450˚.s-1 was 
interrogated. Participants were segregated into two groups based on whether or not 
they achieved peak torque within 0.1 sec of starting the movement. Figure 21 shows 
the mean angular acceleration for the 2 groups. Group 1 includes individuals that did 
not achieve peak torque within the first 0.1 sec of the movement and were 
characterized by a gradual increase in acceleration from 28.12 ± 10.45 rad/s² (Group 
1). In contrast, individuals in group 2 were able to achieve peak torque within the 
first 0.1s and exhibited an average acceleration of 76.31 ± 33.56 rad/s².  
 
 
Figure 21. Knee extension angular acceleration measured using isokinetic 
dynamometry.  
Angular acceleration data are presented as mean ± SD across 3 repeated trials with 
group 1 (n = 5, in each trial) and group 2 (n = 6, in each trial). Angular acceleration 
(rad/s²) was recorded during intervals 0.1 sec isokinetic knee extension at angular 
velocity of 450˚.s-1 ranging from 0-1 sec. 
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To predict variable that correlate most to sport movement like jumping, we used 
backwards stepwise regression. Backwards stepwise regression procedures work to 
deduct from a group the one variable at each stage which makes the smallest 
contribution to R
2
. The dependent variable is regressed on all independent variables. 
If any variables are statistically insignificant, the one making the smallest 
contribution is dropped. Then the remaining variables are regressed on Y, and again 
the one making the smallest contribution is dropped. The procedure continues until 
all remaining variables are statistically significant. 
Table 16.  Regression analysis for maximum power (jump analysis). 
IKD velocities 1 2 3 4 
60 0.473 0.439 0.406  
120 0.927    
240 0.858 0.823   
450 0.004* 0.002* 0.000* 0.000* 
Isometric 0.026* 0.011* 0.004* 0.001* 
Adjusted R
2
 0.763 0.763 0.762 0.756 
Isometric and highest velocities of movement correlated significant with jumping 
power. *P<0.01 
 
 
Test re-test reliability of jump analysis and IKD measurements was assessed using 
repeated measures ANOVA and the coefficient of variation (CV) was calculated for 
major parameters. Jump and IKD data (Table 17) were not significantly different 
across the 3 repeated trials, demonstrating there was no evidence of systematic bias. 
Moreover, post-hoc analysis comparing trials 1-2, 1-3 and 2-3 did not reveal 
significant random effects. The average CV of jump parameters was 3.87 ± 1.9% 
ranging from 1.5 to 5.1%. The CV of IKD measures was relatively greater. The 
average CV was 9.38 ± 3.0 % ranging from 7.0 to 15.7 %. 
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Table 17. Reliability of muscle performance test.  
 Mean ANOVA 
(p) value 
% Coefficient of 
Variation (CV) 
Force Platform 
Height Flight (m) 
Average Force (N) 
Max Force (N) 
Normalised Force 
(N/kg) 
0.334 ± 0.07 0.300 0.0 
1001 ± 163.34 0.487 5.1 
1739.82 ± 212.86 0.633 4.6 
2.18 ± 0.22 0.302 4.8 
Max Power (W) 3649.27 ± 863.44 0.526 5.0 
Normalised Power 
(W/kg) 
4.54 ± 0.90 0.319 5.7 
MuscleLab    
Average Power(W) 1755.55 ± 201.95 0.241 4.4 
Average Force(N) 1014.11 ± 85.9 0.187 1.5 
Average Velocity(m/s) 1.73 ± 0.14 0.231 3.7 
IKD Peak Torque(Nm) 
Isometric 251.22 ± 50.59 0.273 7.9 
60 222.95 ± 40.91 0.181  9.2 
120 195.43 ± 41.95 0.322 7.0 
240 146.39 ± 28.68 0.087 8.4 
450 109.17 ± 17.46 0.213 6.4 
IKD Average 
Power(W) 
   
60 149.87 ± 32.44 0.337 12.7 
120 251.74 ± 58.02 0.308 7.2 
240 331.22 ± 77.55 0.240  15.7 
450 357.03 ± 83.72 0.269 9.9 
Data are presented as means ± SD; n = 11 participants averaged from 3 separate test 
sessions. Jump squat was performed on force platform and recorded using linear 
encoder (MuscleLab). Force and power were normalised by dividing participant 
body weight (kg). Isokinetic dynamometry (IKD) was performed at 5 different 
velocities: 0 (isometric), 60, 120, 240 and 450˚.s-1. Data presented are peak torque 
(Nm) and average power (W) over 3 kicks during knee extension.  
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2.5 DISCUSSION 
 
The overall aim of this study was to investigate the reliability of data produced by 
IKD of knee extension and flexion movement and correlation with jump analysis.  
 
To assess the reliability of force platform and IKD data, ANOVA with repeated 
measures including a correction for ‘sphericity’ (Vincent, 1994) was used for 
assessing systematic bias across repeated tests (Vincent, 1994; Thomas & Nelson, 
1990). Using appropriate post hoc multiple comparisons, random bias between 
individual tests was also assessed. To investigate the correlation of jump and IKD 
methods/protocol, participants performed squat jumps on force platform and then the 
isokinetic dynamometry testing at 5 different velocities at 0˚.s-1, 60˚.s-1, 120˚.s-1, 
240˚.s-1 and 450˚.s-1. In the present study, after 3 repeated sessions of the squat jump 
and isokinetic dynamometry testing, one way ANOVA for repeated measures 
revealed that there was no significant difference across the 3 sessions for any of the 
performance variables that were recorded.   
 
Typically reproducibility is expressed as a coefficient variation (CV) relative to 
measurement value. There are various methods of calculating CV, the simplest 
method is with data from repeated measurements on a single case, where the 
standard deviation (SD) of the error is divided by the total mean and multiplied by 
100 (Sale, 1991). The use of CV assumes that the largest test-retest variation occurs 
in the individuals scoring the highest values on the test (Bland & Altman, 1995). 
Some scientists have arbitrarily chosen an analytical goal of the CV being 10% or 
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less (Stoke, 1985). This does not mean that all variability between tests is always 
less than 10% of the mean. In the current work, percentage of CV was below 10% 
except on 60˚.s-1 (12.7%) and 240˚.s-1 (15.7%) isokinetic knee extension average 
power (W).  Cormack et al (2008) reported in their study on reliability of measures 
obtained during countermovement jumps that all CV were below 10%. In most 
parameters in this study showed no significant different in CV% with current study, 
for instance peak power (W), relative peak power (W/kg), peak force (N), relative 
peak force (N/kg), mean force (N) and height (cm). In height parameter the CV% 
was 5% compared to current study was 0.002%. 
 
Force-velocity relationship 
The force generated by a muscle is a function of its velocity of shortening. The 
force-velocity relationship has been used to define the dynamic properties of the 
cross-bridges which cycle during muscle contraction. Muscles are strengthened 
based on the force placed across the muscle. Higher forces during training produce 
greater adaptation in strength. Therefore, exercise performed with muscle activated 
in a way that allows them to contract at high velocities, necessarily imply that they 
are also contracting with relatively low force. Metaxas et al., (2009) reports the 
physiological profile of soccer and basketball players over a range of peak torques 
based on different velocities using IKD. In soccer division IV players for 60˚.s-1 
testing, the peak torque was 256.1±36.1 Nm and basketball division IV players was 
284.9±51.6 Nm. In 180˚.s-1 testing for soccer the peak torque was 175.5±25.3 Nm 
and basketball was 194.5±33.2 Nm. Meanwhile for velocity 300˚.s-1, soccer player 
peak torque was 123.1±17.5 Nm and basketball 151.5±25.6 Nm. The quite similar 
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peak torque range also detected in professional soccer player in Fousekis et al., 
(2010) study.  
 
Another study made by Alangari & Al-Hazzaa (2004) reports the reference data for 
peak isokinetic muscle strength of hamstring and quadriceps muscles in sedentary 
young adult Saudi males. The peak torque at extension 60˚.s-1 was 172.2±32.9 Nm. 
In 180˚.s-1 testing, the peak torque was 118.2±20.7 Nm and for 300˚.s-1 testing the 
peak torque was 84.5±16.8 Nm. Based on those data, the peak torque data in this 
study is within the expected range for recreational athletes. The result of present 
study indicated that mean knee extension peak torque at 0˚.s-1, 60˚.s-1, 120˚.s-1, 
240˚.s-1 and 450˚.s-1 of the participans during three different test sessions was similar 
with the force-velocity relationship concept. The peak torque at isometric contraction 
was 251.2±49.9 Nm and at extension 60˚.s-1 was 222.9±40.6 Nm. In 120˚.s-1 testing, 
the peak torque was 195.4±40.9 Nm, for 240˚.s-1 the peak torque was 146.3±28.3 
Nm and for 450˚.s-1 testing the peak torque was 109.2±16.9 Nm. The mean peak 
torque at isometric test was high and the peak torque began to decline when the test 
velocity was increased. A previous study by Kanehisa and Fukunaga (1999) reported 
for isokinetic muscle contractions at velocities of 60˚.s-1, 180˚.s-1 and 300˚.s-1 
isokinetic force declined at higher velocities (as expected from muscle f-v curve) in 
both sedentary individuals and Olympic weight lifters. 
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Angle peak torque and muscle acceleration 
Angle at peak torque is the joint angle at which peak torque occurs. The 
characteristic torque-joint angle curve describes relative torque increasing until an 
optimal joint angle is achieved (Margison & Eston, 2001). We observed that the 
angle at which peak torque occurred was affected by movement velocity for some 
participants. This may be due to individual differences in peak angular velocity, 
which only become evident during high movement velocities (i.e. 450˚.s-1). Previous 
study by Kawakami et al., (2002) revealed that angle at peak torque negatively 
correlates with angular velocity, that is as angular velocity increases the angle at 
peak torque decreases.  
 
Kawakami et al., (2002) tested velocities covering a range from 30˚.s-1 to 200˚.s-1 
and reported angles at peak torque occurs ranging from 50-70˚. In the present study 
we also found a distribution of angles at which peak torque occurs of approximately 
60˚ to 80˚ at velocities of 60˚.s-1, 120˚.s-1, and 240˚.s-1. However at velocities of 
450˚.s-1 the distribution was larger, suggesting that the velocity affects the angle at 
which peak torque is developed more so at high movement velocities. The individual 
capability of muscle contraction could be one of the reasons underpinning this 
observation. Therefore, analysis of limb acceleration during 450˚.s-1 knee extension 
may provide important additional information that can be used to correlate with 
molecular difference in muscle composition.  
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2.6  CONCLUSION 
 
The feasibility of isolated knee performance to measure the f-v profile of human 
muscle in vivo using the isokinetic dynamometry (IKD) was investigated. This is an 
appropriate exercise for vastus lateralis, which is a suitable muscle that can be used 
for muscle phenotype/biochemical analysis and muscle function/performance testing. 
Our work began with a pilot study to find the peak angular velocity of human knee 
extension during unloaded kicking. Contrary to previous estimations, we found the 
average peak angular velocity of human knee extension was within the range (0-500 
º/s) of a commercial isokinetic dynamometer. Therefore, we created an IKD protocol 
that encompassed the entire force-velocity range of human knee extension. Next we 
investigated the reliability of isolated knee performance measures across the f-v 
profile of human muscle encompassing a range of velocities using isokinetic 
dynamometry (IKD).  
 
To attempt to relate our work to wider applications in sports performance testing, we 
also assessed the reliability of jump analysis using either a force platform or linear 
encoder. This enabled us to investigate the strength of correlation between indices of 
isolated knee performance and a more complex sport-related movement such as 
jumping. Our knee extension data was consistent with the f-v concept of striated 
muscle and the reliability of each of the measures of knee extensor performance was 
acceptable (<15 % CV). The reliability of jump performance measures was also 
good and we found modest correlations amongst each of the knee measures. Reverse 
regression analysis found isometric and highest velocity knee kicking on IKD was 
the strongest predictor of jump performance. 
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In the next chapter, the IKD protocol will be combined with measurement of peak 
isometric force and rate of force development in order to create a continuum tests 
that span the entire f-v range. Currently it is not known which measure of muscle 
output exhibits the greatest diurnal variation. 
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Chapter 3 
Diurnal Variation in Human Skeletal Muscle Performance 
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3.1 INTRODUCTION 
 
Chapter background 
Diurnal variation in sports performances/muscle function 
The power output of human muscle and human sports performance exhibit diurnal 
variation (Drust et al., 2005; Reilly and Waterhouse, 2009). World records in 
sporting events, such as athletics, are usually broken by athletes competing in the 
early evening, which is the time of day at which muscle function and body 
temperature are at their greatest (Reilly et.,al 1997). Table 1 summaries research 
studies that have investigated the effects of diurnal variation on muscle performance 
(see Table 1). Regardless of the dependant variable measured (e.g. maximum 
isometric force, peak torque etc.) muscle performance is consistently better during 
the evening (~17:00 h) as opposed to the morning (~07:00 h). The magnitude of the 
change in muscle output from morning to evening is reported to range between 5-
20%. The underlying cause of this variation has been attributed to variations in 
metabolism, circulating levels of hormones, and differences in core or local muscle 
temperature, all of which have shown patterns of circadian rhythms and may 
therefore affect performance (Araujo et al., 2011; Racinais & Oksa, 2010).  
 
Life on earth evolved in an environment that changed cyclically and as a result, 
environmental fluctuations such as the light-dark cycle and recurring seasons take 
place (Reilly & Brooks, 1990). As the human is essentially a diurnal creature, 
oscillations occur with a frequency similar to that of a solar day in human processes 
and effect physiological, biochemical and psychological events. Chronobiology is 
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the biology of time and internal biological clocks, the terms is derived from the 
Greek phrases, chronos meaning time, bios meaning life and logos meaning study 
(Dunlap et al., 2004). Minor & Waterhouse (1981) defined chronobiology as the 
science concerned with investigating and objective quantification of the mechanism 
of timing manifestations of life. 
 
Beside the light-dark cycle and melatonin, there are other non-photic signals help 
synchronise the body clock to solar day such as social interaction and the timing of 
food (see review by Mistleberger & Skene, 2005). The body’s internal time keeper is 
localised to a small pair of nuclei in the hypothalamus called the suprachiasmatic 
nuclei (SCN) located at either side of the midline brain, and just above the location 
where the optic nerves cross prior to their entry to the brain (Ralph et al, 1990). The 
SCN expresses ‘clock genes’ that are regulated by a series of feedback loops and are 
considered to be the molecular mechanism of the circadian clock that generates a 
rhythmic response with a singles cycle period of 24-25 h (Piggins, 2002). The SCN 
may function as a master clock, synchronising other peripheral molecular and protein 
clocks, found in muscle and other tissues, in a rhythmical fashion. Because of its 
anatomical location the SCN influence body temperature, and core temperature is 
one of the most easily observed outputs of the SCN circadian clock. 
 
Diurnal variation in core and muscle temperature 
The circadian rhythm of core temperature has been used as a surrogate marker for 
the body clock and has often been described as the fundamental variable (Reilly et 
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al., 2000). Core body temperature is tightly controlled at approximately 37ºC but 
exhibits a daily range of oscillation of about 0.6-1.0ºC. In participants living a 
normal lifestyle, circadian changes in core body temperature are phased such that 
temperature minimum at about 05:00 h and the temperature maximum occurs 
between 14:00 h to 20:00 h (Waterhouse et al., 2002). Local muscle temperature in 
vastus lateralis also varies with time of day and evening (17:00 h) values are higher 
than the morning (07.30 h) values, by ~0.35ºC (Robinson et al., 2013; Edwards et al., 
2013).  
 
Sargent et al. (2010) reports muscle handgrip strength was greater in the evening 
than in the morning and this difference correlated with the circadian rhythm in core 
temperature. The superior muscle force output in the evening has been suggested to 
be evidence of a causal link between core body and muscle temperatures and muscle 
performance. However recent work (Edwards et al., 2013) that used active or passive 
warm-up strategies to manipulate body temperature in the morning did not report an 
improvement in muscle force production despite elevations in core and muscle 
temperature to evening values. Furthermore, Atkinson et al. (2005) used an active 
warm-up (25 min of cycle ergometer at 60% VO2max) in the morning which they 
predicted would improve performance in a 20 km cycle time-trial to afternoon values, 
thus removing any influence of diurnal variation. Even though pre-performance 
intra-aural temperature increased by ~0.5°C to values statistical similar to afternoon 
values, finishing times did not decrease to levels achieved in the evening. Therefore 
diurnal variation in muscle force output and cycling performance cannot be 
completely dependent on core body temperature variation and other mechanisms 
may exist. 
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Hormonal rhythms 
Many hormonal secretions are episodic, evidencing significant ultradian oscillations. 
Rhythm with period less than 20 hours is called ‘ultradian’. Cortisol and growth 
hormone concentrations exhibit marked peaks at several times during sleep 
(Veldhuis et al., 1992). Indeed, growth hormone and cortisol rhythms are strongly 
influenced by sleep characteristics, which are, in turn, affected by habitual levels of 
physical activity. The time structure of the endocrine system is highly complex and 
interactive among its different components, other signalling mechanisms, and the 
environment. It is rhythmic in multiple frequencies. At many sites, the rhythmic 
variations of a hormone like melatonin, prolactin, thyroid stimulating hormone 
(TSH), corticotrophin releasing hormone (CRH) or related messenger are 
deterministic of its effect and efficacy upon a target tissue (Haus, 2007). 
Testosterone levels are higher in the morning compare than evening (Gray et al., 
2004) and chronic testosterone administration can significantly increase muscle 
strength (e.g Bhasin et al., 1996). However this pattern does not correlate with 
studies reporting diurnal variation in muscle performance (see Edwards et al., 2013). 
As yet, it is not clear how relatively acute (i.e. diurnal) changes in testosterone or 
cortisol could influence muscle performance. 
 
Activation – nerve transduction 
Circadian rhythms in motor neuron activity might be responsible for these time of 
day effects. However, many studies showed the higher muscle performance in the 
evening was observed without modification of electrical activity (e.g Guette et al., 
2005). Guette et al., (2005), conducted the test at 06:00, 10:00, 14:00, 18:00, and 
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22:00 h to distinguish the neural and muscular mechanisms that influence muscle 
strength. The electromyographic and mechanical muscle responses associated with 
electrically evoked and/or voluntary contractions of the human quadriceps and semi-
tendinosus muscles for each leg were recorded and compared. The central activation 
of the quadriceps muscle remained unchanged during the day. Furthermore, in an 
investigation into time of day effect on electromyography (EMG) parameters, 
Souissi et al., (2012) found that the root-mean-square (RMS) values produced by 
electromyograph was unaffected by the time of day of testing.  
  
Clock gene and molecular mechanism 
The presence of molecular clock within a cell or organism provides the necessary 
timekeeping for anticipation of daily changes in environmental (Albrecht, 2002; 
Gekakis et al., 1998). The timing of these circadian rhythms is synchronized to the 
environment by external cues (Green, et al., 2008). At the molecular level, the 
circadian clock represents as well defined gene regulatory network composed of 
transcriptional-translational feedback loops such as CLOCK, BMAL1 and E-box on 
target genes like Per1 for instance (Lowrey & Takahashi, 2004). Zhang et al., (2009) 
suggests there may also be a skeletal muscle molecular clock modulating skeletal 
muscle physiology. Recent research has focused on the components of molecular 
clock in the SCN but there is still little known about the regulation and function of 
molecular diurnal mechanisms in skeletal muscle. 
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Rational of this study 
Diurnal variation in muscle force and sports performance in young healthy 
individuals is widely reported but the mechanism underpinning this phenomenon are 
not yet understood. Muscle force production is least between the hours of 06.00 – 
08.00 in the morning and greatest from 16.00 – 18.00 in the afternoon.  
 
Fluctuations in force production co-occur alongside biological rhythms in core 
temperature but we have found diurnal variation in muscle performance is not 
entirely explained by differences in muscle temperature. For example, passive 
heating in the morning to stimulate the warmer afternoon muscle temperature did not 
bring about similar elevation in muscle performance. Similarly, passive cooling in 
the afternoon to replicate the cooler muscle temperature of the morning was not 
associated with the decrease in performance. Thus intrinsic differences occur in the 
ability of skeletal muscle to produce force during the course of the day. The 
parameters of muscle performance (i.e. maximum force and maximum speed) are 
determined by collections of contractile proteins. Differences in genetic background, 
habitual activity or training status affect the relative amounts of each muscle protein 
and are one of the main reasons for the broadly different physique and physical 
performance of sprinters compared to marathon runners. The same contractile 
proteins can also be rapidly modified to cope with short-term changes in demand. 
This latter mechanism contributes to the positive effect of warming up prior to 
strenuous exercise, and similar mechanisms could able responsible for the greater 
output of skeletal muscle in the afternoon compared to the morning. Therefore 
123 
 
further investigation involving proteomic analysis of muscle biopsies needs to be 
done.  
 
Prior to invasive analysis of muscle biopsy samples we wanted know which aspect 
of muscle performance exhibits the greatest level of diurnal variation. Previous 
studies related to this area are summarised in Table 1. The most common techniques 
that have been used include isokinetic dynamometer and the measurement of peak 
isometric force produced during maximal voluntary contraction (MVC). Because 
these data were collected during individual studies that used different populations of 
participants it is not clear which muscle output (i.e. peak isometric force, power, 
velocity maximum, etc.) or which measurement technique exhibits the greatest 
diurnal variations and is therefore optimal for subsequent studies that aim to 
correlate differences in muscle output with individual proteins. 
 
Therefore we choose a selection of isolated knee extension exercise that cover the 
entire range of velocities from isometric to velocity maximum. In the current work 
we used the IKD protocol from Chapter 2 that encompasses 4 different angular 
velocities (60, 120, 240 and 450 degrees per second). In addition, we measured 
MVC peak isometric force using the twitch interpolation technique and also the 
maximum rate of force development (RFD) during the initial 150 ms of the isometric 
contraction. During this technique, participants perform voluntary rapid sub-maximal 
isometric contraction (1s duration to approximately 80% of MVC) in order to 
calculate the maximum rate of force development (RFD; Nm.s
-1
). Previously, 
Aagaard et al., (2002) reported increasing in the rate of force development and 
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neural drive of in response to resistance training. Currently, it is not known whether 
this measure of muscle output exhibits diurnal variation. 
 
The aim of this study 
To find which method of measurement or which feature of muscle function shows 
the greatest in diurnal variation e.g four different velocities on IKD, MVC and RFD.   
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3.2 METHODS 
3.2.1  Participants 
Twenty male participants were recruited. Procedures were explained in full to 
participants with questions answered prior to participation. The study was approved 
by the local Ethics Committee of University. Inclusion criteria required previous 
strength training experience (≥ 2 years) with exclusion criteria stating recent shift-
work or travel across multiple time zones.  
 
3.2.2 Protocol  
Participants performed two separate experimental sessions in this experiment (Figure 
22).  These were an isokinetic dynamometry (IKD) protocol of knee extension and 
flexion, and an isometric protocol of maximal voluntary contractions (MVC) and 
rate force development (RFD) of the quadriceps group.  
 
Figure 22. Two separate experimental sessions; MVC & RFD and IKD. Each 
protocol was completed by the participants in the morning (M) and evening (E) in a 
counter balanced order. 
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Each participant completed two experimental conditions a minimum of 48 h apart in 
either the morning (07:30 h) or evening (17:30 h) for both the IKD and ISO 
protocols. A limitation to our experiment is that participants were free to live 
normally between sessions, however they were asked to refrain from caffeinated or 
alcoholic beverages and from other training or intense exertion 48 h before 
experiments. Participants reported in a fasted state for ≥ 7 h prior the morning 
sessions and were instructed not to consume food for ≥ 4 h prior to the evening 
session so we cannot rule out difference due to ‘fed/fasted state. Prior to 
familiarization participants completed Composites Morningness, Sleep 
Flexibility/Rigidity [F/R] and Languid/Vigour [L/V] questionnaires (Smith et al., 
1989) in order to profile their chronotype. In addition, during each laboratory visit, 
participants completed a Profile of Mood States (POMS) questionnaire (McNair, 
1971). Thermal comfort (TC) (Bakkevig, & Nielsen, 1994) was measured at rest and 
during warm-up, and perceived exertion (RPE) (Birk & Birk, 1987) and effort (0-10 
liekert scale; “0” representing no effort and “10” maximal) were measured during 
warm-up following each MVC.   
 
Rectal, Skin and Muscle Temperatures 
Participants arrived 30 min prior to experimental procedures and lay down in the 
laboratory after inserting a flexible temperature probe ~10 cm beyond the external 
anal sphincter (Mini Thermistor; Grant Instruments, Shepreth, UK). Skin 
temperature (Tsk) was measured as the average value of four sites using skin 
thermistors (Mini Thermistor, Grant Instruments, Shepreth, UK). The thermisters 
were affixed via tape (Micropore, 3 M) to the left calf, left thigh, left forearm and 
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lower sternum according to (Ramathan, 1964). Participans remained awake and 
semisupine while rectal (Trec) and Tsk continuously recorded for 30 min using a data 
logger (Squirrel 1000, Grant Instruments, Shepreth, UK). This standardised body 
position was used because core temperature is influenced by other factors than that 
of the endogenous 24 h oscillator, such as feeding, activity and sleep. After 
participants had rested for 30 min, a 5 min active warm-up was performed at 150 W 
on a cycle ergometer (Monark Ergomedic 839E, Vansbro, Sweden). Measurement of 
Trec was the average value of the final 5 min recorded at rest and both Trec and Tsk 
were recorded at rest and following active warm-up, MVC and RFD. Muscle 
temperature (Tm) was assessed in the vastus lateralis of the right leg using the 
method described by Gregson et al. (2003) at rest, after active warm-up and between 
MVC and RFD by needle thermistor (13050; ELAB electronic measurement system 
(CTF 9004; ELAB, Rodovre, Denmark). 
 
3.2.3 Maximum voluntary contractions 
Participants completed five familiarization sessions separated by at least 3 d to 
ensure full acquaintance with the experimental protocol. During familiarisation 
sessions, participants alternated between performing MVCs with and without twitch 
interpolation, so that approximately three trials of each were performed within each 
session. This approach was suggested by Morton et al. (2005), whom reported naïve 
participants perform weaker contractions when they anticipate stimulation (attributed 
to the potential apprehension due to the prospect of receiving noxious stimuli) 
compared to when they were not expecting stimulation. Familiarisation sessions 
were conducted until the participant’s MVC force and voluntary activation 
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demonstrated a plateau effect and the average percentage of voluntary muscle 
activation was greater than 80 % (consistent with Morton et al. 2005). This level of 
initial consistency was achieved within 3 sessions, therefore data from sessions 4 and 
5 were used to calculate the reproducibility of the peak isometric force data.  
 
3.2.4  Maximal isometric quadriceps Force and Percutaneous Stimulation 
For each session, the position of the participant in the isometric chair (Lido Active, 
Loredan, Davis, CA, USA) was standardized in accordance with the guidelines set 
by the manufacturers and also taking into account any adjustment required by the 
individual (established during familiarisation sessions). In brief, these guidelines are 
as follows: The backrest was positioned to ensure 80° of hip flexion and the knee 
joint was aligned with the axis of the actuator. A belt and straps were tightly secured 
across the shoulders, hips and chest in order to stabilize the upper body. Quadriceps 
muscle force was measured from the ankle where the attachment was connected to a 
strain gauge (Tadea, Tension/Compression cell, Huntleigh, Sweden) by a metal force 
transducer (previously calibrated with known weights). Participants performed 
isometric maximum voluntary contractions (MVCs) of the quadriceps muscles (4-s 
duration), both with and without twitch interpolation. During the initial session, 
participants practiced performing MVCs without twitch interpolation, to become 
accustomed to achieving and maintaining voluntary force for the time required. This 
session was also used to obtain maximal current tolerance (mA) and establish the 
supra-maximal current amplitude for superimposition during an MVC (Digimeter, 
DS7, Hertfordshire, UK). Whilst remaining at rest, the amperage of a 240 V square-
wave pulse (100 μs, 1 Hz) was progressively increased until the point that further 
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increases in intensity caused no further increase in twitch force (Newman et al. 2003; 
Morton et al. 2005).  
 
The quadriceps were electrically stimulated using two moistened surface electrodes 
(Dura-stick II, Chattanooga Group, Hixson, TN, USA, 7 x 12.7 cm) positioned on 
the anterolateral side of the thigh, on the belly of the rectus femoris and vastus 
lateralis muscles. The skin was prepared prior to the placement of each electrode by 
shaving and light abrasion of the skin followed by cleansing with an isopropyl 
alcohol swab. A permanent marker pen was used to identify the position of each 
electrode in order to minimise electrode placement variability between sessions 
(Giacomoni et al. 2005; Keogh et al. 1999). Eight single square-wave electrical 
impulses (100 μs) were delivered during the 8-s sampling period. Each impulse was 
computer driven and was delivered at 240 V AC (RMS) at 50 Hz. Two impulses 
were delivered before and after the contractions; the other four impulses were 
administered during the contraction period and tested the peak value of the MVC. 
The peak forces of the pre- and post-contraction twitches were then averaged, 
allowing comparison of resting twitch amplitudes in both an un-potentiated and 
potentiated condition (Oskouei et al. 2003). The amplitude of supra-maximal 
superimposed current was to 10% above the level required to evoke a resting muscle 
twitch of maximal amplitude (Todd et al. 2004), determined in familiarization 
sessions. 
 
Standardised verbal encouragement was provided throughout with real-time bio-
feedback of force development projected on a large display screen in front of 
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participants. Data were acquired for 8 s and analysed with commercially software 
(AcqKnowledge III software for Windows, Biopac Systems Inc, Aero Camino 
Goleta, CA, USA). The calculation of voluntary activation was conducted according 
to an interpolated twitch ratio (as recommended by Merton, 1954), whereby the size 
of the interpolated twitch is expressed as a ratio of the amplitude elicited by the same 
stimulus delivered to a relaxed un potentiated muscle. The average force recorded 
during the 100-ms period before the application of each stimulus during the 
contraction and, subsequently, the maximal force recorded during the 100-ms period 
after each stimulus was used. The highest pre-stimulus force (taken as MVC force) 
and the resulting maximal post-stimulus force were then used to calculate the size of 
the interpolated twitch. Interpolated twitch size was calculated by subtraction of the 
mean pre-stimulus force from the maximal post-stimulus force. To calculate 
voluntary activation of the quadriceps using the following equation: 
 
Voluntary Activation =   [1 −  {
𝑆𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑝𝑜𝑙𝑎𝑡𝑒𝑑 𝑡𝑤𝑖𝑡𝑐ℎ
𝑆𝑖𝑧𝑒 𝑜𝑓 𝑟𝑒𝑠𝑡𝑖𝑛𝑔 𝑡𝑤𝑖𝑐𝑡ℎ
}]  𝑋 100 
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Figure 23. A typical MVC with twitches superimposed. Panel A illustrates the 
timing of the twitches whilst panel B illustrates the participants achieved force rate. 
                                  
3.2.5 Rate of Force Development  
For each session, the position of the participant in the isometric chair (Lido Active, 
Loredan, Davis, CA, USA) was standardized in accordance with the guidelines set 
by the manufacturers and also taking into account any adjustment required by the 
individual (established during familiarisation sessions). In brief, the process is 
identical to that described for MVC. Peak rate of force development (RFD) was 
analysed using AcqKnowledge III software. Participants kicked as quickly and 
forcefully as possible without producing any countermovement and were encouraged 
to achieve at least 80 % of maximum isometric force. Visual data representation was 
utilised to provide feedback and ensure no counter-movement preceded each kick. 
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Ten kicks were performed interspersed by 30 s rest, with the three efforts of greatest 
force and no discernable counter-movement selected for analysis. Measurement of 
RFD represented the highest positive value from the first derivative of the force 
signal (the greatest slope of the force-time curve).  
 
3.2.6 Isokinetic dynamometer protocol 
Consistent with Chapter 2, IKD was performed at different velocities to investigate 
the data across force-velocity curve in morning and evening. Test angular velocities 
were set at 60˚.s-1, 120˚.s-1, 240˚.s-1 and 450˚.s-1. Participants were asked to do 3 
repetitions of extension and flexion for each angular velocity. Thirty seconds rest 
was given between each repetitions and three minutes between each angular velocity 
delivered in randomised order. Three warm-up trials were be performed prior each 
velocity during which the participant were instructed to complete the protocol using 
up to 50 % of maximal effort. Trails were interspersed by 3 min recovery periods 
and standard performance parameters, including torque and power output was 
recorded.  
 
The schematic of IKD protocol is shown in Figure 24. Meanwhile for maximal 
isometric quadriceps force, percutaneous stimulation and RFD were measured as 
described in 3.2.4 and 3.2.5 and the schematic protocol for MVC and RFD showed 
as figure 25. 
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Figure 24. Schematic of the protocol for IKD in the morning (M, 07.30 h) and 
evening (E, 18:00 h) conditions. Rectal (Trec), skin (Tsk) and muscle (Tm) 
temperatures, thermal comfort (TC) and perceived onset of mood (POMS) were 
measured after the participants had reclined for 30 min at the start of the protocol, 
after the warm-up and after 120˚.s-1. Rating of perceived exertion (RPE) was taken 
during warm-up and after each velocity kicking. Black bars indicate muscle 
temperature taken at these points; grey bars indicate recovery between tests.  
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Figure 25. Schematic of testing protocol for MVC and RFD in the morning (M, 
07.30 h) and evening (E, 18:00 h) conditions. Rectal (Trec), skin (Tsk) and muscle 
(Tm) temperatures and thermal comfort (TC) were measured after the participants 
had reclined for 30 min at the start of the protocol and after the warm-up. Rating of 
perceived exertion (RPE) was taken during warm-up and after each MVC, with 
rating of effort taken after each MVC. Black bars indicate muscle temperature taken 
at these points; grey bars indicate recovery between tests. 
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3.2.7 Statistical Analysis 
The data were analysed using the Statistical Package for Social Sciences (SPSS) for 
Windows (SPSS, Chicago, IL, USA) version 20. Comparisons by paired sample t-
test were used to test the primary hypothesis that muscle output is greater in the 
evening. The results are presented as the mean ±  the standard deviation (SD) 
throughout the text unless otherwise stated. Ninety-five percent confidence interval 
(CIs) are presented where appropriate. The alpha level of significance was set at 5% 
(p < 0.05).  
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3.3 RESULTS 
 
3.3.1 Participants 
Twenty male participants were recruited of age (mean±SD) 25.9 ± 4.4 years, height 
177.3 ± 6.8 cm, body mass 75.1 ± 8.2 kg with habitual retiring and waking times 
11:36 ± 0:36 p.m. and 06:24 ± 0:18 a.m., respectively. Mean chronotype score was 
35.2 ± 4.5 (all intermediate type); F/R score 43.0 ± 5.6; and L/V score, 43.0 ± 9.3. 
POMS data for both IKD and MVC sessions identified significantly greater (p < .05) 
“happy” and “vigour” in the evening. As anticipated, both Trec and Tm were 
significantly greater in the evening than the morning, whereas diurnal variation in 
Tsk was not robust. Effort levels of 10 (i.e. maximum effort) were consistently 
reported contributing no difference between conditions. Thermal confort was not 
significantly different between morning and evening, but mean RPE was 
significantly greater during the MVC protocols performed in the morning compared 
to the evening. 
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3.3.2 Isokinetic measures 
Peak torque during knee extension at velocities of 60˚.s-1, 120˚.s-1, 240˚.s-1 and 
450˚.s-1 is shown in Figure 26. Consistent with force-velocity characteristics of 
skeletal muscle, peak torque was greatest during slow contraction and declined as the 
velocity of contraction increased. At each of the velocities tested, peak torque during 
extension was significantly (p<0.05) greater in the evening than the morning. The 
magnitude of diurnal variation ranged from 9.8 % at 60˚.s-1 (245.4 ± 42.8 Nm vs. 
223.4 ± 35.7 Nm) to 8.1 % at 240˚.s-1 (143.5 ± 24.1Nm vs. 132.8 ± 26.6 Nm) . 
 
 
Figure 26. Knee extension torque-velocity relationship measured using isokinetic 
dynamometry.  
Peak torque data are presented as mean ± SD (n = 20, in each trial). Peak torque 
(Nm) was recorded during isokinetic knee extension at angular velocities of 60˚.s-1, 
120˚.s-1, 240˚.s-1 and 450˚.s-1.  
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Table 18. Analysis IKD measurements were assessed using paired t-test and the 
percentage of difference was calculated for major parameters. 
 
Morning Evening (p) value Diff. (%) 
Rectal  Temperature (˚C)    
 Rest 36.8 ± 0.3 37.3 ± 0.3* 0.000 
 Post Warm-Up 36.8 ± 0.3 37.3 ± 0.3* 0.000 
 Trec (post 60˚.s
-1
) 37.0 ± 0.4 37.4 ± 0.3* 0.000 
 Trec (post 120˚.s
-1
) 37.0 ± 0.4 37.4 ± 0.4* 0.000 
 Trec (post 240˚.s
-1
) 37.0 ± 0.4 37.3 ± 0.4* 0.004 
 Trec (post 450˚.s
-1
) 37.0 ± 0.4 37.3 ± 0.4* 0.006 
 Muscle Temperature (˚C) 
    Rest 35.9 ± 0.4 36.3 ± 0.5* 0.003 
 Post Warm-Up 37.3 ± 0.5 37.8 ± 0.4* 0.002 
 Tm (post 120˚.s
-1
) 36.9 ± 0.4 37.4 ± 0.4* 0.000 
 Skin Temperature (˚C) 
    Rest 32.3 ± 0.9 32.5 ± 0.9 0.664 
 Post Warm-Up 31.6 ± 0.6 31.9 ± 0.8 0.078 
 Tsk (post 60˚.s
-1
) 32.3 ± 0.5 32.6 ± 0.6* 0.041 
 Tsk (post 120˚.s
-1
) 32.2 ± 0.7 32.5 ± 0.6 0.127 
 Tsk (post 240˚.s
-1
) 32.3 ± 0.5 32.4 ± 0.6 0.467 
 Tsk (post 450˚.s
-1
) 32.3 ± 0.6 32.5 ± 0.6 0.320 
 IKD Peak Torque(Nm) 
    Extension (60˚.s-1) 223.4 ± 35.7 245.4 ± 42.8* 0.000 9.8 
Flexion (60˚.s-1) 124.4 ± 26.7 130.9 ± 28.5* 0.018 5.2 
Extension (120˚.s-1) 180.2 ± 32.1 195.4 ± 29.1* 0.001 8.4 
Flexion (120˚.s-1) 118.5 ± 24.2 128.2 ± 21.5* 0.003 8.2 
Extension (240˚.s-1) 132.8 ± 26.6 143.5 ± 24.1* 0.003 8.1 
Flexion (240˚.s-1) 84.0 ± 19.7 93.7 ± 19.8* 0.010 11.5 
Extension (450˚.s-1) 90.3 ± 19.3 98.1 ± 18.8* 0.033 8.6 
Flexion (450˚.s-1) 62.8 ± 12.1 70.3 ± 12.9* 0.048 11.9 
IKD Average Power(W) 
   
 
Extension (60˚.s-1) 151.1 ± 28.1 167.2 ± 27.7* 0.001 10.6 
Flexion (60˚.s-1) 81.8 ± 21.3 89.9 ± 20.4* 0.003 9.9 
Extension (120˚.s-1) 217.1 ± 37.8 244.4 ± 43.1* 0.000 12.5 
Flexion (120˚.s-1) 152.2 ± 27.7 167.3 ± 32.3* 0.000 9.9 
Extension (240˚.s-1) 272.4 ± 52.8 299.8 ± 60.6* 0.002 10.1 
Flexion (240˚.s-1) 163.8 ± 36.2 203.2 ± 49.2* 0.000 24.1 
Extension (450˚.s-1) 283.2 ± 72.8 306.4 ± 68.8 0.087 8.2 
Flexion (450˚.s-1) 180.9 ± 48.6 190.2 ± 51.3 0.535 5.1 
Data are presented as means ± SD; n = 20 participants. Isokinetic dynamometry 
(IKD) was performed at 4 different velocities: 60, 120, 240 and 450˚.s-1. Data 
presented are peak torque (Nm) and average power (W) over 3 kicks during knee 
extension and flexion. 
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3.3.3 MVC and RFD 
MVC was significantly greater (10.2 %) in the evening compared to morning. There 
was no significant difference in voluntary activation level (p > .05) between morning 
and evening conditions. RFD Peak was greater in E vs. M (+953.2 N.s
-1
, see Table 
19). There was no difference in the time to RFD peak between M and E (p > .05). 
 
Table 19. Analysis MVC & RFD measurements were assessed using paired t-test 
and the percentage of difference was calculated for major parameters. 
Data are presented as means ± SD; n = 20 participants. MVC and RFD were 
performed on isometric chair (Lido Active, Loredan, Davis, CA, USA). 
 
 Morning Evening  (p) 
value 
 (%) 
Rectal  Temperature 
(˚C) 
    
Rest 36.8 ± 0.3 37.2 ± 0.4* 0.000  
Post Warm-Up 36.9 ± 0.3 37.2 ± 0.4* 0.000  
Post MVC 37.1 ± 0.3 37.3 ± 0.2 0.056  
Post RFD 37.1 ± 0.3 37.2 ± 0.2 0.090  
Muscle Temperature 
(˚C) 
    
Rest 36.1 ± 0.5 36.4 ± 0.4* 0.008  
Post Warm-Up 37.5 ± 0.4 37.8 ± 0.5* 0.042  
Post MVC 37.0 ± 0.6 37.4 ± 0.4* 0.009  
Skin Temperature (˚C)     
Rest 32.1 ± 0.7 32.2 ± 0.9 0.449  
Post Warm-Up 31.5 ± 0.7 31.6 ± 0.8 0.682  
Post MVC 32.1 ± 0.5 32.3 ± 0.6 0.378  
Post RFD 32.0 ± 0.5 32.1 ± 0.5 0.281  
Performance Measures     
MVC force (N.m
-1
) 654.0 ± 78.9 720.8 ± 79.7* 0.000 10.2  
MVC activation (%) 82.8 ± 7.7 86.5 ± 6.4 0.061 4.5 
Peak RFD (N.s
-1
) 5972.3 ± 
1500.7 
7051.6 ± 1261.1* 0.002 18.0 
Time to Peak RFD (ms) 72.8 ± 17.2 67.2 ± 11.7 0.141 7.8 
RPE     
During Warm-Up 10.6 ± 2.0 10.9 ± 2.0 0.863  
During MVC efforts 13.9 ± 2.8 12.7 ± 2.9 0.002  
Thermal Comfort      
Resting 5.0 ± 0.9 5.1 ± 0.2 0.825  
During Warm-Up 5.4 ± 0.6 5.6 ± 0.8 0.287  
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Test re-test reliability of MVC and RFD measurements was assessed using paired t-
test and the coefficient of variation (CV) was calculated for major parameters. MVC 
and RFD data (Table 20) were not significantly different across the 2 repeated trials, 
demonstrating there was no evidence of systematic bias. The CV of the parameters 
was ranging from 1.1 to 6.7%.  
 
Table 20. Reliability of muscle performance test on MVC and RFD.  
 Mean Paired t-test 
(p) value 
% Coefficient of 
Variation (CV) 
MVC 
MVC force (N.m
-1
) 679.6 ± 120.2 0.188 1.1 
MVC activation (%) 84.6 ± 7.3 0.138 3.1 
RFD    
Peak RFD (N.s
-1
) 6447.3 ± 1847.5 0.949 6.7 
Time to Peak RFD (ms) 72.9 ± 15.8 0.480 6.2 
Data are presented as means ± SD; n = 20 participants averaged from 2 separate test 
sessions.  
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3.4 DISCUSSION 
 
The investigations of daily variation in muscle force output have been establish using 
methods of measurement including Biodex Isokinetic Dynamometry and maximal 
voluntary isometric contractions. Many studies show the diurnal variation in 
performance by using IKD (Reilly, 2007; Edwards et al., 2013) and MVC (Martin et 
al., 1999; Racinais et al., 2005; Reilly, 2007; Edwards et al., 2013). The main idea of 
this study was to optimize the technique in muscle performance and determine which 
measure of muscle function exhibits the greatest diurnal variation. The measurement 
techniques chosen covered the entire range from isometric to velocity maximum 
using IKD at 4 velocities (60˚.s-1, 120˚.s-1, 240˚.s-1 and 450˚.s-1), MVC and RFD. 
 
Our work investigated IKD knee extension and flexion at movement speeds of 60, 
120, 240 and 450°s
-1
, paying particular attention to the 450 speed as it has rarely 
been studied in the literature. There was a diurnal variation in temperature and IKD 
peak torque extension at all velocities. This data is in agreement with the current 
literature suggesting that performance and core temperature follower similar patterns 
of diurnal variation, with lows in the morning and peaks around the evening 
(Atkinson et al., 2005; Edwards, et al., 2013; Pullinger, et al., 2014; Robinson et al., 
2013). 
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Measures of MVC, RFD and IKD all displayed significant time-of-day variation 
with higher values in the evening when compared to the morning (P<0.05) in current 
study. The range of morning to evening diurnal variation displayed by this cohort of 
participants varied from 8.1 % to 18 % for all measurements. It was established that 
MVC and RFD showed the greatest diurnal variation when compared to IKD (10.2 % 
and 18 %, respectively). The present study used a counterbalanced design and 
considered all factors such as light and room temperature (within the test 
laboratories), prior training history and status; and calorific intake. The only 
parameter which was not directly controlled was sleep, and this was due to the live-
normal conditions of protocol. The principal finding was that in highly motivated 
individuals muscle output applied to range of measurements that have been shown in 
this study and in the literature (see Giacomoni et al., 2005, Sedliak et al., 2007 and 
Edwards et al, 2013) to exhibit diurnal variation when measured under a rigorous 
research design still peak in the late afternoon/early evening (~18:00 h).   
 
During this live-normal protocol there was a significant diurnal variation effect for 
the perception of mood state (POMS) variables vigour and happy which revealing 
higher in evening. These observations coincided with measured factors of muscle 
force output, with vigour and happy corresponding with later time-points and highest 
values of muscle force output. These results lend support towards the statements 
made by Reilly and Bambaeichi (2003), who proposed that there might be times of 
day when an individuals are less inclined to produce a maximal effort. Other than the 
physiological mechanisms discussed previously it has been suggested that participant 
motivation can mask diurnal variation in performance (Edwards et al., 2013; 
Robinson et al., 2013). This limitation can be assessed through subjective measures 
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of motivation, effort and arousal. However, MVC performance was implemented 
with the superimposed technique which has been shown to override the central 
mechanisms related to motivation (Morton et al. 2005). Indeed, this is evident by the 
fact that no significant difference was found between voluntary muscle activation 
levels for all conditions which is further supported by all participants giving a 
maximum of 10 for effort rate. Based on this data it can be assumed that the MVC 
data is a true reflection of diurnal variation of performance and not heavily 
influenced by other central mechanisms.    
 
Possible factors to be considered other than temperature could be that previously 
observed of hormonal behaviours. Hayes et al., (2010) have proposed that, whilst 
basal levels of testosterone are greater in the morning, responsiveness of testosterone 
to exercise is increased later in the day, which might therefore be related to this 
observed increase in muscle temperature. It is widely recognised that morning 
resting levels of cortisol are higher than those observed during the afternoon or 
evening (Sedliak et al., 2007). As cortisol is generally regarded to be a catabolic 
hormone which counteracts the effects of testosterone, this is an important factor 
when considering muscle force output. Sedliak et al., (2007) concluded that, whilst 
training at a specific time of day reduced morning resting cortisol concentration, but 
did not affect the diurnal pattern of maximum strength. Therefore, further work is 
needed to determine the mechanisms underpinning the diurnal variation in muscle 
performance. 
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In current work test retest in quadriceps MVC was showed with no significant 
different after three familiarisation of performance in activation, as previously 
observed that this level of initial consistency was typically achieved within three to 
five sessions, after which participants were then considered eligible to participate 
(Edwards et al., 2013; Robinson et al., 2013). We present comparable force and 
activation data to previous work in this muscle group (Edwards et al., 2013; 
Robinson et al., 2013) and suggest participant familiarization and parallels in 
protocol contribute to similarities. Nevertheless, 679.58 ± 120.20 (Nm) mean in 
maximum isometric force is consistent with literature where force is apparent in 
isometric contractions (Racinais et al., 2005). Contraction velocity is key to time-
restricted explosive actions such as kicks, sprints and jumps (Andersen & Aagard, 
2006) and with peaks occurring inside 100 ms of force onset and durations > 300 ms 
required to achieve maximum force (Thorstensson et al., 1976). We report there was 
not significantly difference in test retest for RFD and showed the RFDForce in this 
study is within the expected range for athletes (Tillin et al., 2010).  With greatest 
velocity occurring between 50 and 100 ms as observed in previous knee extensors 
studies (Andersen & Aagard, 2006) and those in other musculature (Erskine et al., 
2014). 
 
In current study of the RFD diurnal difference (18 %) was almost double that of the 
diurnal difference (10.2 %) in peak isometric force.  Pereira et al., (2011) reported 
explosive muscle force was greater in the evening than morning. The difference in 
magnitude of diurnal variation reported here between MVC and RFD could represent 
a physiological phenomenon or could be due to a difference in precision of the 
analytical techniques. Taylor et al., (2011) reported if single trial protocol was used, 
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the error associated with mean force was lower compare to RFD. When a six-trial 
protocol was used, the error was reduced however RFD still remained high at 
approximately 13-16 %.  Herein we performed 5 familiarisation sessions and found 
that participants produced consistent results after the third session. Therefore, data 
from sessions 4 and 5 were used to assess the reproducibility of the MVC and RFD 
techniques (Table 20). Consistent with Taylor et al., 2011, we report the 
reproducibility of MVC data is greater than RFD. Nonetheless, RFD data was not 
associated with significant error and the coefficient of variation was approximately 
6 %. 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
3.5 CONCLUSION 
 
Twenty young healthy males completed measures spanning maximum force 
production through to maximum speed of contraction. Diuranl variation ranged from 
8.1 % to 18 % across six different measures. Rate of force development (RFD) and 
isometric force during maximal voluntary contraction (MVC) exhibited the greatest 
diurnal variation (5972.3 ± 1500.7 - 7051.6 ± 1261.1 N/s, p= 0.002 and 654.0 ± 78.9 
- 720.8 ± 79.7 Nm, p= 0.000 respectively). The proposed work were used these 
robust measures of performance and attempt to discover changes within muscle that 
correlate with the differences in muscle output. 
 
In summary, irrespective of the type of testing modality, the evidence provided here 
supports the previously reported circadian variability of muscle force output and 
strength performance. However, it was established that RFD and MVC showed the 
greatest diurnal variation when compared to IKD (10.2 % and 18%, respectively). 
Therefore these methods will be used as diurnal variation performance before the 
biopsies taken to investigate whether modifications occur to the contractile proteins 
of the skeletal muscle that effect its ability to produce force at different time of day.  
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Chapter 4 
Proteomic Analysis of Diurnal Variation in Human Myofibrillar 
Proteome 
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4.1 INTRODUCTION 
 
Chapter background 
The proteome dictates cellular function, therefore differences in function that occur 
between morning and evening must be underpinned by differences in the proteome. 
Candidate mechanisms such as temperature, arousal and hormones etc. are 
associated with diurnal differences in muscle output but none of these mechanisms 
have been causally linked to daily changes in muscle force. Irrespective of the 
upstream stimulus, the aim of this chapter was to investigate whether modifications 
occur to the contractile proteins of the skeletal muscle that underpin its ability to 
produce force at different times of day. By using non-targeted proteomic analysis to 
measure differences in the abundance of dozens of important myofibrillar proteins 
new information might be discovered that can help to understand the mechanisms of 
diurnal variation. The main proteins of interest (in addition to myosin heavy chain 
isoforms) were the isoform, splice variant and post-translational sub-species of 
regulatory and essential myosin light chains, tropomyosins and troponins, which 
may modulate muscle contractile characteristics.  
 
Proteomics is the large-scale comprehensive study of proteins using various 
separation techniques and non-targeted mass spectrometry-based analysis. To date, 
33 peer-review journal articles report proteomic analysis of human skeletal muscle, 
i.e. from 2003 to 2015 (Table 21). The first proteomic analysis of human skeletal 
muscle was by Gelfi et al., (2003) reporting a 2DGE map of human vastus lateralis 
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that provides a valuable resource for the definition of the functional properties of 
muscle.  Since this initial publication, proteomic analysis of human samples has been 
used to address experimental questions including diabetes (Hojlund et al., 2003; Al-
Khalili et al., 2014), aging (Gelfi et al., 2006; Lanza et al., 2008; Staunton et al., 
2012), muscular dystrophies (Moriggi et al., 2010; Brocca et al., 2012), obesity 
(Hittel et al, 2005; Hojlund et al., 2010; Hwang et al., 2010; Giebelstein et al., 2012) 
and exercise training (Holloway et al., 2009; Hody et al., 2011; Egan et al, 201; Son 
et al., 2012; Malik et al., 2013; Schild et al., 2015).  
 
Typically biopsy samples from human vastus lateralis have been analysed (Gelfi et 
al., 2003; Lefort et al., 2009; Wijers et al., 2010; Zhao et al., 2011; Son et al., 2012), 
but some researchers have also used deltoideus (Capitanio et al., 2005), rectus 
femoris (Hody et al., 2011) and soleus (Moriggi et al., 2010). In addition, primary 
myoblasts have been cultured from human muscle (e.g. Norheim et al., 2011; 
Hartwig et al., 2014). Many of the studies included proteome mining and provide 
important catalogues of accessible muscle proteins (Gelfi et al., 2003; Yi et al., 2008; 
Lefort et al., 2009; Baraibar et al., 2011; Zhao et al., 2011). By considering the 
number of proteins identified it is clear the combination of SDS-PAGE with LC-
ESI-MS/MS, known as GeLC-MS/MS is of particular utility in skeletal muscle 
protein mining. Alternatively, protein profiling has been conducted using 2DGE or 
DIGE which offers robust comparative analysis of protein species, proteome 
profiling and differential expression (Hojlund et al., 2003; Gelfi et al., 2006; 
Holloway et al., 2009; Giebelstein et al., 2012;; Hartwig et al., 2014; Schild et al., 
2015). More recently, some studies (Hwang et al., 2010; Hussey et al., 2013; Malik 
et al., 2013) have also applied LC-MS profiling in human skeletal muscle. 
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Table 21. Summary of studies on proteomics of human skeletal muscle  
Reference Sample Area of research Technique Number of proteins 
Hojlund et al., (2003) VL Diabetes 2DGE, MS 489 spots, 11 sig diff 
Gelfi et al., (2003) VL Mining 2DGE, MALDI-MS, LC-ESI-MS/MS >500 spots, 124 identified 
Hittel et al., (2005) RA Obesity 2DGE, MS 7 sig diff 
Capitanio et al., (2005) VL, D Mining 2DGE, MS 37 sig diff 
Gelfi et al., (2006) VL Aging DIGE, SDS-PAGE, LC-ESI-MS/MS. ~2700 spots, 39 sig diff 
Viganò et al., (2008) VL Altitude 2DGE, LC-ESI-MS/MS 122 spots, 56 sig diff 
Yi et al., (2008)  VL Mining GeLC-MS/MS 507 identified 
Lanza et al., (2008)   VL Aging LC-ESI-MS/MS, iTRAQ 50 sig diff 
Hojlund et al., (2008)  VL Mining GeLC-MS/MS 741 identified 
Lefort et al., (2009)  VL Mining GeLC-MS/MS 823 identified 
Højlund et al., (2009) VL Mining GeLC-MS/MS 127 identified 
Parker et al., (2009)  VL Mining GeLC-MS/MS >2000 identified 
Holloway et al., (2009) VL Exercise 2DGE, iTRAQ, SDS-PAGE, LC-MALDI 
MS/MS. 
256 spots, 168 identified, 38 
sig diff 
Højlund et al., (2010) VL Obesity SDS-PAGE, LC-ESI-MS/MS 7 sig diff 
Hwang et al., (2010)  VL Obesity LC-ESI-MS/MS 334 identified, 15 sig diff 
Wijers et al., (2010) VL Thermo-genesis 2DGE MALDI-MS/MS 224 spots, 52 sig diff 
Moriggi et al., (2010) VL, S Muscular dystrophies DIGE, MALDI- MS/MS, LC-ESI MS/MS 33 sig diff 
Hody et al., (2011) RF Exercise 2DGE, MALDI- MS/MS 191 spots, 61 identified, 52 
sig diff 
Baraibar et al., (2011) PM Primary cell 2DGE, SDS-PAGE, MALDI-MS/MS ~4000 spots 
Zhao et al., (2011) VL Mining LC-ESI-MS/MS 878 identified 
Egan et al., (2011) VL Exercise DIGE, LC-ESI-MS/MS 800 spots, 31 sig dif 
Norheim et al., (2011) VL, T, PM Exercise & Primary SDS-PAGE, LC-ESI-MS/MS 236 identified, 25 sig diff 
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cell 
Brocca et al., (2012) VL Muscular dystrophies 2DGE, MALDI MS/MS, LC-ESI-MS/MS >800 spots, 33 sig diff 
Giebelstein et al., (2012) VL Obesity 2DGE, LC/ESI-MS/MS 2852 spots, 107 identified, 
44 sig diff 
Staunton et al., (2012). VL Aging DIGE, LC-ESI-MS/MS 19 sig diff 
Son, et al., (2012) VL Exercise 2DGE, MALDI-MS/MS ~600 spots, 16 sig diff 
Malik et al., (2013) VL Exercise LC-ESI-MS/MS  207 identified, 16 sig diff 
Hussey et al., (2013) VL 
 
Exercise & Diabetes GeLC-MS/MS 438 identified, 15 sig diff 
Conti et al., (2014) VL, G Muscle 2DGE, LC-ESI-MS/MS 11 sig diff 
Hartwig et al., (2014) VL, PM Primary cell 2DGE, SDS-PAGE, MALDI-MS/MS 1200 spots, 171 identified, 
12 sig diff 
Al-Khalili, et al. (2014a)  VL, PM Diabetes DIGE, LC-ESI-MS/MS 166 identified, 11 sig diff 
Al-Khalili, et al. (2014b)  VL, PM Diabetes DIGE, LC-ESI-MS/MS 1804 spots, 47 sig diff 
Schild, et al. (2015) VL Exercise LC-ESI-MS/MS 3481 identified, 115 sig diff 
Summary of proteomic studies of human muscle, including vastus lateralis (VL), rectus abdominus (RA), deltoid (D), gracilis (G), primary 
myoblast (PM), soleus (S), rectus femoris (RF), trapezius (T). Proteomic techniques that have been used on human muscle include two-
dimensional gel electrophoresis (2DGE), one-dimensional denaturing gel electrophoresis (SDS-PAGE), matrix-assisted laser desorption tandem 
mass spectrometry (MALDI-MS/MS), liquid chromatography-electrospray ionisation-tandem mass spectrometry (LC-ESI-MS/MS), isobaric 
tags for relative and absolute quantitation (iTRAQ), difference in-gel electrophoresis (DIGE) and one-dimensional denaturing gel electrophoresis 
coupled with liquid chromatography-electrospray ionisation-tandem mass spectrometry (GeLC-MS/MS). 
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Proteome mining work (Hojlund et al., 2008) has identified 954 different proteins in 
human vastus lateralis muscle obtained from three healthy, non-obese subjects using 
GeLC-MS/MS. Meanwhile Parker et al., (2009) investigated various combinations 
of SDS-PAGE and HPLC separations coupled with ESI-MS/MS to identify almost 
2000 proteins, and determined how 370 very abundant proteins behave upon 
differential solubilisation. These results provide the comprehensive characterization 
of the human skeletal muscle proteome. The current thesis also used the GeLC-
MS/MS techniques to catalogue the proteins present in the myofibrillar fraction. 
 
Work from our laboratory (Holloway et al., 2009) was the first to report proteomic 
analysis of the response of human skeletal muscle to exercise training. Since our 
initial publication, exercise physiology has become a major theme in muscle 
proteomics and to date 7 further studies have investigated the effects of exercise. Son 
et al., (2012) investigated the effect of resistance and endurance training on muscle 
proteome expression, samples of vastus lateralis from 10 physically active young 
men were analysed by 2DGE and MALDI-MS/MS. They concluded that endurance 
and resistance exercise training differently alter the expression of individual muscle 
proteins, and that the response of muscle protein expression may be associated with 
specific myofibre adaptations to exercise training. Our current study focuses on 
muscle performance and diurnal variation and, to date, no other human muscle 
chronobiology study has attempted to use proteomic analysis.  
 
Indeed it was difficult to find chronobiology studies reporting effects in human 
muscle. Rather the majority of studies (e.g. Bae et al. 2006; McCarthy et al., 2007; 
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Andrews et al., 2010; Wolff et al., 2013) have used laboratory animal models 
involving genetic deletion of molecular clock genes. Bae et al., (2006) reported the 
differential effects of the two period genes (Per1 and Per2) on the physiology and 
proteomic profiles of mouse anterior tibialis muscles using 2DGE. Loss of the Per2 
clock gene affected forced locomotor performance in mice but did not alter muscle 
contractility. At the proteome level, Per2 knockout altered the abundance of 
glycolytic enzymes (e.g. triosephosphate isomerase and beta-enolase) and the 
chaperone protein, Hsp90. However, relatively few biological replicates were 
analysed in Bae et al., 2006, which makes it difficult to know if the reported changes 
are statistically relevant. Moreover, this work failed to recognise that changes in the 
abundance of individual spots on a 2D gel often reflect changes in the post-
translational state of a protein rather than a change in its total abundance (see 
Burniston 2008 and Burniston & Hoffman 2011 for discussion). 
 
Muscle phenotype can be determined biochemically by analysing the relative 
abundances of each MyHC isoform. However, diurnal variations in muscle 
performance are unlikely to be due to changes in protein abundance because for most 
muscle proteins the time required to degrade and synthesise new proteins is much 
greater than 12 h. Using the proteomic technique of 2DGE it is possible to measure 
the relative abundance of each myofibrillar protein species encompassing different 
protein isoforms, splice-variants and post-translational states. Of particular interest 
are changes in reversible post-translational modifications (PTM) because these can 
occur within minutes to hours and could represent a feasible mechanism by which 
the muscle proteome differs during the course of the day. 
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Post-translational modifications are chemical modifications that are crucially 
important in regulating the basic biological functions and dynamics of proteins. 
There are many different types of PTM, among them, the most common and 
important PTM are phosphorylation, acetylation, glycosylation, methylation, 
sulfation, nitration, deamidation, and disulfide bond formation (Mann & Jansen, 
2003). PTM function in various ways, for example, phosphorylation can reversibly 
activate/inactivate enzyme activity, regulate cellular processes including cell cycle, 
growth, apoptosis and signal transduction pathways; acetylation can regulate 
protein–deoxyribonucleic acid (DNA) interactions, and stabilize the structures of 
proteins; glycosylation can regulate cell-cell recognition and signalling, and affect 
the folding, conformation, stability, and activity of proteins; disulfide bonds 
commonly stabilize the secondary structure of proteins (Mann & Jansen, 2003). The 
study of PTMs can therefore provide invaluable insight into the cellular function 
processes. 
 
Aim of this study 
The current study will use state of art proteomic techniques described in Chapter 1 to 
simultaneously investigate modifications to numerous contractile proteins in human 
skeletal muscle. Information regarding changes at the protein level will be compared 
with measures of muscle performance to determine the level of association between 
muscle output and a particular protein modification. If successful, this work will 
provide candidate biomarkers that could be used to develop and optimise 
interventions aimed at forestalling morning decrements in muscle performance. 
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4.2 METHODS 
To correlate functional and molecular responses it is necessary to obtain muscle 
samples by percutaneous needle biopsy. While invasive, this technique is established 
and routinely used in the Department for studies of this nature (e.g. Holloway 2009). 
A trained practitioner obtained biopsies from the vastus lateralis at 2 different time 
points (morning and evening). Samples of vastus lateralis were fractionated and sub-
fractions enriched and myofibrillar proteins were ‘mined’ using GeLC-MS/MS, 
whereas differential profiling by 2DGE was used to investigate diurnal variations in 
the myofibrillar proteome.  
 
4.2.1 Participants 
Participants were selected from the cohort reported in Chapter 3, and their muscle 
function was assessed again using MVC and RFD, also described in the Chapter 3. 
Procedures were explained in full to the participants and questions were answered 
prior to participation. The study was approved by the National Research Ethics 
Committee (14/WM/0065) and was registered with the Liverpool John Moores 
University Research Ethics Committee (14/SPS/015 “Mechanisms underpinning 
diurnal variation in human muscle”). Inclusion criteria required previous strength 
training experience (≥ 2 years) with exclusion criteria stating recent shift work or 
travel across multiple time zones.  
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Muscle Performance testing 
4.2.2 Protocol and Measures  
The protocol and measurement were identical to the MVC, RFD and temperature 
measures reported in Chapter 3 and, for convenience, are illustrated in Figure 27. In 
the current work samples were provided from ten healthy young males randomly 
assigned to 2 counterbalanced groups: Group 1 (morning-evening) and Group 2 
(evening-morning).   
 
 
Figure 27. Schematic diagram of the testing protocol following biopsy for all 
conditions, rectal (Trec), skin (Tsk) and muscle (Tm) temperatures and thermal 
comfort (TC) were measured after the participants had reclined for 30 min at the start 
of the protocol and after the warm-up. Rating of perceived exertion (RPE) was taken 
during warm-up and after each MVC, with rating of effort taken after each MVC. 
Black bars indicate muscle temperature taken at these points; grey bars indicate 
recovery between tests.   
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4.2.3 Quadriceps Muscle biopsies 
Each participant underwent a quadriceps (vastus lateralis) muscle biopsy of their 
right leg in the morning (0700h) and evening (1700h). The biopsies were taken 
within 5 min of completing MVC and RFD measurements. Participants were placed 
comfortably on an examination couch in the supine position. Dorsiflexion of the 
ankle was used to help define the rectus femoris muscle, and the vastus lateralis was 
identified as lying along its lateral border. The biopsy site was marked as the 
junction between the upper third and lower two-thirds of the thigh (Figure 28). 
Muscle biopsies were obtained using a Bard Monopty Disposable Core Biopsy 
Instrument 12 gauge x 10 cm length (Bard Biopsy System, Tempe, AZ).  Samples 
(~15 mg) were obtained under local anesthesia (0.5% Marcaine). A small 1cm 
longitudinal stab incision was made and extended deeper down until the muscle 
fascia was pierced. The core biopsy needle was attached to the biopsy gun and 
inserted through the incision. A muscle biopsy was obtained by pressing the trigger 
button on the biopsy gun, which unloads the spring and activates the needle to 
collect muscle tissue. The sample was immediately frozen in liquid nitrogen and 
stored at -80C for further analysis. Using the same skin incision, 2 to 3 further 
biopsies were taken to ensure adequate quantities (~70 mg) of muscle tissue were 
available for analysis. At the end of the procedure, firm pressure was applied over 
the biopsy site for 5 minutes to prevent excessive bleeding. Sterile strips were then 
placed over the incision site and covered by a water-proof dressing. Finally a crepe 
bandage was firmly applied around the thigh in order minimize bleeding and 
bruising when the participant starts to mobilize. Instructions were provided to 
remove the crepe bandage after 8 hours, and to keep the biopsy site dry for about 2 to 
3 days. No adverse effects were reported by participants of this study. 
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Figure 28. Quadriceps muscle biopsy procedure 
 
 
4.2.4  Muscle processing  
Muscle samples were ground using a pestle and mortar, under liquid nitrogen. The 
powder was accurately weighed (70 mg) and homogenised on ice in 10 volumes of 
lysis buffer, using a glass-teflon homogeniser. The lysis and solubilising buffer 
consisted of 1 % (v/v) Triton X-100, 40 mM Tris pH 7.4, phosphatase inhibitor and 
complete protease inhibitor cocktail (Roche, Indianapolis, USA). Homogenates were 
centrifuged at 1,000 x g, 4 °C for 10 min and the supernatant (containing soluble 
proteins) was decanted and stored in 100 µl aliquots at -80 °C. The current thesis 
reports analysis of the pellet that contains myofibrillar proteins. The pellet was re-
suspended in 2DGE Lysis buffer containing 7 M urea, 2 M thiourea, 4 % (w/v) 
CHAPS, 30 mM Tris including phosphatase and protease inhibitor cocktails (Roche). 
A Bradford Assay (Bradford, 1976) was performed as described previously in 1.2.7 
and the samples were analysed using a variety of different protein/proteomic analysis 
(Figure 29).  
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Analysis of human muscle proteins 
 
 
 
Figure 29. Several methods were used in this study including GeLC-MS/MS (a). 
MyHC profiling used traditional method by 1D SDS-PAGE and latest method with 
high throughput profiling (b). 2D gel electrophoresis was used to discover which 
myofibrillar proteins were resolved in to multiple species by several pH separation 
and size of gel like preparative pH 3-11 in 13 cm gel (c), pH 3-11 in 13 cm gel (d) 
and pH 4-7 in 7 cm gel (e). 
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4.2.5 Mining of the myofibrillar proteome by GeLC-MS/MS 
A pooled sample was created from aliquots of the individual myofibrillar fractions 
and 50 μg was precipitated in 5 volumes of acetone and then resuspended in 
Laemmli buffer. The pooled protein sample was boiled (5 min at 95 ºC) separated by 
15 % SDS-PAGE as described in Chapter 1 (Section 1.2.9). The entire gel lane, 
encompassing was cut in to 10 equal segments. Each segment was diced into 1 mm 
cubes and the proteins were digested with trypsin, as described in section 1.2.13. LC-
ESI-MS/MS analysis of each of the 10 molecular weight fractions was performed 
according to section 1.2.15 and the protein identifications were combined in to a 
single non-redundant list that describes the entire catalogue of MS-accessible 
proteins in the myofibrillar fraction. 
 
4.2.6 Analysis of Myosin heavy chain isoforms. 
MyHC isoforms were analysed according to molecular weight by 8 % SDS-PAGE as 
described in Chapter 1. In addition, multiple reaction monitoring (MRM) of isoform 
specific peptides was performed. An aliquot of the myofibrillar fraction of human 
muscle was prepared for in-solution digest, by precipitating supernatants in 5 
volumes of acetone and resuspended in Lysis Buffer: 7 M urea, 2 M thiourea, 4 % 
(w/v) CHAPS, 30 mM Tris, containing Complete™ protease inhibitor (Roche 
Diagnostics, Lewes, UK). After clearing by centrifugation (12,000 xg, 4 ºC for 45 
min) protein concentrations were measured using the Bradford assay (Sigma, Poole, 
Dorset, UK) and each sample adjusted to 5 μg μl-1. Aliquots containing 100 μg 
protein were precipitated in 5 volumes of acetone for 1 h at -20 ºC. Pellets were 
resuspended in 0.1% (w/v) Rapigest SF (Waters; Milford, MA) in 50 mM 
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ammonium bicarbonate and incubated at 80 ºC for 15 min. DTT was added (final 
concentration 1 mM) and incubated at 60 ºC for 15 min followed by incubation 
whilst protected from light in the presence of 5 mM iodoacetamide at 4 ºC. 
Sequencing grade trypsin (Promega; Madison, WI) was added at a protein ratio of 
1:50 and digestion allowed to proceed at 37 ºC overnight. Digestion was terminated 
by the addition of 2 μL concentrated TFA and peptide solutions were cleared by 
centrifugation at 13 000 xg for 5 min.  
MRM transitions (parent ion – fragment ion) for isoform specific peptides were 
767.33-987.52 m/z for residues 387-400 (AAYLQNLNSADLLK) of MYH1 (MyHC 
IIx), 577.2-912.32 m/z for residues 1286-1295 (LQTESGEFSR) of MYH2 (MyHC 
IIa) and 773.35-917.38 m/z for residues 745-757 (LLSSLDIDHNQYK) of MYH7 
(MyHC I). In addition, a pan-MyHC isoform peptide (LASADIETYLLEK) was 
monitored using the transition 733.3-895.41 m/z. 
 
4.2.7 Differential profiling of Myofibrillar proteins by 2DGE 
Samples were precipitated in acetone and resuspended in rehydration containing 7 M 
urea, 2 M thiourea, 2 % (w/v) CHAPS, 20 mM dithiothreitol, and 0.5% (v/v) 
ampholytes. Broad-range analysis of myofibrillar proteins was conducted using 
large-format (13 cm) 2D gels over the range pH 3-11. In addition, smaller format (7 
cm) narrow-range (pH 4-7) gels were used to specifically investigate differences in 
myosin light chain protein species. 
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Large-format 2D gels were loaded with 250 µg of protein and isoelectric focusing 
was conducted as follows: 300 V for 3 h, 600 V for 3 h, linear gradient to 8,000 V 
over 3 h and 8,000 for 4 h. The IPG strips were then equilibrated in 50 mM Tris-HCl 
(pH 8.8), containing 6 M urea, 30 % (v/v) glycerol, 2 % (w/v) sodium dodecylsulfate, 
and a trace of bromophenol blue. Proteins were electrophoresed through a linear 11 % 
polyacrylamide gel at 20 °C; initially at a constant current of 15 mA per gel for 30 
min and then at 30 mA per gel. Following the process, the gel was removed from the 
glass plates and washed 3 times in ddH2O, with each wash taking ~5 minutes. The 
ddH2O was poured off and then the gels were stained in 100 ml of colloidal 
Coomassie blue (Bio-safe, Bio-rad laboratories, Hercules, USA) for 1 hour before 
being de-stained overnight in ddH2O.  The gel image was analysed using Progenesis 
SameSpots software to detect within participant differences between morning and 
evening samples. 
 
Small-format 2D gels, similar to those used in section 1.2.11, were loaded with 40 
µg protein. Isoelectric focusing was conducted as follows: 50 V for 15 min, 250 V 
for 15 min, linear gradient to 4,000 V over 2 h and 4,000 for 2 h.  The IPG strips 
were then equilibrated in 50 mM Tris-HCl (pH 8.8), containing 6 M urea, 30 % (v/v) 
glycerol, 2 % (w/v) sodium dodecylsulfate, and a trace of bromophenol blue. 
Proteins were electrophoresed through a linear 15 % polyacrylamide gel at 20 °C; 
initially at a constant voltage of 100 V per gel for 30 min and then at 200 V per gel. 
After electrophoresis, the gel was removed from the glass plates and washed 3 times 
in ddH2O, with each wash taking ~5 minutes. The ddH2O was poured off and then 
the gels were stained in 100ml of colloidal Coomassie blue (Bio-safe, Bio-rad 
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laboratories, Hercules, USA) for 1 hour before being de-stained overnight in ddH2O. 
Progenesis PG 2000 software was used to analyse within participant differences. 
 
4.2.8  In-gel digestion and LC-MS 
Standard in-gel digestion was performed as described in section 1.2.13. In addition 
for identification of phosphorylated proteins, HyperSepTM SpinTip Porous Titanium 
Dioxide was used to enrich phosphopetpides according to the manufacturer 
instructions. Briefly, each SpinTip was washed by 50 µl of 50 mM formic acid and 
repeated 3 times. Fifty microliters of sample digest was added in the SpinTip and air 
pressured was applied to force the solution through the porous TiO2 material. Then 
the packed bed was washed 3 times with 50 µl of ddH2O and the solution labelled as 
Non-Phosphorylation. The bound molecule from the packed bed was eluted with 50 
µl of 50 mM Ambic and the solution labelled as Phosphorylated peptides.   
    
4.2.9 Protein identification 
Mass spectrometry analysis was performed using a quadrupole-high capacity ion-
trap (HCT Ultra ETD II; Bruker Daltonics, Bremen, Germany) coupled online via an 
electrospray ionisation source to a nano-flow HPLC system (Ultimate 3000; Dionex, 
Sunnyvale, CA).  MS/MS spectra were exported in Mascot generic format and 
searched against the Swiss-Prot database (2011.6) restricted to ‘Human’ using a 
locally implemented Mascot (www.matrixscience.com) server (version 2.2.03). The 
enzyme specificity was trypsin allowing 1 missed cleavage, carbamidomethyl 
modification of cysteine (fixed), deamidation of asparagine and glutamine (variable), 
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oxidation of methionine (variable) and an m/z error of ± 0.5 Da. Post-translational 
modifications were analysed using error tolerant searches followed by modification 
specific searches that included either phosphorylation (S,T,Y) or acetylation (K) as 
variable modifications. 
 
4.2.10 Statistical Analysis 
The data were analysed using the Statistical Package for Social Sciences (SPSS) for 
Windows (SPSS, Chicago, IL, USA) version 20. Comparison by paired sample t-test 
was used to test the primary hypothesis and identify presence of a diurnal variation. 
The results are presented as the mean ± the standard deviation (SD) throughout the 
text unless otherwise stated. Ninety-five percent confidence interval (CIs) are 
presented where appropriate. The alpha level of significance was set at 5% (p < .05).  
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4.3 RESULTS 
 
4.3.1 Characteristics of human muscles samples 
Ten male participants were recruited of age (mean±SD) = 26.7 ± 3.7 years; height 
177.8 ± 8.4 cm, body mass 74.9 ± 9.8 kg with habitual retiring and waking times of 
11:24 ± 0:36 p.m. and 06:12 ± 0:12 h a.m., respectively. Mean chronotype score was 
35.5 ± 3.1 (all intermediate types), F/R score 44.9 ± 5.9; and L/V score, 44.8 ± 8.0. 
Procedures were explained in full to participants with questions answered prior to 
participation. POMS data identified significantly greater “happy” and “vigour” score 
in the evening than in the morning. Throughout the testing protocol, both core 
temperature (Trec) and muscle temperature were significantly greater in the evening 
than in the morning (Figure 30). 
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Figure 30. Means and standard deviations for rectal, skin and muscle temperatures 
measured at rest, post warm-up, post MVC and post RFD. * Significantly higher 
than morning (p<0.05).  
 
Muscle Performance testing 
4.3.2 MVC and RFD 
Consistent with our findings in Chapter 3, MVC was significantly greater (11%) in 
the evening compared to morning (Table 22). There was no statistically significant 
difference in the level of voluntary activation between morning and evening 
conditions. Peak RFD (N·s
-1
) was significantly greater (15.7 %) in the evening than 
in the morning. There were no significant differences in the rate of perceived 
exertion (RPE) or thermal comfort (TC). 
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Table 22. Diurnal differences in muscle performance.   
 Morning Evening  P value  (%) 
MVC force (Nm) 679.9 ± 104.9 754.4 ± 112.9* 0.004 11.0  
MVC activation (%) 85.5 ± 8.7 87.2 ± 7.9 0.532 2.0 
Peak RFD (N.s
-1
) 6077.3 ± 1371.7 7030.5 ± 1100.7* 0.008 15.7 
Time to Peak force (ms) 76.6 ± 15.2 70.8 ± 12.5 0.214 8.2 
RPE     
During Warm-Up 10.9 ± 2.2 10.9 ± 2.0 1.000  
During MVC efforts 14.0 ± 3.1 13.2 ± 3.3 0.104  
Thermal Comfort      
Resting 4.8 ± 0.3 4.9 ± 0.3 1.000  
During Warm-Up 5.9 ± 0.6 6.0 ± 0.8 0.591  
Data are presented as means ± SD; n = 10 repeated measures taken in the morning 
and evening. * Significantly different from morning condition. 
 
 
Analysis of human muscle proteins 
4.3.3 GeLC-MS/MS mining of the human myofibrillar fraction 
GeLC-MS/MS analysis was used to catalogue proteins in the myofibrillar fraction. 
In total 193 proteins were detected (Table 23) and 33 of these proteins were 
specifically associated with the myofibrillar apparatus and identified with high 
degrees of confidence and the protein list (Table 24) encompassed the majority of 
expected thin and thick filament proteins of the myofibrillar apparatus (Figure 31).  
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Table 23. Entire list of proteins detected in the myofibrillar fraction. 
UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
1433E 14-3-3 protein epsilon  217 29326 4.63 26.7 10 
1433G 14-3-3 protein gamma  118 28456 4.8 16.6 6 
GRP78 78 kDa glucose-regulated protein  103 72402 5.07 4.1 3 
THIL Acetyl-CoA acetyltransferase, mitochondrial  74 45456 8.98 10.1 4 
ASM3A Acid sphingomyelinase-like phosphodiesterase 3a  41 51741 5.88 1.8 5 
ACTC Actin, alpha cardiac muscle 1  1554 42334 5.23 67.1 133 
ACTS Actin, alpha skeletal muscle  3750 42366 5.23 73.2 288 
ACTA Actin, aortic smooth muscle  1515 42381 5.23 64.2 126 
ACTB Actin, cytoplasmic 1  1597 42052 5.29 64.3 157 
ACTG Actin, cytoplasmic 2  99 42108 5.31 9.9 8 
ACTH Actin, gamma-enteric smooth muscle  1445 42249 5.31 60.9 116 
ACYP2 Acylphosphatase-2  64 11190 9.52 30.3 3 
ADT1 ADP/ATP translocase 1  217 33271 9.78 24.5 12 
ADT ADP/ATP translocase 2  101 33059 9.71 12.8 7 
ADT3 ADP/ATP translocase 3  113 33073 9.76 16.4 8 
A1AT Alpha-1-antitrypsin  96 46878 5.37 10.5 6 
ACTN1 Alpha-actinin-1  122 103563 5.25 2.6 3 
ACTN2 Alpha-actinin-2  1387 104358 5.31 38 103 
ACTN3 Alpha-actinin-3  407 103917 5.37 23.5 34 
ENOA Alpha-enolase  410 47481 7.01 32.3 23 
ALMS1 Alstrom syndrome protein 1  37 463078 5.87 0.4 4 
AATC Aspartate aminotransferase, cytoplasmic  132 46447 6.52 18.9 7 
AATM_ Aspartate aminotransferase, mitochondrial  77 47886 9.14 6.5 3 
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UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
ATPA ATP synthase subunit alpha, mitochondrial  421 59828 9.16 29.3 23 
ATPB ATP synthase subunit beta, mitochondrial  457 56525 5.26 35.9 22 
ATPG ATP synthase subunit gamma, mitochondrial 57 33032 9.23 10.1 4 
ACTBL Beta-actin-like protein 2  592 42318 5.39 23.1 41 
ENOB Beta-enolase  767 47244 7.59 48.2 45 
CASQ1 Calsequestrin-1  319 44471 4.02 23.8 16 
CAH1 Carbonic anhydrase 1  446 28909 6.59 57.1 22 
CAH2 Carbonic anhydrase 2  142 29285 6.87 27.7 8 
CAH3 Carbonic anhydrase 3  477 29824 6.86 55 24 
CATA Catalase  58 59947 6.9 6.5 3 
CHCH3 Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 3, mitochondrial  
137 26421 8.48 15 4 
KCRM Creatine kinase M-type  982 43302 6.77 54.1 61 
KCRS Creatine kinase S-type, mitochondrial  97 47988 8.46 15 7 
CSRP3 Cysteine and glycine-rich protein 3  159 21867 8.89 23.2 5 
QCR1 Cytochrome b-c1 complex subunit 1, mitochondrial 88 53297 5.94 8.5 5 
DESM Desmin  1955 53560 5.21 57.4 90 
EF1A1 Elongation factor 1-alpha 1  92 50451 9.1 11.5 7 
EF1A2 Elongation factor 1-alpha 2 92 50780 9.11 8.9 6 
CAZA2 F-actin-capping protein subunit alpha-2  68 33157 5.57 12.6 3 
FABPH Fatty acid-binding protein, heart  90 14906 6.29 12.8 4 
FHL1 Four and a half LIM domains protein 1  129 38006 9.25 7.1 3 
ALDOA Fructose-bisphosphate aldolase A 342 39851 8.3 41.2 28 
ALDOB Fructose-bisphosphate aldolase B  47 39961 8 1.9 4 
ALDOC Fructose-bisphosphate aldolase C 70 39830 6.41 8.2 7 
LEG1 Galectin-1 79 15048 5.34 23.7 3 
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UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
ENOG Gamma-enolase 173 47581 4.91 12 10 
GELS Gelsolin  47 86043 5.9 3.1 3 
G3P Glyceraldehyde-3-phosphate dehydrogenase  688 36201 8.57 47.5 38 
PYGB Glycogen phosphorylase, brain form  85 97319 6.4 4.6 7 
PYGL Glycogen phosphorylase, liver form  74 97486 6.71 3.7 7 
PYGM Glycogen phosphorylase, muscle form  207 97487 6.57 18.8 32 
HSP71 Heat shock 70 kDa protein 1A/1B  165 70294 5.48 16.8 11 
HSP7C Heat shock cognate 71 kDa protein  290 71082 5.37 17 13 
HSPB1 Heat shock protein beta-1  253 22826 5.98 47.8 17 
HSP72 Heat shock-related 70 kDa protein 2  202 70263 5.56 11.4 9 
HB Hemoglobin subunit alpha  620 15305 8.72 62 51 
HB Hemoglobin subunit beta 1925 16102 6.75 84.4 133 
HBD Hemoglobin subunit delta 895 16159 7.85 83 71 
HBE Hemoglobin subunit epsilon  113 16249 8.67 6.8 6 
HBG1 Hemoglobin subunit gamma-1 113 16187 6.64 6.8 6 
HBG2 Hemoglobin subunit gamma-2  113 16173 6.64 6.8 6 
H4 Histone H4  70 11360 11.36 17.5 3 
IGHG1 Ig gamma-1 chain C region  163 36596 8.46 18.2 11 
IGHG2 Ig gamma-2 chain C region  44 36505 7.66 8.6 7 
IGHG3 Ig gamma-3 chain C region  161 42287 8.23 11.4 9 
IGHG4 Ig gamma-4 chain C region  96 36431 7.18 13.1 7 
IGKC Ig kappa chain C region 241 11773 5.58 65.1 13 
LAC2 Ig lambda-2 chain C regions  80 11458 6.92 46.2 5 
LAC7 Ig lambda-7 chain C region  77 11467 8.49 32.1 4 
IGLL5 Immunoglobulin lambda-like polypeptide 5 64 23391 9.08 17.8 3 
IDHP Isocitrate dehydrogenase [NADP], mitochondrial  386 51333 8.88 28.3 19 
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UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
KBTBA Kelch repeat and BTB domain-containing protein 10  328 68792 5.14 29.9 22 
KT81L Keratin-81-like protein  107 54972 6.05 7.8 8 
K1H1 Keratin, type I cuticular Ha1  43 48633 4.84 7 5 
K1H Keratin, type I cuticular Ha2 41 51793 4.78 4.5 4 
KT33A Keratin, type I cuticular Ha3-I  32 47166 4.78 17.1 8 
KT33B Keratin, type I cuticular Ha3-II  43 47325 4.81 6.7 4 
KRT36 Keratin, type I cuticular Ha6  36 53354 4.9 3.4 3 
KRT38 Keratin, type I cuticular Ha8  36 52044 4.79 3.5 3 
K1C10 Keratin, type I cytoskeletal 10  1038 59020 5.13 39.2 52 
K1C13 Keratin, type I cytoskeletal 13 64 49900 4.91 4.1 3 
K1C14 Keratin, type I cytoskeletal 14  255 51872 5.09 15.3 15 
K1C15 Keratin, type I cytoskeletal 15 135 49409 4.71 6.1 6 
K1C16 Keratin, type I cytoskeletal 16  238 51578 4.99 7.8 10 
K1C17 Keratin, type I cytoskeletal 17  67 48361 4.97 8.8 8 
K1C19 Keratin, type I cytoskeletal 19  36 44079 5.04 6 5 
K1C24 Keratin, type I cytoskeletal 24  47 55567 4.89 3.4 4 
K1C25 Keratin, type I cytoskeletal 25 229 49858 5 4 8 
K1C26 Keratin, type I cytoskeletal 26  137 52620 4.86 1.9 4 
K1C27 Keratin, type I cytoskeletal 27  111 50419 4.98 3.9 5 
K1C28 Keratin, type I cytoskeletal 28  236 51163 5.33 5.6 12 
K1C9 Keratin, type I cytoskeletal 9  362 62255 5.14 29.4 19 
KRT81 Keratin, type II cuticular Hb1  110 56832 5.4 12.1 13 
KRT83 Keratin, type II cuticular Hb3  114 55928 5.54 13.8 14 
KRT85 Keratin, type II cuticular Hb5  77 57306 6.28 11.6 12 
K2C1 Keratin, type II cytoskeletal 1  1154 66170 8.15 34.9 49 
K2C1B Keratin, type II cytoskeletal 1b 183 62149 5.73 8.3 11 
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UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
K22E Keratin, type II cytoskeletal 2 epidermal  867 65678 8.07 40.7 37 
K22O Keratin, type II cytoskeletal 2 oral  75 66370 8.38 4.7 5 
K2C3 Keratin, type II cytoskeletal 3  69 64549 6.12 7.2 8 
K2C5 Keratin, type II cytoskeletal 5  179 62568 7.59 11.7 10 
K2C6A Keratin, type II cytoskeletal 6A  130 60293 8.09 13.3 11 
K2C6B Keratin, type II cytoskeletal 6B  167 60315 8.09 12.1 13 
K2C7 Keratin, type II cytoskeletal 7  42 51411 5.4 2.6 3 
K2C73 Keratin, type II cytoskeletal 73  43 59457 6.93 11.7 8 
K2C75 Keratin, type II cytoskeletal 75  148 59809 7.6 8.5 7 
K2C79 Keratin, type II cytoskeletal 79  90 58085 6.75 4.5 4 
K2C8 Keratin, type II cytoskeletal 8  42 53671 5.52 2.5 3 
LDHA L-lactate dehydrogenase A chain  199 36950 8.44 22.6 11 
LDHB L-lactate dehydrogenase B chain  70 36900 5.71 8.4 3 
LDB3 LIM domain-binding protein 3  548 78226 8.47 19.5 25 
MDHC Malate dehydrogenase, cytoplasmic  117 36631 6.91 14.4 7 
IMMT Mitochondrial inner membrane protein  61 84026 6.08 8.6 6 
MYG Myoglobin  304 17230 7.14 42.9 15 
MYL1 Myosin light chain 1/3, skeletal muscle isoform 767 21189 4.97 69.1 27 
MYL3 Myosin light chain 3  418 22089 5.03 54.4 16 
MYL10 Myosin regulatory light chain 10  65 25520 5.56 11.5 4 
MLRS Myosin regulatory light chain 2, skeletal muscle isoform  698 19116 4.91 69.8 26 
MLRV Myosin regulatory light chain 2, ventricular/cardiac 
muscle isoform  
334 18777 4.92 61.4 15 
MYH1 Myosin-1  1273 223976 5.59 24.4 101 
MYH13 Myosin-13  162 224605 5.54 4.2 15 
MYH2 Myosin-2  1765 223932 5.64 31 133 
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UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
MYH3 Myosin-3  137 224850 5.62 3.6 6 
MYH4 Myosin-4  163 223902 5.65 3.6 6 
MYH6 Myosin-6  645 224394 5.58 12.4 32 
MYH7 Myosin-7  1726 223757 5.63 30.2 125 
MYH Myosin-8  732 223594 5.59 11.9 40 
MYPC1 Myosin-binding protein C, slow-type  207 129240 5.78 14.1 23 
MYOTI Myotilin  456 55760 9.18 29.7 27 
MYOZ1 Myozenin-1  398 31725 8.86 35.8 14 
NDUAD NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 13 
53 16688 8.04 20.8 4 
NDUA4 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 4 
99 9421 9.42 37 6 
NDUV1 NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial  
54 51469 8.51 5.8 4 
NEB Nebulin  103 775406 9.11 1.7 15 
SYNE1 Nesprin-1  41 1017069 5.38 0.4 5 
NFL Neurofilament light polypeptide  62 61536 4.64 1.7 3 
PDLI5 PDZ and LIM domain protein 5  274 65102 8.55 17.3 17 
PRDX6 Peroxiredoxin-6  53 25133 6 21 4 
PGM1 Phosphoglucomutase-1  268 61696 6.3 22.2 13 
PGK1 Phosphoglycerate kinase 1  43 44985 8.3 12 3 
PGAM1 Phosphoglycerate mutase 1  69 28900 6.67 13.8 6 
PGAM2 Phosphoglycerate mutase 2 94 28919 8.99 30.4 10 
POTEE POTE ankyrin domain family member E  603 122882 5.83 8.3 39 
POTEF POTE ankyrin domain family member F  603 123020 5.83 6.1 37 
POTEI POTE ankyrin domain family member I  88 122858 5.83 3.4 11 
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UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
POTEJ POTE ankyrin domain family member J  182 118740 5.66 3.8 20 
LMNA Prelamin-A/C  43 74380 6.57 10.1 7 
ABEC2 Probable C->U-editing enzyme APOBEC-2  93 25915 4.81 19.6 6 
PGAM4 Probable phosphoglycerate mutase 4  51 28930 6.19 9.4 3 
PHB_H Prohibitin  44 29843 5.57 8.5 3 
AHNK2 Protein AHNAK2  39 617383 5.2 0.1 3 
NIPS2 Protein NipSnap homolog 2 75 33949 9.42 23.1 8 
ACTBM Putative beta-actin-like protein 3  276 42331 5.91 7.2 14 
YI016 Putative tubulin beta chain-like protein 
ENSP00000290377  
64 42204 4.77 11.3 5 
TBB4Q Putative tubulin beta-4q chain  59 48917 5.11 6.5 4 
ODPB Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  
88 39550 6.2 7.5 3 
KPYM Pyruvate kinase isozymes M1/M2  492 58470 7.96 36 28 
ALBU_ Serum albumin  1323 71317 5.92 63.9 110 
TBC19 TBC1 domain family member 19  40 60455 5.67 1.5 3 
TITIN Titin  62 3843119 6.01 0.2 8 
ECHB_ Trifunctional enzyme subunit beta, mitochondrial  158 51547 9.45 18.4 11 
TPIS_ Triosephosphate isomerase  706 26938 6.45 55 29 
TRI72 Tripartite motif-containing protein 72  155 53609 6.05 8.6 5 
TPM1_ Tropomyosin alpha-1 chain  1767 32746 4.69 51.1 131 
TPM3_ Tropomyosin alpha-3 chain  1650 32856 4.68 52.8 113 
TPM4_ Tropomyosin alpha-4 chain  1022 28619 4.67 21.8 61 
TPM2_ Tropomyosin beta chain  1390 32945 4.66 50.4 103 
TNNC1 Troponin C, slow skeletal and cardiac muscles 347 18505 4.04 24.2 24 
TNNI2 Troponin I, fast skeletal muscle  120 21496 8.87 20.3 6 
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UniProt 
Accession 
Protein Description MOWSE 
score 
Mass (Da) Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
Number 
of 
peptides 
TNNI1 Troponin I, slow skeletal muscle 204 21850 9.61 23 7 
TNNT2 Troponin T, cardiac muscle  40 35902 4.94 6.7 7 
TNNT3 Troponin T, fast skeletal muscle 526 31805 5.71 36.8 34 
TNNT1 Troponin T, slow skeletal muscle 381 32985 5.86 30.9 31 
TBA1A Tubulin alpha-1A chain  66 50788 4.94 9.5 3 
TBA4A Tubulin alpha-4A chain  45 50634 4.95 11.6 6 
TBB5_ Tubulin beta chain  226 50095 4.78 29.5 13 
TBB1_ Tubulin beta-1 chain  59 50865 5.05 6.2 4 
TBB2A Tubulin beta-2A chain  160 50274 4.78 23.4 10 
TBB2B Tubulin beta-2B chain  160 50377 4.78 23.4 10 
TBB2C Tubulin beta-2C chain  160 50255 4.79 23.4 10 
TBB4_ Tubulin beta-4 chain  160 50010 4.78 18.9 8 
TBB6_ Tubulin beta-6 chain  88 50281 4.77 10.8 6 
TBB8_ Tubulin beta-8 chain 64 50257 4.79 9.5 5 
TBB8B Tubulin beta-8 chain B  64 50168 4.75 9.5 5 
CH074 Uncharacterized protein C8orf74  46 33942 7.74 2.7 3 
ACADV Very long-chain specific acyl-CoA dehydrogenase, 
mitochondrial 
194 70745 8.92 9.9 5 
VIME_ Vimentin  375 53676 5.06 35.6 27 
VDAC1 Voltage-dependent anion-selective channel protein 1 199 30868 8.62 25.8 11 
VDAC2 Voltage-dependent anion-selective channel protein 2 128 32060 7.49 21.4 6 
VDAC3 Voltage-dependent anion-selective channel protein 3  214 30981 8.85 19.1 6 
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Figure 31. Scheme of structure of thin filament and thick filament; and its main 
protein components that are known to exist as multiple isoforms from 15% gels. 
 
 
 
 
 
177 
 
Table 24. Proteins detected by GeLC-MS/MS of the myofibrillar fraction of human vastus lateralis. 
UniProt 
Accession 
Protein Description MOWSE 
score 
Mass 
(Da) 
Isoelectric 
point (pH) 
Sequence 
coverage 
(%) 
No of 
peptides 
ACTS Actin, alpha skeletal muscle 3750 42366 5.23 73.2 288 
DESM Desmin 1955 53560 5.21 57.4 90 
TPM1 Tropomyosin alpha-1 chain 1767 32746 4.69 51.1 131 
MYH2 Myosin-2 1765 223932 5.64 31 133 
MYH7 Myosin-7 1726 223757 5.63 30.2 125 
TPM3 Tropomyosin alpha-3 chain 1650 32856 4.68 52.8 113 
ACTC Actin, alpha cardiac muscle 1 1554 42334 5.23 67.1 133 
TPM2 Tropomyosin beta chain 1390 32945 4.66 50.4 103 
MYH1 Myosin-1 1273 223976 5.59 24.4 101 
TPM4 Tropomyosin alpha-4 chain 1022 28619 4.67 21.8 61 
MYL1 Myosin light chain 1/3, skeletal muscle isoform 767 21189 4.97 69.1 27 
MYH8 Myosin-8 732 223594 5.59 11.9 40 
MLRS Myosin regulatory light chain 2, skeletal muscle isoform 698 19116 4.91 69.8 26 
MYH6 Myosin-6 645 224394 5.58 12.4 32 
TNNT3 Troponin T, fast skeletal muscle 526 31805 5.71 36.8 34 
MYOTI Myotilin 456 55760 9.18 29.7 27 
MYL3 Myosin light chain 3 418 22089 5.03 54.4 16 
MYOZ1 Myozenin-1 398 31725 8.86 35.8 14 
TNNT1 Troponin T, slow skeletal muscle 381 32985 5.86 30.9 31 
TNNC1 Troponin C, slow skeletal and cardiac muscles 347 18505 4.04 24.2 24 
MLRV Myosin regulatory light chain 2, ventricular/ muscle isoform 334 18777 4.92 61.4 15 
MYPC1 Myosin-binding protein C, slow-type 207 129240 5.78 14.1 23 
TNNI1 Troponin I, slow skeletal muscle 204 21850 9.61 23 7 
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MYH4 Myosin-4 163 223902 5.65 3.6 6 
MYH13 Myosin-13 162 224605 5.54 4.2 15 
MYH3 Myosin-3 137 224850 5.62 3.6 6 
TNNI2 Troponin I, fast skeletal muscle 120 21496 8.87 20.3 6 
NEBU Nebulin 103 775406 9.11 1.7 15 
CAZA2 F-actin-capping protein subunit alpha-2 68 33157 5.57 12.6 3 
MYL10 Myosin regulatory light chain 10 65 25520 5.56 11.5 4 
TITIN Titin 62 3843119 6.01 0.2 8 
GELS Gelsolin 47 86043 5.9 3.1 3 
TNNT2 Troponin T, cardiac muscle 40 35902 4.94 6.7 7 
Data represent myofibrillar proteins were identified by mass spectrometry and database searches, proteins are ranked by database score, highest 
to lowest. 
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4.3.4 Traditional muscle phenotyping: Analysis of Myosin heavy chain isoforms 
by SDS-PAGE.  
Figure 32 shows representative images and analysis of MyHC band volumes. Using 
this method we were able to separate MyHC isoforms into 3 distinct bands 
representing type IIx, type IIa and type I isoforms. The average percentages of each 
isoform were 42.5 % MyHC I, 48.3 % MyHC IIa and 9.2 %  MyHC IIx (Table 25).  
 
Figure 32. Separation of MyHC isoforms from Diurnal pooled sample by SDS-
PAGE. (A) Representative image of gel lanes showing separation of MyHC 
isoforms. (B) Density plot showing area of interest, in to distinct bands (IIx, IIa, I) 
based in differences in migration (Pooled standard sample from all participants). (C) 
Images of lanes aligned with the area of interest. 
 
Table 25. Technical variation of duplicate analysis of ‘pooled standard’.  
Band 
Lane 1 
(Volume) % 
Lane 2 
 (Volume) % 
Volume  
Mean ± SD 
% 
Mean ± SD 
IIx 824 9.3 864 9.0 844 ± 28 9.2 ± 0.2 
IIa 4123 46.7 4772 49.9 4448 ± 459 48.3 ± 2.3 
I 3881 44.0 3935 41.1 3908 ± 38 42.5 ± 2.1 
Data represented ‘pooled standard’ proteins were identified by T120 software which 
enables the concentration of each band to be measured by densitometry and can be 
used to calculate the relative percentage of each MyHC isoform. Data represent band 
volume (arbitrary units) and relative percentage for each band from pooled standard 
sample in two different lanes. 
 
Type IIx
Type IIa
Type I
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Morning and evening samples from each participant were separated using this 
optimised method (examples from 2 participants are shown in Figure 33). As might 
be expected, there was no difference in the relative abundance of IIx, IIa and I 
MyHC isoforms between the morning and evening, but this analysis afforded the 
calculation of the reproducibility of this technique (Table 26). The coefficient of 
variation for MyHC isoform analysis ranged from 6.4 % to 3.2 %.  
 
Figure 33.  (a) Separation of myofibrillar isoforms by SDS-PAGE into distinct 
bands (IIx, IIa, I) based in differences in migration. (b) Example of non-existence of 
type IIx in one of the participant.  
 
 
Table 26. Coefficient of variation of MyHC isoform analysis. 
Band Average % Range %  CV % p value 
IIx 6.8 ± 7.8 (0 - 21.5) 6.4 0.194 
IIa 52.8 ± 14.5 (33.7 - 93.6) 3.2 0.181 
I 40.4 ± 11.9 (6.4 - 57.4) 3.9 0.305 
Data are from n = 10 participants (biological replicates) 
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4.3.5 MRM myofibrillar proteins profiling.  
SDS-PAGE analysis of MyHC isoforms exhibits good levels of reproducibility 
(Table 26) but this technique is relative time consuming so we also investigated the 
use of multiple reaction monitoring (MRM) to perform similar MyHC isoform 
profiling. The intensity of a peptide ion is dependent upon both the abundance of the 
peptide and also its readiness to undergo ionisation, therefore we first analysed 
mixtures of synthetic peptides produce by a commercial supplier. Table 27 reports 
the abundance measurements of MRM analysis of an equimolar mixture of isoform-
specific and pan-isoform MyHC peptides. The peptide mixture was analysed in 
duplicate and the coefficient of variation for each peptide was less than 3 %. A 
multiplication factor was derived from these data that could be used to calculate the 
abundance of each isoform in ‘unknown’ muscle samples relative to the pan-isoform 
internal control (Table 28 ). 
 
Table 27. MRM analysis of synthetic peptide of MyHC isoforms.  
 
Pan Type I Type IIa Type IIx 
 
66758 25350 149791 64820 
 
69157 26320 143867 66610 
Mean 67957 25835 146829 65715 
SD 1696 685 4189 1266 
CV 0.0249636 0.026531257 0.028527074 0.019260351 
%CV 2.5 2.7 2.9 1.9 
 
Multiplication 
factor 0.38016714 2.160613026 0.967012822 
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Table 28. MRM analysis of MyHC isoforms in human muscle. 
 1
st
 measure 2
nd
 measure Average 
 Type I Type 
IIa 
Type 
IIx 
Type I Type 
IIa 
Type 
IIx 
Type I Type 
IIa 
Type 
IIx 
 7.6 73.3 19.1 9.6 65.2 25.2 8.6 69.2 22.2 
 7.4 87.9 4.6 7.5 87.9 4.6 7.5 87.9 4.6 
 5.5 90.0 4.4 5.0 90.3 4.7 5.3 90.2 4.6 
 1.7 95.1 3.2 1.7 95.4 2.9 1.7 95.2 3.1 
 10.0 87.0 3.0 9.8 87.5 2.8 9.9 87.2 2.9 
 4.6 92.4 2.9 4.7 92.2 3.1 4.7 92.3 3.0 
 8.0 84.2 7.9 8.1 83.9 8.0 8.0 84.0 7.9 
 9.0 75.6 15.4 9.5 74.9 15.6 9.2 75.2 15.5 
 7.4 86.5 6.2 7.2 86.5 6.3 7.3 86.5 6.3 
 10.2 70.2 19.6 10.0 71.8 18.2 10.1 71.0 18.9 
 2.9 93.1 4.1 2.7 93.3 4.0 2.8 93.2 4.0 
 13.4 79.4 7.2 14.2 78.7 7.2 13.8 79.0 7.2 
 4.5 92.4 3.0 4.7 92.3 3.1 4.6 92.4 3.1 
 9.2 83.2 7.5 7.6 85.5 6.9 8.4 84.4 7.2 
 7.3 85.0 7.7 7.3 84.7 8.0 7.3 84.8 7.9 
 
SDS PAGE Type I Type IIa Type IIx 
 (%) 40.4 52.8 6.8 
 
(A) Data represent the calculated relative percentage of each myosin heavy chain 
isoform by MRM analysis of human muscle and applying the multiplication factor 
derived from similar analysis of synthetic peptides (reported in Table 27). (B) 
Represent data from SDS-PAGE analysis for comparison. 
 
B 
A 
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There was little to no connection between the MyHC isoform profile measured by 
traditional SDS-PAGE analysis (Table 28B) and the data collected by MRM analysis 
(Table 28A). Therefore, we attempted to back-calculate a new correction factor from 
the average SDS-PAGE results, and we applied this to the MRM data then tested the 
correlation between SDS-PAGE and MRM on individual biological replicates 
(Figure 34). In all, the correlation was weak (R
2
 less than 0.6) between MyHC 
isoform relative abundance measured by MRM and SDS-PAGE. 
A  
 
B 
 
C 
 
Figure 34. Correlation of percentage MyHC type IIx (A) type IIa (B) and type I (C) 
from MRM and 1D gel result. Correlation of MyHC percentage measured by two 
different methods. The correlation coefficient at 0.4829 for type IIx, 0.535 for type 
IIa and 0.5348 for type I. 
y = 1.3114x - 1.8904 
R² = 0.4829 
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4.3.6 Two-dimensional gel electrophoresis.  
 
Individual samples from both morning and evening sessions were analysed and the 
proteins were separated according to their isoelectric point using isoelectric focusing 
(IEF) and molecular weight (SDS-PAGE). All gel spots were cut and from the gel 
and processed by manual in-gel tryplic digestion in preparation for LC-MS/MS 
analysis. Figure 35 illustrates separation of human myofibrillar proteins by large-
format 2DGE. Using this technique we were able to resolve 122 protein spots. Each 
of the protein spots was identified by LC-ESI-MS/MS analysis and (Table 29) 
reports the spot number, protein name, database score, number of peptides, sequence 
percentage, MW and pI. From the 122 spots there were 40 unique proteins, i.e. some 
proteins were discovered in multiple spots. Meanwhile small format (7 cm) 2DGE 
(Figure 36) was used to specifically investigate differences in the abundance of 
essential and regulatory myosin light chains, which were also identified by mass 
spectrometry (Table 30). 
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Figure 35. Separation of myofibrillar protein species by 2DGE in human vastus 
lateralis muscle. Representative colloidal Coomassie stained gel used for protein-
expression profiling. Annotations correspond to reference numbers in Table 29. 
 
 
 
 
 
 
 
186 
 
Table 29. Proteins detected in 2D gel spots. 
Spot 
# 
Accession Name MOWSE % 
coverage 
MW pI 
270 ACTN2 Alpha-actinin-2  3558 69 104358 5.2 
271 ACTN2 Alpha-actinin-2  3354 71 104358 5.2 
274 ACTN2 Alpha-actinin-2  3445 69 104358 5.2 
275 ACTN2 Alpha-actinin-2  3512 71 104358 5.2 
795 ACTS Actin, alpha skeletal muscle  1011 54 42366 5.1 
855 ACTS Actin, alpha skeletal muscle  1319 65 42366 5.1 
900 ACTS Actin, alpha skeletal muscle  415 39 42366 5.1 
902 ACTS Actin, alpha skeletal muscle  962 63 42366 5.1 
903 ACTS Actin, alpha skeletal muscle  1009 62 42366 5.1 
904 ACTS Actin, alpha skeletal muscle  877 55 42366 5.1 
925 ACTS Actin, alpha skeletal muscle  1277 63 42366 5.1 
544 ALBU Serum albumin  1539 56 71317 5.9 
546 ALBU Serum albumin  1622 59 71317 5.9 
550 ALBU Serum albumin  1852 65 71317 5.9 
553 ALBU Serum albumin  1838 60 71317 5.9 
1603 ALBU Serum albumin  1625 58 71317 5.9 
599 ALBU Serum albumin  59 8 71317 5.9 
992 ALDOA Fructose-bisphosphate aldolase A  733 58 39851 9.2 
997 ALDOA Fructose-bisphosphate aldolase A  812 60 39851 9.2 
812 ATPA ATP synthase subunit alpha, mitochondrial  1275 45 59828 9.6 
813 ATPA ATP synthase subunit alpha, mitochondrial  963 42 59828 9.6 
798 ATPB ATP synthase subunit beta, mitochondrial  1882 68 56525 5.1 
1278 CAH1 Carbonic anhydrase 1  578 54 28909 6.7 
1251 CAH3 Carbonic anhydrase 3  419 44 29824 7.1 
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1266 CAH3 Carbonic anhydrase 3  690 67 29824 7.1 
1284 CAH3 Carbonic anhydrase 3  533 54 29824 7.1 
616 CATA Catalase  710 38 59947 7.0 
731 DESM Desmin  2161 72 53560 5.1 
739 DESM Desmin  1884 63 53560 5.1 
741 DESM Desmin  1927 67 53560 5.1 
874 ENOB Beta-enolase  1040 55 47244 8.6 
878 ENOB Beta-enolase  1196 53 47244 8.6 
1074 G3P Glyceraldehyde-3-phosphate dehydrogenase  1068 54 36201 9.3 
1552 HERC1 Probable E3 ubiquitin-protein ligase HERC1  52 2 538790 5.6 
499 HSP71 Heat shock 70 kDa protein 1A/1B  1070 39 70294 5.4 
500 HSP71 Heat shock 70 kDa protein 1A/1B  1470 46 70294 5.4 
498 HSP76 Heat shock 70 kDa protein 6  54 5 71440 5.8 
505 HSP7C Heat shock cognate 71 kDa protein  1246 39 71082 5.2 
934 KCRM Creatine kinase M-type  1134 54 43302 6.9 
941 KCRM Creatine kinase M-type  890 54 43302 6.9 
943 KCRM Creatine kinase M-type  1126 59 43302 6.9 
944 KCRM Creatine kinase M-type  1100 53 43302 6.9 
947 KCRM Creatine kinase M-type  1295 57 43302 6.9 
455 KPYM Pyruvate kinase isozymes M1/M2  815 36 58470 9.0 
703 MYBPH Myosin-binding protein H  425 23 52531 6.3 
106 MYH2 Myosin-2  3726 33 223932 5.5 
121 MYH2 Myosin-2  4044 37 223932 5.5 
123 MYH2 Myosin-2  3325 34 223932 5.5 
386 MYH2 Myosin-2  1266 13 223932 5.5 
387 MYH2 Myosin-2  915 12 223932 5.5 
390 MYH2 Myosin-2  1367 14 223932 5.5 
391 MYH2 Myosin-2  1510 18 223932 5.5 
392 MYH2 Myosin-2  709 12 223932 5.5 
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443 MYH2 Myosin-2 978 13 223932 5.5 
471 MYH2 Myosin-2 1204 15 223932 5.5 
477 MYH2 Myosin-2 2036 26 223932 5.5 
479 MYH2 Myosin-2 1359 18 223932 5.5 
533 MYH2 Myosin-2 1084 13 223932 5.5 
534 MYH2 Myosin-2 1360 16 223932 5.5 
535 MYH2 Myosin-2 1195 17 223932 5.5 
604 MYH2 Myosin-2 1104 13 223932 5.5 
1132 MYH2 Myosin-2 616 8 223932 5.5 
115 MYH7 Myosin-2 4288 35 223757 5.5 
187 MYH7 Myosin-2 3534 31 223757 5.5 
195 MYH7 Myosin-2 4307 32 223757 5.5 
596 MYH7 Myosin-2 1229 17 223757 5.5 
1374 MYL3 Myosin light chain 3  856 77 22089 4.9 
1109 MYOZ1 Myozenin-1  596 54 31725 9.3 
1078 MYOZ1 Myozenin-1  848 85 31725 9.3 
1108 MYOZ1 Myozenin-1  708 50 31725 9.3 
1115 MYOZ1 Myozenin-1  378 30 31725 9.3 
1272 MYOZ1 Myozenin-1  154 29 31725 9.3 
1200 MYOZ3 Myozenin-3  278 36 27254 10.0 
1198 MYOZ3 Myozenin-3  538 37 27254 10.0 
150 MYPC1 Myosin-binding protein C, slow-type  2849 50 129240 5.7 
153 MYPC1 Myosin-binding protein C, slow-type  2648 51 129240 5.7 
158 MYPC1 Myosin-binding protein C, slow-type  2460 49 129240 5.7 
163 MYPC1 Myosin-binding protein C, slow-type  2135 42 129240 5.7 
164 MYPC1 Myosin-binding protein C, slow-type  2581 51 129240 5.7 
165 MYPC1 Myosin-binding protein C, slow-type  2366 51 129240 5.7 
135 MYPC2 Myosin-binding protein C, fast-type  2015 45 128847 8.2 
136 MYPC2 Myosin-binding protein C, fast-type  1838 41 128847 8.2 
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154 NEBU Nebulin  964 6 775406 9.5 
532 PGM1 Phosphoglucomutase-1  876 37 61696 6.3 
1046 PLCB2 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase  37 2 134908 5.9 
332 PYGM Glycogen phosphorylase, muscle form  1651 44 97487 6.6 
333 PYGM Glycogen phosphorylase, muscle form  1611 47 97487 6.6 
335 PYGM Glycogen phosphorylase, muscle form  1938 53 97487 6.6 
336 PYGM Glycogen phosphorylase, muscle form  1778 50 97487 6.6 
344 PYGM Glycogen phosphorylase, muscle form  1560 43 97487 6.6 
751 TBA4A Tubulin alpha-4A chain  539 33 50634 4.8 
755 TBA4A Tubulin alpha-4A chain  642 36 50634 4.79 
1304 TITIN Titin  52 1 3843119 6.0 
1451 TNNI2 Troponin I, fast skeletal muscle  378 50 21496 9.6 
1029 TNNT1 Troponin T, slow skeletal muscle  146 12 32985 5.8 
1043 TNNT1 Troponin T, slow skeletal muscle  599 33 32985 5.8 
1048 TNNT1 Troponin T, slow skeletal muscle  738 32 32985 5.8 
1049 TNNT1 Troponin T, slow skeletal muscle  652 36 32985 5.8 
1056 TNNT1 Troponin T, slow skeletal muscle  687 37 32985 5.8 
1044 TNNT3 Troponin T, fast skeletal muscle  257 22 31805 5.6 
1080 TNNT3 Troponin T, fast skeletal muscle  552 33 31805 5.6 
1047 TNNT3 Troponin T, fast skeletal muscle  403 32 31805 5.6 
1032 TNNT3 Troponin T, fast skeletal muscle  491 27 31805 5.6 
1051 TNNT3 Troponin T, fast skeletal muscle  507 36 31805 5.6 
1059 TNNT3 Troponin T, fast skeletal muscle  394 24 31805 5.6 
1060 TNNT3 Troponin T, fast skeletal muscle  481 26 31805 5.6 
1061 TNNT3 Troponin T, fast skeletal muscle  457 36 31805 5.6 
1065 TNNT3 Troponin T, fast skeletal muscle  421 26 31805 5.6 
1073 TNNT3 Troponin T, fast skeletal muscle  482 26 31805 5.6 
1083 TNNT3 Troponin T, fast skeletal muscle  583 34 31805 5.6 
1090 TNNT3 Troponin T, fast skeletal muscle  520 32 31805 5.6 
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1095 TNNT3 Troponin T, fast skeletal muscle  452 28 31805 5.6 
1100 TNNT3 Troponin T, fast skeletal muscle  474 37 31805 5.6 
1101 TNNT3 Troponin T, fast skeletal muscle  540 33 31805 5.6 
1328 TPIS Triosephosphate isomerase  597 71 26938 6.6 
330 TPM1 Tropomyosin alpha-1 chain  947 47 32746 4.5 
1085 TPM1 Tropomyosin alpha-1 chain  1662 70 32746 4.5 
330 TPM2 Tropomyosin beta chain  980 42 32945 4.5 
1034 TPM2 Tropomyosin beta chain  1450 69 32945 4.5 
330 TPM3 Tropomyosin alpha-3 chain  1102 47 32856 4.5 
1085 TPM3 Tropomyosin alpha-3 chain  1478 72 32856 4.5 
1606 VIME Vimentin  1861 69 53676 4.9 
Data represent proteins were identified by mass spectrometry and database searches, these were categorised further and ranked by score to 
determine the primary protein typically found in each spot.  
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Figure 36. Separation of myosin light chain isoforms by 2DGE. Distinct spots 
separated based in differences in pH and migration (A). Three-dimensional 
representations of essential myosin light chains MyLC1/3 (B) and regulatory myosin 
light chains MLRV and MLRS spots (C). 
 
 
Table 30. Quantitation of myosin light chain spots presented in Figure 36. 
Spot 
Volume (CV) 
MORNING 
Volume (CV) 
EVENING T-test (p) 
1 924,159.287 (54%) 785,715.196 (78%) 0.727 
2 4,426,879.775 (34%) 3,968,444.580 (50%) 0.884 
3 10,942,407.536 (29%) 9,788,719.908 (50%) 0.485 
4 2,378,350.901 (34%) 2,192,077.289 (59%) 0.431 
5 2,675,675.493 (57%) 2,985,660.793 (73%) 0.498 
6 4,176,636.325 (44%) 3,699,562.525 (59%) 0.459 
7 1,940,942.123 (49%) 1,600,503.123 (63%) 0.381 
8 1,557,280.702 (66%) 2,206,068.415 (85%) 0.216 
9 4,675,429.898 (34%) 5,214,473.788 (60%) 0.151 
10 4,420,774.648 (26%) 3,762,817.375 (47%) 0.467 
11 1,286,723.923 (42%) 982,627.086 (58%) 0.426 
12 282,739.081 (76%) - Unknown 
MyLC1/3 
MLRS 
MLRV 
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4.3.7 Analysis of two-dimensional gels using SameSpots.  
 
Colloidal coomassie stained gels (total n = 20) were analysed in Same Spots 
(TotalLab v3.3) and data were exported for analysis in SPSS. Statistical analysis was 
conducted by repeated measures one-way analysis of variance. The abundance of 8 
spots was statistically (P<0.05) different between the morning and evening. In the 
evening greater abundances were observed in myosin binding protein C1 (80 %), 
glycogen phosphorylase (43 %) and beta enolase (24 %), whereas the abundances of 
nebulin (-48 %), troponin T slow (-22 %), and 3 spots identified as keratin II 
(average -30 %) was less abundant in the evening compared to morning. In addition, 
regression analysis was performed to investigate whether the changes in protein 
sport abundance correlated significantly with muscle function data such as peak 
isometric force or rate of force development (Table 32). 
 
193 
 
Table 31. Proteins in human muscle vastus lateralis detected significant difference in diurnal variations.   
# Protein 
Accession 
Protein Description Protein 
MW 
Morning 
Mean ± SD 
Evening 
Mean ± SD 
Anova (p) Fold 
difference 
335 PYGM Glycogen phosphorylase, muscle  97487 245 ± 44 350 ± 103 0.01549 1.42961 
163 MYPC1 Myosin-binding protein C, slow type 129240 34 ± 85 616 ± 356 0.0226 1.79941 
703 K2C1 Keratin type II 65678 133 ± 28 113 ± 26 0.03128 -1.17229 
758 K2C1 Keratin type II 66170 193±32 160 ± 23 0.03331 -1.20963 
874 ENOB Beta-enolase 47244 814 ± 20 1007 ± 174 0.03348 1.23823 
975 K2C1 Keratin type II 66170 172 ± 112 112 ± 32 0.04029 -1.52349 
1046 TNNT1 Troponin T, slow skeletal muscle  32985 239 ± 71 196 ± 45 0.04329 -1.22008 
154 NEBU Nebulin 775406 959 ± 648 352 ± 251 0.04347 -1.47945 
Data showed the abundance of 8 spots was statistically (P<0.05) different from morning to evening. In the evening greater abundances were 
observed in myosin binding protein C1 (80 %), glycogen phosphorylase (43 %) and beta enolase (24 %), whereas the abundances of nebulin (-48 
%), troponin T slow (-22 %), and 3 spots identified as keratin II (average -30 %) was less in the evening compared to morning.  
 
194 
 
 
Figure 37. The graph highlighted standardised normalised volume. Three proteins associated with the diurnal variation, that were differentially 
expressed greater evening than morning (see Table 31) shared patterns of variation 
 
MyBPC1 
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Table 32. Pearson correlations between spots normalised volume and two muscle 
performance measurement (MVC force and peak RFD).  
# Protein 
Accession 
Protein Description MVC force Peak RFD 
335 PYGM Glycogen phosphorylase, 
muscle 
0.478* 0.259 
163 MYPC1 Myosin-binding protein C, 
slow type  
0.311 0.219 
703 K2C1 Keratin type II 0.320 -0.055 
758 K2C1 Keratin type II -0.121 0.001 
874 ENOB Beta-enolase 0.290 0.120 
975 K2C1 Keratin type II -0.046 -0.283 
1046 TNNT1 Troponin T, slow skeletal 
muscle 
0.198 0.021 
154 NEBU Nebulin -0.114 -0.140 
Table I shows the correlation coefficients between the MVC force and peak RFD 
measures with the normalised volume in all 8 spots. These ranged from r = -0.283 to 
r = 0.478 but the only significant correlation was between the MVC force with spot 
number 335 which was Glycogen phosphorylase muscle form OS (r = 0.478, P = 
0.033). 
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4.4 DISCUSSION 
 
Muscle Performance testing 
Previously, in Chapter 3, we reported peak isometric force, rate of force 
development and peak torque (measured at 4 velocities using IKD) of the knee 
extensors each displayed significant (P<0.05) time-of-day variation. That is, the 
performance of the knee extensor muscles was greater in the evening than in the 
morning. We established that RFD and MVC exhibited the greatest diurnal variation 
(10.2 % and 18 %, respectively) when compared to IKD (typically < 10 %). 
Therefore these methods (MVC and RFD) were used as the preferred indicators of 
diurnal variation in muscle performance for the current biopsy study. In this chapter, 
percutaneous needle biopsy samples were taken to investigate which modifications 
occur to the contractile proteins of the skeletal muscle that may affect its ability to 
produce force at different times of day.  
 
One of the primary aims of this study was to confirm that the previously observed 
rhythm of muscle force output remained when it was applied to the research design. 
A diurnal variation in quadriceps MVC was evident with performance being superior 
in the evening compared to morning without any difference in the level of voluntary 
activation (consistent with Chapter 3). Indeed, we present comparable force and 
activation data to previous work from our group (Edwards et al., 2013; Robinson et 
al., 2013) and suggest participant familiarization and parallels in protocol contribute 
to similarities. Similarly, an 11 % variation in maximum isometric force is consistent 
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with literature where diurnal variation is apparent in isometric force output 
(Coldwells et al., 1994; Guette et al., 2005) and ranges from 6 to 18 %. Contraction 
velocity (i.e. RFD) is key to time-restricted explosive actions such as kicks, sprints 
and jumps (Andersen & Aagard, 2006). Consistent with Chapter 3, we confirm RFD 
is superior (15.7 % improvement) in the evening compared to the morning, and that 
the magnitude of diurnal variation in RFD is greater than that exhibited by peak 
isometric force.  
 
Analysis of human muscle proteins 
The profile of MyHC isoforms in the vastus lateralis was 42.5 % type I, 48.3 % type 
IIa and 9.2 % type IIx, and is consistent with literature in this area (e.g. Putman et al., 
2004) and the strength-training background of the participants recruited. The fact 
that biopsy samples were taken in morning/evening in a within participant design 
enabled us to investigate the reproducibility of this entire method from biopsy 
through to MyHC isoform analysis. We found MyHC isoform profiling by 
traditional SDS-PAGE was remarkably precise. The coefficient of variation was 6.4 % 
for type IIx, 3.2 % for type IIa and 3.9 % for type I, and these values of variation 
encompass potential differences due to biopsy sampling, muscle processing and 
SDS-PAGE analysis.   
 
MyHC proteins are highly abundant and we hypothesised that automated profiling of 
this fraction by mass spectrometry may also be used to resolve the MyHC isoforms. 
The advantage of the mass spectrometry approach would be time efficiency and the 
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development of a largely automated technique. Multiple reactions monitoring (MRM) 
was used to verify differences in the abundance of MyHC. While each MYHC 
isoform could be readily resolved the final profiling results were not similar to the 
SDS-PAGE analysis. The exact cause of this difference is not known but is most 
likely due to ion suppression when the isoform-specific peptides were analysed 
against a complex background of other myofibrillar proteins. To overcome this issue, 
greater sample fractionation/separation would be necessary, which would increase 
the complexity and duration of the analysis to a level equivalent to 1D SDS PAGE. 
Therefore MRM is not a suitable technique for muscle phenotyping. 
 
Prior to differential analysis of the myofibrillar proteome we performed GeLC-
MS/MS mining in order to characterise the entire myofibrillar fraction used in this 
work. Simple fractionation using a low-salt and mild detergent buffer readily 
precipitated the myofibrillar apparatus. In total, 193 proteins were identified and of 
these 33 were know components of the myofibrillar structure. This characterisation 
work is important because it enables us to interpret and discuss the subsequent 
profiling data in the context of the entire proteome that was analysed.  
 
As discovered in Chapter 1, LC-MS/MS-based analysis of tryptic peptide mixtures 
does not resolve proteins to their individual species because protein identification 
and quantitation are often based on a small selection of proteotypic peptides that 
often represent small percentage of the entire protein chain. Therefore, based on our 
experience from Chapter 1, we used large-format 2D gel electrophoresis to perform 
differential profiling of morning-evening differences in the human myofibrillar 
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proteome. A weakness of 2DGE is its inability to span a large dynamic range of 
protein abundances. Indeed, we found that when we optimised the protein load to 
detect the greatest number of spots on the large-format gels, the abundance of the 
myosin light chain proteins was so great that their spots had become merged and 
were there for no longer suitable for quantitation. Rather than reducing the protein 
load and potentially missing information about low abundance proteins we chose to 
use small-format narrow-range gels and a low protein load to specifically investigate 
diurnal differences in the abundance of myosin light chain species. Although post-
translational modifications to myosin light chains have previously been reported to 
alter muscle contractility (e.g. twitch potentiation reported by Ryder et al., 2007) we 
did not find any significant difference in the abundance of 2DGE spots of the 
essential or regulatory myosin light chain isoforms.  
 
In addition to GeLC-MS/MS mining we also performed proteome mining of the 
2DGE separation. All gel spots were cut and from the 2D gels and processed by in-
gel tryptic digestion and LC-ESI-MS/MS analysis. Using this approach, we 
identified proteins in all 122 spots (Table 29). The majority of proteins are resolved 
as multiple spots by 2DGE because different post-translational states of a protein 
migrate to their own specific isoelectric point and relative mass positions (Burniston 
& Hoffman 2011). Indeed, from these 122 spots, 40 unique proteins were detected in 
multiple spots. Previous work in our laboratory (Holloway et al., 2009) used similar 
large-format (13 cm) gels and resolved 256 spots from whole muscle homogenates 
of human vastus lateralis, whereas studies using larger format (18cm) 2D gels and 
more sensitive silver staining techniques resolved more than 500 protein spots.This 
mining work provides a direct comparison of the proteome resolving ability of 
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GeLC-MS/MS (193 proteins) compared to 2DGE (40 proteins).  The much lower 
number of proteins identified in 2DE is a limitation to the current work and 
information regarding diurnal differences in other myofibrillar proteins will have 
been missed. 
 
One of the primary aims of this study was to investigate whether modifications occur 
to the contractile proteins of the skeletal muscle that effect its ability to produce 
force at different times of day. As far as we are aware, no previous study has 
specifically investigated the human myofibrillar sub-proteome. Furthermore, no 
previous study has used proteomics to investigate diurnal differences in human 
muscle performance. Proteomic profiling using two-dimensional gel electrophoresis 
resolved 122 proteins and each of these were unambiguously identified by mass 
spectrometry. The abundance of 8 spots was statistically (P<0.05) different between 
the morning and evening samples. Three of these spots were identified as keratin 
type II, 3 spots were known myofibrillar proteins (troponin T, myosin binding 
protein c and nebulin) and 2 spots were glycolytic enzymes (glycogen phosphorylase 
and beta-enolase). The greatest diurnal difference was in the abundance of the slow 
isoform of myosin binding protein C (MyBPC1). This protein was resolved as 5 
species and one of these spots was 80 % more abundant in the evening compared to 
morning, therefore the difference in abundance reported here may represent a change 
in post-translational modification. 
 
Myosin binding protein C is known to modulate the activity of actin-bound myosin 
ATPases and MyBPC1 is a substrate for protein kinase C (PKC) phosphorylation 
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(Ackermann et al., 2011). Therefore the difference in MYBPC1 may also be linked 
with the changes observed in the cytoskeletal protein, keratin II, which acts as a 
scaffold for interactions between beta integrin and PKC signalling. The greater 
isometric force and rate of force development in the evening than morning may be 
related with MyBPC1 modification because this protein acts as an adaptor to connect 
the ATP consumer (myosin) with actin. The similarities observed during the present 
study because of MyBPC1 reported mediates recruitment of muscle-type creatine 
kinase (CK) to myosin and its role as the regenerator for efficient energy metabolism 
and homoeostasis (Chen et al., 2011). Our data provide associational evidence of 
changes in muscle protein modifications and diurnal differences in muscle 
performance. However, the strength of this association may be relatively weak 
because there was no correlation between an individual’s difference in MyBPC and 
diurnal variation in muscle performance. 
 
The peak isometric force and rate of force development of human skeletal muscle 
was significantly greater (~11-16 %) in the evening compared to the morning. This 
was associated with an 80 % greater abundance of a myosin binding protein C spot, 
as well as difference in the abundance of 7 other proteins. To determine the strength 
of association between change in muscle function and the myofibrillar proteome we 
performed post-hoc regression analysis. Unfortunately we found no correlation 
between myosin binding protein C abundance and either peak isometric force or the 
rate of force development. However, we did find a significant (P=0.033) but 
relatively weak correlation between the abundance of glycogen phosphorylase spot 
335 and peak isometric force. Similar to MYBPC1, glycogen phosphorylase was 
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also resolved as numerous protein species and this protein is also known to be 
regulated by phosphorylation.   
 
This was a ‘discovery’ proteomics experiment designed to generate hypothesis 
regarding which muscle protein might be responsible for diurnal differences in 
muscle performance. We discovered 8 spots was statistically (P<0.05) different 
between the morning and evening samples. Three of these spots were identified as 
keratin type II, 3 spots were known myofibrillar proteins (troponin T, myosin 
binding protein c and nebulin) and 2 spots were glycolytic enzymes (glycogen 
phosphorylase and beta-enolase). However our experiment cannot provide causal 
evidence to prove the involvement of MyBPC, nebulin, glycogen phosphorylase etc. 
in diurnal variation. Fututre studies are required to specifically test these hypotheses 
and could use gain or loss of function studies in animal models.  
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4.5 CONCLUSION 
 
In summary, the evidence provided here supports the previously reported circadian 
variability of muscle force output. Peak isometric force and the rate of force 
development each exhibited significant diurnal variation. Proteomic analysis of the 
myofibrillar fraction profiled the abundance of 122 gel spots and discovered 8 
species that differed in abundance between the morning and evening. Post-hoc 
analysis did not find strong correlations between the changes in protein abundance 
and muscle function. Nonetheless, the proteins that exhibited diurnal variation could 
be related to muscle force output through published literature. In particular, our work 
provides a rationale for future studies on the role of myosin binding protein C in 
regulating muscle force production. 
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Synthesis of Findings 
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SYNTHESIS 
 
The overall aim of this thesis was to combine proteomic analysis of muscle biopsy 
samples with measurements of muscle performance in humans. Because the 
proteome is what defines a cell (or tissue) and dictates its functional properties we 
reasoned that changes in muscle function must be underpinned by changes in the 
muscle proteome. More specifically, changes in muscle force production will be 
underpinned by changes to the myofibrillar proteins. To achieve our overall aim we 
conducted a series of experiments to establish and optimise techniques for proteomic 
analysis of muscle biopsy samples and techniques for the analysis of human muscle 
function in vivo. The purpose of this chapter is to summarise the findings from each 
of the foregoing experimental chapters and detail how the main aims of this thesis 
were met. A secondary purpose of this chapter is to provide recommendations for 
further research based upon this body of work. 
 
Analysis of the myofibrillar sub-proteome of human muscle 
In Chapter 1 the applicability of label-free profiling in skeletal muscle was assessed 
using rat muscle samples. We found the high enrichment of metabolic enzymes in 
skeletal muscle to be an asset to high-throughput and time-efficient profiling. Indeed, 
a relatively simple LC-MS process was able to analyse more than 200 of the most 
abundant soluble muscle proteins (i.e. metabolic enzymes). We next investigated 
whether LC-MS profiling could also be used to analyse the myofibrillar sub-
proteome. Compared to the soluble protein fraction, the myofibrillar proteome 
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contained fewer proteins but a more complex array of protein isoforms and splice 
variants. LC-MS profiling of human muscle was able to identify significant 
differences in the abundance of myosin light chain isoforms between young and 
elderly people that were either physically active or habitually sedentary. Moreover, 
we were able to confirm these findings using multiple reaction monitoring assays.  
 
Because many of the myofibrillar protein isoforms share high degrees of sequence 
homology we were not able to identify isoform-specific peptides for proteins such as 
MyHC. Instead, we complimented our proteomic techniques using traditional 
biochemical analysis of MyHC isoforms. We successfully resolved the 2 isoforms of 
MyHC (types I and IIa/x) that are expressed in human locomotive muscles and 
report differences in MyHC profile that correspond with the differences in MyLC 
measured using LC-MS. This demonstrates that we were able to use the traditional 
biochemical analysis as a point of comparison for developing proteomic techniques 
in human muscle samples. To delve deeper in to the myofibrillar proteome we used 
1D gel electrophoresis of low-molecular weight (~ 90-10 kDa) proteins. However, 
this approach was unable to resolve all low molecular weight myofibrillar proteins 
and many of the 1D gel bands contained numerous different proteins. Therefore we 
proceeded to a more sophisticated 2D gel electrophoresis method. Mining of the 
human myofibrillar proteome using 2D gel electrophoresis confirmed that the 
majority of 1D gel bands are composed of a number of different protein species. The 
proteome mining work conducted in Chapter 1 using small (7 cm) 2D gels also 
suggested that future work would require larger format (e.g. 13 cm) separation in 
order to more clearly resolved myofibrillar proteins. 
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Measurement of knee extensor force-velocity profile in vivo 
This aim was addressed in Chapter 2. Our work began with a preliminary study to 
find the peak angular velocity of human knee extension during unloaded kicking. 
Contrary to previous estimations, we found the average peak angular velocity of 
human knee extension (461 º/s) was within the range (0-500 º/s) of a commercial 
isokinetic dynamometer. Therefore, we created an IKD protocol that encompassed 
the entire force-velocity range of human knee extension. Next we investigated the 
reliability of isolated knee performance measures across the f-v profile of human 
muscle encompassing a range of velocities using isokinetic dynamometry (IKD). To 
attempt to relate our work to wider applications in sports performance testing we 
also assessed the reliability of jump analysis using either a force platform or linear 
encoder. This enabled us to investigate the strength of correlation between indices of 
isolated knee performance and a more complex sport-related movement such as 
jumping. Our knee extension data was consistent with the f-v concept of striated 
muscle and the reliability of each of the measures of knee extensor performance was 
acceptable (<15 % CV). The reliability of jump performance measures was also 
good and we found modest correlations amongst each of the knee measures. Reverse 
regression analysis found isometric and highest velocity knee kicking on IKD was 
the strongest predictor of jump performance. 
 
Diurnal variation muscle force production 
After investigating proteomic methods in Chapter 1 and muscle function methods in 
Chapter 2 our next goal was to combine these techniques and apply them to a 
relevant question in sports physiology. We chose diurnal variation because time-of-
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day differences in muscle force and sports performance are widely reported but the 
mechanisms underpinning this phenomenon are not yet understood. Muscle force 
production is poorest in the morning and greatest in the evening, and the magnitude 
of this diurnal variation is large (i.e. ~10 %) in comparison to gains that can be made 
through sports training in elite athletes. Previous literature reports diurnal variation 
in a diverse range of measures of sports/ muscle performance (e.g. hand grip-
strength, isokinetic dynamometry, vertical jump, time-trial performance etc.) but it 
was not clear which aspect of muscle output (e.g. high force or high velocity 
contractions) exhibits the greatest diurnal variation. In Chapter 3 we investigated this 
question by conducting a battery of muscle performance tests in a population of 
well-familiarised participants. Our data show that RFD exhibits the greatest diurnal 
variation (18 %) followed by isometric force (10.2 %). The diurnal variation in IKD 
data was less robust (range 8.1 - 9.8 %), which may have been due to the lesser 
precision of this technique compared to MVC and RFD. Therefore MVC and RFD 
were used in the final study and biopsies were taken from the vastus lateralis to 
investigate whether modifications occur in the myofibrillar proteome that effect its 
ability to produce force at different times of day. 
 
Proteomic analysis of diurnal differences in muscle performance 
Chapter 4 is the culmination of our work establishing techniques for the analysis of 
the myofibrillar proteome (Chapter 1) and the output of human knee extensor 
muscles across their force-velocity range (Chapter 2). Furthermore, the specific 
experiment design and analysis techniques for investigating diurnal differences in 
muscle performance were optimised in Chapter 3. In Chapter 4 we re-recruited a 
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subset of the participants from the experiment reported in Chapter 3 and took biopsy 
samples of their vastus lateralis in the morning and evening immediately after they 
had completed the measurement protocols for maximum isometric force and rate of 
force development. We confirmed that both the rate of force development and 
maximum isometric force were significantly greater in the evening compared to the 
morning. Comprehensive analysis of the myofibrillar sub-proteome was conducted, 
encompassing proteome mining using GeLC-MS/MS and differential proteome 
profiling using 2D gel electrophoresis. This is the first study to specifically focus on 
proteomic analysis of the myofibrillar fraction of human skeletal muscle. GeLC-
MS/MS mining identified 193 unique proteins, which included a large proportion of 
the know myofibrillar structure of skeletal muscle. Differential analysis using 2D gel 
electrophoresis resolved 122 protein species and identified 8 statistically significant 
in abundance. These may represent candidate biomarkers that could be used to 
develop and optimise interventions aimed at forestalling morning decrements in 
muscle performance. Information regarding changes at the protein level was 
compared with measures of muscle performance to determine the level of association 
between muscle output and a particular protein modification. For example, a shift in 
the post-translational state of slow myosin binding protein C (MyBPC1) was 
detected, and this protein is known to modulate the activity of actin-bound myosin 
ATPases. However it was weakly correlated with peak isometric force. Meanwhile 
other protein modifications including glycogen phosphorylase showed a significant 
correlation with the MVC force.  
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Figure 37. An illustration of the structure, procedures and key findings of the experiment. 
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Recommendations for future research 
The current work investigated the link between the myofibrillar proteome and 
muscle function in humans in vivo. Because this was the first work of its kind we 
used robust laboratory measures of isolated limb movements (i.e. knee extension) 
and took biopsy samples from the vastus lateralis, which is one of the major 
contributors to this movement. Using this approach we found significant diurnal 
differences in myofibrillar protein abundance. The most robust difference was 
myosin binding protein C, but the abundance of this protein did not correlate closely 
with muscle force output. While the statistical association between myosin binding 
protein C and muscle force is not strong there was clear corroborating evidence in 
the literature to suggest a role for myosin binding protein C in modulating force 
output of myosin-actin cross bridges. Therefore, we recommend future work should 
characterise the exact post-translational modification that occurs to myosin binding 
protein C and then use gain or loss of function studies to find the effects of this 
modification on muscle performance. 
 
The second most prominent difference was glycogen phosphorylase (r = 0.478, P = 
0.033). This is also a viable target for future study because there is evidence for 
diurnal variation in muscle metabolism. However, the connection between glycogen 
phosphorylase activity and muscle force output is not direct and our experiment 
design did not tightly control feeding. That is participants were fast 7h or 4 h in 
morning versus evening. Therefore more control study is required to confirm this 
finding. 
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Register for MPhil WTP PhD 
 
From: "McKeon, Jo" <J.M.McKeon@ljmu.ac.uk> 
Subject: Application to Register for MPhil WTP PhD 
Date: 5 April 2012 14:26:57 GMT+01:00  
To: "Ab Malik, Zulezwan" <Z.Ab-Malik@2011.ljmu.ac.uk> 
Cc: "Burniston, Jatin" <J.Burniston@ljmu.ac.uk> 
 
 
 
 
 
Dear Zulezwan, 
 
Further to the consideration of your Application to Register for MPhil WTP PhD which was considered 
by the University’s Research Degrees Committee (RDC) at it’s meeting of Thursday 22nd March 2012. 
 
Please note that your application was approved subject to your project being granted full approval by 
the LJMU Research Ethics Committee (REC).  Therefore, please may I ask that you submit your 
Ethics application by Thursday 19th April 2012 which is the deadline for agenda items for the REC 
meeting on Thursday 3rd May 2012. 
 
The Research Ethics website is available at:  http://www.ljmu.ac.uk/RGSO/93042.htm 
 
Please call me if you have any queries. 
 
Kind regards, 
 
 
Jo McKeon 
Research Support Officer 
Research Support Office 
Liverpool John Moores University 
Kingsway House 
Hatton Garden 
Liverpool 
L3 2AJ 
Tel:  (0151) 904 6463 
Fax:  (0151) 904 6462 
Email:  j.m.mckeon@ljmu.ac.uk 
Website:  http://www.ljmu.ac.uk/RGSO/index.htm 
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Ethical Approval 
 
 
 
From: "McKeon, Jo" <J.M.McKeon@ljmu.ac.uk> 
Subject: Application for Ethical Approval No.: 12/SPS/013 
Date: 9 May 2012 15:28:57 GMT+01:00 
To: "Ab Malik, Zulezwan" <Z.Ab-Malik@2011.ljmu.ac.uk> 
Cc: "Burniston, Jatin" <J.Burniston@ljmu.ac.uk> 
 
 
 
Dear Zulezwan, 
 
With reference to your application for Ethical approval: 
Lower-limb muscle performance in athletes from different sport disciplines 
 
Liverpool John Moores University Research Ethics Committee (REC) has reviewed the above application at 
the meeting held on 3rd May 2012. I am happy to inform you that the Committee are content to give a 
favourable ethical opinion and recruitment to the study can now commence. 
 
Approval is given on the understanding that: 
· any adverse reactions/events which take place during the course of the project will be reported to the 
Committee immediately; 
· any unforeseen ethical issues arising during the course of the project will be reported to the Committee 
immediately; 
· any substantive amendments to the protocol will be reported to the Committee immediately. 
· the LJMU logo is used for all documentation relating to participant recruitment and participation eg poster, 
information sheets, consent forms, questionnaires.  
 
The JMU logo can be accessed at http://www.ljmu.ac.uk/corporatecommunications/60486.htm 
 
For details on how to report adverse events or amendments please refer to the information provided at 
http://www.ljmu.ac.uk/RGSO/RGSO_Docs/EC8Adverse.pdf 
 
Please note that ethical approval is given for a period of five years from the date granted and therefore the 
expiry date for this project will be 3rd May 2017. An application for extension of approval must be submitted if 
the project continues after this date. 
 
 
Yours sincerely 
PP: 
 
Professor Andrew Young 
Chair of the LJMU REC 
Tel: 0151 904 6463 
E-mail: j.m.mckeon@ljmu.ac.uk 
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Transfer from MPhil to PhD 
 
 
 
 
 
Personal & Confidential 
 
Dear Zulezwan, 
 
I am very pleased to confirm that the Chair of the University’s Research Degrees Committee 
has approved your application for transfer of registration from MPhil to PhD.  This will be 
reported to RDC at its next scheduled meeting. 
 
The Chair approved the application on behalf of RDC subject to the Independent Assessor’s 
comments.  These have been seen by your Director of Studies to enable you to receive 
feedback on your application. 
 
Congratulations on your successful transfer from MPhil to PhD. 
 
Yours sincerely 
 
 
 
Jo McKeon  
Research Support Officer 
Tel: (0151) 904 6463 
E-mail :  j.m.mckeon@ljmu.ac.uk  
 
Click logo to view our PGR Facebook page. Like for news and information 
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Ethical approval 
 
 
From: Jarvis, Jonathan  
Sent: 27 January 2014 10:52 
To: Hall, Elliott 
Cc: Edwards, Ben 
Subject: ethics approval 
 
 
Full Ethical Approval - ethics number: P13SEC003 
 
Lower-limb muscle performance in diurnal variation conditions 
 
With reference to your application for ethical approval 
 
On behalf of the School of Sport and Exercise Science I can confirm that the study has been 
approved and participant recruitment can now commence. Approval is given on the 
understanding that: 
 
1.    You check the major project handbook for details of the pre-data collection procedures 
that need to be satisfied BEFORE you are permitted to commence data collection; 
 
2.    You use participant codes to protect the anonymity and confidentiality of the 
participants: 
 
3.    Any adverse reactions/events which take place during the course of the project will be 
reported to the School Research Ethics Committee immediately (contact Jonathan Jarvis); 
 
4.    Any unforeseen ethical issues arising during the course of the project will be reported 
to the School Research Ethics Committee immediately (contact Jonathan Jarvis); 
 
5.    Any substantive amendments to the protocol will be reported to the School Research 
Ethics Committee immediately (contact Jonathan Jarvis). 
 
6.    The LJMU logo is used for all documentation relating to participant recruitment and 
participation e.g. poster, information sheets, consent forms, questionnaires. The JMU logo 
can be accessed at http://www.ljmu.ac.uk/corporatecommunications/60486.htm. 
 
Please note that ethical approval is given for a period of one year from the date granted. 
An application for extension of approval must be submitted if the project continues after 
this date (contact Jonathan Jarvis). 
 
Yours sincerely 
 
Jonathan Jarvis 
 
 
Jonathan Jarvis  
Professor, Sport and Exercise Sciences 
Tom Reilly Building Byrom Street, Liverpool, L3 3AF 
t: 01519046253 e: J.C.Jarvis@ljmu.ac.uk m: 07973247895 
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From: Williams, Mandy A.F.Williams@ljmu.ac.uk 
Subject: Approval for NHS Studies 
Date: 21 March 2014 16:39 
To: Burniston, Jatin J.Burniston@ljmu.ac.uk 
 
 
 
Approval for NHS Studies 
 
With reference to your application for Ethical approval: 
14/SPS/015 - Mechanisms underpinning diurnal variation in human muscle 
(14/WM/0065) 
 
I am pleased to inform you that, following confirmation of full, unconditional ethical 
approval from your NRES REC, Liverpool John Moores University Research Ethics 
Committee (REC) is content to endorse this approval. 
 
Approval is given on the understanding that the approving REC, named above, will be 
made aware of any adverse events or substantive changes in protocol and that LJMU 
REC will be informed of any such events. 
 
Please note that ethical approval is given for a period in line with that approved by 
NRES and application for extension of approval must be submitted to the approving 
REC named above and LJMU. 
 
 
 
Mandy Williams, Research Support Officer 
Graduate School, Research and Innovation Services 
Kingsway House, Hatton Garden, Liverpool L3 2AJ 
t: 01519046467 e: a.f.williams@ljmu.ac.uk 
 
Click logo to view our PGR Facebook page. Like for news and information 
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Recruitment letter 
 
 
 
Title of Project: Lower-limb muscle performance in athletes from different 
sport disciplines. 
Name of Researcher (Student):  Zulezwan Ab Malik 
 
Name of Research Supervisors: Dr Jatin Burniston, Dr Ben Edwards & Dr Jos 
Vanrenterghem 
Dear All, 
 
You are invited to take part in a research project investigating lower-limb muscle 
performance in athletes from different sport disciplines. The project will 
investigate how muscle strength and speed contribute to maximum power 
output during a squat jump. 
 
We would like to recruit male and female participants aged between 18-30 years 
that are experienced in strength training and free of recent musculoskeletal 
injuries. 
 
You will be required to visit the laboratory on 4 separate occasions, each session 
lasting approximately 1 and half hour.  You will have the opportunity to practice 
and become familiarised with each performance test before your maximum 
effort is recorded. The tests include measurement of your one-repetition back 
squat and your power output whilst squat jumping with 30 %, 60 % or your 
maximum lift. In addition, you will also be asked to perform a number of knee 
extension exercises to measure your maximum strength and speed of movement.  
 
This study has been approved by the ethics committee of Liverpool John Moores 
University. All data collected from you will be identified by a code from which 
you cannot be identified by simply reading the code. Data collected from you will 
remain strictly confidential between you and the researcher. 
 
You will be required to undertake at least 4 sessions including 2 muscle strength 
sessions (isolated knee exercise and squat jump), each session lasting 
approximately 1 and half hour. The study has received full unconditional ethical 
approval from LJMU. 
 
Those who wish to take part will gain first-hand experience of the latest sports 
science techniques. Also, the data obtained from the testing protocol could be of 
benefit to the individual’s in the continuing pursuit of their own fitness goals. 
Another potential benefit for individual participants is that they will help towards 
findings that could have a potential breakthrough for future athletes showing 
benefiting in an increase in overall their performance. 
 
If you are interested in participating in this study then please read the attached 
participant information sheet and contact: 
 (Z.Ab-Malik@2011.ljmu.ac.uk) 
 
Regards, 
Zulezwan 
 
LIVERPOOL JOHN MOORES UNIVERSITY 
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Participant Information Sheet 
 
 
Title of Project: Lower-limb muscle performance in athletes from different 
sport disciplines. 
Name of Researcher (Student):  Zulezwan Ab Malik 
 
Name of Research Supervisors: Dr Jatin Burniston, Dr Ben Edwards & Dr 
Josh Vanrenterghem. 
 
School:      Sport and Exercise Sciences 
Contact details:    Z.Ab-Malik@2011.ljmu.ac.uk 
 
You are being invited to take part in a student research study. Before you decide 
it is important that you understand why the research is being done and what it 
involves. Please take time to read the following information. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide if you want to take part or not. 
 
1. What is the purpose of the study? 
 
In many sports, success depends on an athlete’s peak power output, which is 
based on their ability to produce both rapid and forceful movements. This 
project will investigate how the components of maximum strength and 
maximum speed of movement contribute to the peak power output during a 
whole-body exercise (i.e. squat jump). To achieve this we intend to investigate 
lower-limb muscle performance in accomplished athletes from different sport 
disciplines using a range of different scientific tests. We will use the information 
collected in these experiments to draw links between muscle performance during 
specific knee exercises such as knee extension and the more complex squat 
jump movement. 
The knowledge we gain from completing this work will help us to devise 
optimised training programmes for improving power output. 
 
2. Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you do you will be 
given a copy of this information sheet keep and asked to sign a consent form. 
You are still free to withdraw at any time and without giving a reason. A decision 
to withdraw will not affect your rights/any future treatment/service you receive. 
 
3. What will happen to me if I take part? 
 
 The research will take part in the LJMU muscle strength laboratory (Tom 
Reilly Building).There are specific labs designed to implement the work 
with specific equipment.  
 You will be familiarised with the tests then you will need to perform the 
tests day at least 3 more times over the period of a view weeks.  
 You will be required to participate in at least four sessions.  
 
LIVERPOOL JOHN MOORES UNIVERSITY 
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 The sessions will be spread over two or three weeks, with at least one day 
between each session.  
 Each visit should last about one and half hour, so therefore you will be 
required to spend 6 hours in the laboratory (please note each visit will be 
on a separate occasion).  
 You will only be permitted to participate in the study if: 
- You are aged between 18-30 years 
- You have history of sport specific training  
 
 During the first sessions you will be familiarised with the equipment and 
you will have the opportunity to practice each of the tests. You will be 
required to wear normal training clothing and abstain from alcohol 24 
hours before each session and caffeine 2 hours before each session. 
 During muscle strength testing you will again be required to wear your 
usual training clothing and abstain from alcohol and caffeine 2 hours 
before each session. You will participate in a warm up on a cycle 
ergometer at 150 W for 5-min before the test.  
 This tests will involve :- 
 
• Visit the laboratory on 4 occasions each separated by at least 24 h 
• Squat jumps (0%, 30 % and 60 % of 1RM) & isometric squat test. 
• Isolated knee exercise {Isokinetic dynamometry (Biodex).} 
- 1 RM squat test. During the first session, subjects will complete a 1 
repetition maximum (RM) squat test. 1 RM is the maximum weight 
that they can lift for one repetition. This will consist of a standardise 
protocol, which will establish their 1RM within 4 attempts. Sufficient 
rest (3 minutes) will be allocated between each repetition to allow for 
recovery and to give enough amount of rest to lift with maximum 
effort for the next trial. The results of the 1RM squat test will then be 
used to calculate their individual external loads required to represent 
each of the sub maximal squat jumps. This will enables us to record 
the force-velocity relationship which is used to calculate your peak 
power output. 
- Jump squat. Subjects will be required to perform a maximal isometric 
strength using an isometric squat test and squat jump across a series 
of intensities (0%, 30% and 60% of the individual’s 1RM). They will be 
asked to standing on a force plate in a back squat position pushing 
against an immovable rigid bar for isometric squat test. For jump 
squat performance, they will be required to do the jump squat while 
holding a rigid bar across their shoulder.   
- Isokinetic dynamometry flexion and extension. Subject will be 
seated on the equipment (BIODEX) and tightly secured to the seat 
with straps, and their dominant leg will be strapped to the lever arm 
on the machine. Biodex machine is an equipment that allow your limb 
move at constant fast and slow speed.  You will be asked to push 
against the lever  arm at two different speeds (fast and slow). The 
subjects were asked to do 4 repetitions for each angular velocity. 1 
minute rest was given between each angular velocity. 
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- DEXA. Subjects will undergo a whole body fan-beam DEXA scan. It is 
for assess their body composition, lean body mass and to see the 
cross sectional area (CSA) of the thigh.  
 During visit 1 your body mass (kg) and height (m) will be measured 
using calibrated scales and equipment. 
 
Other relevant issues 
 You will be required to fill in a physical activity readiness questionnaire 
(PAR-Q) and each individual’s recent training history will be recorded. 
 
 
 
Table 1: List of assessments 
SESSIONS ACTIVITIES 
1 QUESTIONNAIRE, FAMILIARISATION TEST, DEXA, 1RM TEST 
2, 3 & 4 TESTING FOR JUMP SQUATS AND ISOLATED KNEE EXERCISE. 
 
 
 
 
 
 
4. Are there any risks, discomforts, benefits involved? 
 
 Each of the tests requires you to perform maximal muscle contractions, 
which may be associated with some tiredness and risk of injury. However, 
it is unlikely that you will feel any more discomfort than usual high-
intensity training session.  
 The twitch interpolation may at first cause a little discomfort but after 
familiarisation you should become used to the sensation. 
 Exercise may result in muscle soreness up to 72 hours after testing if you 
are unaccustomed to the specific exercise. 
 There is a small risk of soft tissue injury involved in the testing. Should 
you become injured you may need to withdraw from the study, however 
to minimise the risk of injury you will be closely supervised and you will 
also participate in a warm up before muscle strength testing. 
 You will be closely supervised throughout the tests and the researcher 
has ensured that the location of the study is appropriate and any 
potential risks have been minimised. 
 
5. Will my taking part in the study be kept confidential? 
 
Data collection 
 No personal data will be collected from you beyond gender and residential 
status therefore all data will be anonymous.  
 All data collected from you will be identified by a code from which you 
cannot be identified by simply reading the code. 
 Data collected from you will remain strictly confidential between you and 
the researcher. 
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 To ensure confidentiality please do not include your name or any 
information that could be used to identify you on this questionnaire. 
 Personal information will be treated in the strictest confidence with no 
association been made between your identity and the data observed.  
 People will not know which answers are yours, apart from me and the 
other researchers. 
 
Data storage 
 All information/data will be stored confidentially and only accessed by the 
researcher. At the end of the study all personal identifiable information 
will be deleted and the data stored anonymously.  
 Information linking you to the participant code is stored in a password 
protected file, which is only accessible by the researcher. 
 All data will be stored on a password protected computer system. 
 
Data access 
 No one other than the researcher will have access to the data collected 
from you as part of this study. 
 
Breaking confidentiality 
 In accordance with UK law, the researchers are obliged to breach the 
promise of confidentiality if they have reason to believe that you are in 
danger from others or are likely to cause danger to others. 
 It is possible that some participants may disclose other participants’ 
confidential information. 
 
 
NB.  You must freely volunteer to be a subject and are able to withdraw, 
without prejudice, at any time. Thank you for your time and interest in 
the study. 
 
Contact Details of Researcher  
 
Z.Ab-Malik@2011.ljmu.ac.uk 
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Participant Consent Form 
 
 
 
Project title: Lower-limb muscle performance in athletes from different sport 
disciplines. 
 
Researcher: Zulezwan Ab Malik 
        Sport and Exercise Sciences 
 
1. I confirm that I have read and understand the information provided for 
the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered 
satisfactorily 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving a reason and that this will not 
affect my legal rights. 
 
3. I understand that any personal information collected during the study 
will be anonymised and remain confidential 
 
4. I agree to take part in the above study (if appropriate please specify 
the type of study or particular intervention you are seeking consent for 
– eg focus group, interview, training programme) 
 
 
 
Name of Participant    Date    Signature 
 
 
 
Name of Researcher   Date   Signature 
 
 
 
Name of Person taking consent  Date   Signature 
(if different from researcher) 
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Physical activity readiness questionnaire 
 
 
 
 
Title of Project: Lower-limb muscle performance in athletes from different 
sport disciplines. 
 
Name of Researcher (Student):  Zulezwan Ab Malik 
 
Name of Research Supervisors: Dr Jatin Burniston, Dr Ben Edwards & Dr Jos 
Vanrenterghem. 
School:      Sport and Exercise Sciences 
Contact details:    Z.Ab-Malik@2011.ljmu.ac.uk 
For most people, physical activity should not pose any problem or hazard. 
The PAR-Q is designed to identify the small number of adults for whom 
physical activity might be inappropriate or those who should seek 
medical advice concerning the type of activity most suitable for them.  
 
1. Do you have a muscle, ligament bone or joint problem such 
as arthritis or previous injuries, which has been aggravated by 
exercise or might be made worse with exercise?  
YES  NO  
2. To your knowledge, do you have high blood pressure?  YES  NO  
3. To your knowledge, do you have low blood pressure?  YES  NO  
4 Do you have Diabetes mellitus or any other metabolic 
disorder?  
YES  NO  
5. Has your doctor ever said that you have raised cholesterol 
(serum level above 6.2mmol/L)?  
YES  NO  
6. Do you have or ever suffered a heart condition?  YES  NO  
7 Have you ever felt pain in your chest when you do physical 
exercise?  
YES  NO  
8. Is your doctor currently prescribing you drugs or 
medication?  
YES  NO  
9. Have you ever suffered from shortness of breath at rest or 
with mild exercise?  
YES  NO  
10. Is there any history of Coronary Heart Disease within your 
family?  
YES  NO  
11. Do you ever feel feint, have spells of dizziness or have ever 
lost consciousness?  
YES  NO  
12. Do you currently drink more than the average amount of 
alcohol per week (21units for men and 14 units for women (1 
unit = 1⁄2 pint of beer/cider/larger or 1small glass of wine))  
YES  NO  
13. Do you currently smoke?  YES  NO  
14. Do you NOT currently exercise regularly (at least 3 times 
per week) and/or work in a job that is physically demanding.  
YES  NO  
15. Are you, or is there any possibility that you might be 
pregnant?  
YES  NO  
16. Do you know of any other reason why you should not 
participate in a programme of physical activity?  
YES  NO  
LIVERPOOL JOHN MOORES UNIVERSITY 
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Training history questionnaire 
 
 
 
 
 
 
Title of Project: Lower-limb muscle performance in athletes from different 
sport disciplines. 
These questions are designed to gather information about your recent training 
that will help us to interpret the results of the exercise tests. Please answer each 
question to the best of your ability. If you are unsure about any of these 
questions, do not hesitate to refer to the researcher.  
1. What is your primary sport 
discipline? ……………………………………………………………………….. 
2. How many times per week do you perform each of these types of training? 
Training mode Number of days per 
week 
 1 2 3 4 5 6 7 
Heavy resistance exercise        
Metabolic resistance training        
Plyometric jumping        
Calisthenics        
Aerobic endurance exercise        
Sport-specific/ technical training        
Other (please specify)        
Other (please specify)        
 
3. If you perform resistance training how much of your training is performed at 
these different intensities? 
 
Intensity/ Typical number of reps 
to failure 
Frequency: Please rank each of these on a 
continuum from 1 to 10 where 1 indicates that you 
seldom work at this intensity and 10 indicates that 
you almost always work at this intensity 
 1 2 3 4 5 6 7 8 9 10 
≥ 95 % Max / 1-2 reps           
85 - 95 % Max / 3-6 reps           
75-85 % Max / 6-10 reps           
67-75 % Max / 10-15 reps           
≤67 % Max / >15 reps           
 
4. If you perform resistance training how much of your training is performed at 
these different speeds? 
 
Speed 
Frequency: Please rank each of these on a 
continuum from 1 to 10 where 1 indicates that you 
seldom work at this speed and 10 indicates that 
you almost always work at this speed 
 1 2 3 4 5 6 7 8 9 10 
Slow controlled movements           
Ballistic/ explosive movements           
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Recruitment letter 
 
 
 
Title of Project: Lower-limb muscle performance in diurnal variation conditions. 
 
Name of Researcher (Student):  Zulezwan Ab Malik 
 
Name of Research Supervisors: Dr Jatin Burniston, Dr Ben Edwards & Dr Jos 
Vanrenterghem 
 
Dear All, 
 
You are invited to take part in a research project investigating lower-limb 
muscle performance in different time of day. The project will investigate 
how muscle strength and speed of movement contribute to your 
maximum power output. 
 
We would like to recruit male participants aged between 18-39 years that 
are experienced in strength training and free of recent musculoskeletal 
injuries. 
 
You will be required to visit the laboratory on 8 separate occasions, each 
session lasting approximately 1 h.  You will have the opportunity to 
practice and become familiar with each performance test before your 
maximum effort is recorded. The tests include measurement of your 
power output during maximum voluntary contraction and a number of 
knee extension exercises performed at different speeds.  
 
This study has been approved by the ethics committee of Liverpool John 
Moores University. All data collected from you will be anonymous and will 
remain strictly confidential between you and the researcher. 
 
Those who wish to take part will gain first-hand experience of the latest 
sports science techniques. The data obtained during this work could be of 
benefit to individuals in their continuing pursuit of performance goals. In 
addition, we hope the findings from this research will help to advance 
elite training practices in the future. 
 
If you are interested in participating in this study then please contact: 
 (Z.Ab-Malik@2011.ljmu.ac.uk) 
 
 
Regards, 
Zulezwan 
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Participant Information Sheet 
 
 
 
Title of Project: Lower-limb muscle performance in diurnal variation conditions. 
 
Name of Researcher (Student):  Zulezwan Ab Malik 
 
Name of Research Supervisors: Dr Jatin Burniston, Dr Ben Edwards & Dr Jos 
Vanrenterghem. 
 
School:      Sport and Exercise Sciences 
Contact details:    Z.Ab-Malik@2011.ljmu.ac.uk 
 
You are being invited to take part in a post-graduate student research study. 
Before you decide whether to take part it is important that you understand why 
the research is being done and what it involves. Please take time to read the 
following information. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide if you want to take part or not. 
 
6. What is the purpose of the study? 
In many sports, success depends on an athlete’s peak power output, which is 
based on their ability to produce both rapid and forceful movements. This 
project will investigate the range of difference in maximum strength at slow, 
moderate, fast and very fast movement speeds and how this might contribute to 
the peak power output during a different time of day. (i.e. morning and evening). 
To achieve this we intend to investigate lower-limb muscle performance using a 
range of different scientific tests. We will use the information collected in these 
experiments to draw links between muscle performance during specific knee 
exercises on morning and evening. The knowledge we gain from completing this 
work will help us to look further in differences of diurnal for improving power 
output. 
 
7. Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do you will be 
given a copy of this information sheet keep and asked to sign a consent form. 
You are still free to withdraw at any time and without giving a reason. A decision 
to withdraw will not affect your rights/any future treatment/service you receive. 
 
8. What will happen to me if I take part? 
To participate in this study you must meet the following criteria: 
Aged between 18 and 39 Years. 
Greater than 2 years of strength training. 
Free from recent serious musculoskeletal injuries. 
 
This study will be conducted at the Research Institute for Sport and Exercise 
Sciences, Tom Reilly Building, Liverpool John Moores University, Byrom Street, 
Liverpool L3 3AF. You will be required to visit the Research Institute on 8 
occasions consisting of 4 familiarization sessions and 4 experiment sessions (2 
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morning and 2 evening). Each session is likely to last for less than 1 h and must 
be interspersed by a rest period of ~48 h. So, it is likely that you will need to 
attend the laboratory over a duration of 4 weeks. During each session you will 
need to wear normal gym/training clothing and you should abstain from alcohol 
for 24 hours and caffeine for 2 hours before each visit.  
 
Introductory session. 
During your initial session you will be asked to complete 3 short questionnaires 
about your health status, chronotype and recent activity and your body mass 
(kg) and height (m) will be measured. You will then be introduced to the 
exercise tests and you will have the opportunity to practice each test and 
become familiar with the equipment and test procedures. You will be familiarised 
with MVC and isolated knee exercises that will be used in the experiment 
sessions. These techniques are explained in detail in the paragraph below.  
 
Our aim is to accurately measure lower-limb muscle performance using the 
state-of-the-art techniques and a robust scientific approach. Therefore you will 
be required to perform the experiment session described below on 4 separate 
occasions. This will enable us to determine the differences in each measurement 
so that we can be certain which differences in performance are due to 
differences in training status rather errors in measurement.  
 
Experiment Session. 
Each experiment session will begin with a general warm up of 5 minutes on a 
cycle ergometer at a low to moderate intensity of 75 W followed by a specific 
warm up of 5 sub-maximal jumps. 
The power output of the knee extensor muscles (quadriceps) is a key factor in 
squat jump performance and the second part of the experiment session will 
focus on measuring your maximum force and speed during knee extension 
exercise. You will be seated in a specifically designed chair, straps will be used 
to minimise the movement of your thigh and upper body and the ankle of your 
dominant leg will be clamped. The test will measure the maximum force that you 
can produce while your leg is held stationary. You will be asked to push against 
it quickly and as hard as possible for a period of 4 seconds with and without 
twitch interpolation. This test will be repeated 3 times with a few minutes rest 
between each attempt. Next the power output of your leg will be measured 
using a technique known as isokinetic dynamometry. In this mode, the machine 
will only allow you to move your leg at a predetermined speed even though you 
will be asked to push against the resistance of the machine as hard and as fast 
as possible. You will perform warm up sets of 3 kicks at approximately 50 % 
maximum effort and then during each test you will be required to kick and pull 
your leg back 3 times with maximum effort. This test will be conducted at four 
speeds, i.e. slow, moderate, fast and very fast.  
 
9. Are there any risks, discomforts, benefits involved? 
 Each of the tests requires you to perform maximal muscle contractions, 
which may be associated with some tiredness and risk of injury. However, 
it is unlikely that you will feel any more discomfort than usual high-
intensity training session.  
 Exercise may result in muscle soreness up to 72 hours after testing if you 
are unaccustomed to the specific exercise. 
 There is a small risk of soft tissue injury involved in the testing. Should 
you become injured you may need to withdraw from the study, however 
to minimise the risk of injury you will be closely supervised and you will 
also participate in a warm up before muscle strength testing. 
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 You will be closely supervised throughout the tests and the researcher 
has ensured that the location of the study is appropriate and any 
potential risks have been minimised. 
 
10. Will my taking part in the study be kept confidential? 
Data collection 
 All data collected from you will be identified by a code from which you 
cannot be identified by simply reading the code. 
 Data collected from you will remain strictly confidential between you and 
the researcher. 
 Personal information will be treated in the strictest confidence with no 
association been made between your identity and the data observed.  
Data storage 
 All information/data will be stored confidentially and only accessed by the 
researcher. At the end of the study all personal identifiable information 
will be deleted and the data stored anonymously.  
 Information linking you to the participant code is stored in a password 
protected file, which is only accessible by the researcher. 
 All data will be stored on a password protected computer system. 
Data access 
 No one other than the researchers will have access to the data collected 
from you as part of this study. 
Breaking confidentiality 
 In accordance with UK law, the researchers are obliged to breach the 
promise of confidentiality if they have reason to believe that you are in 
danger from others or are likely to cause danger to others. 
 It is possible that some participants may disclose other participants’ 
confidential information. 
 
NB.  You must freely volunteer to be a subject and are able to withdraw, 
without prejudice, at any time. Thank you for your time and interest in 
the study. 
 
Contact Details of Researcher  
 
Z.Ab-Malik@2011.ljmu.ac.uk 
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Physical activity readiness questionnaire 
 
 
 
Title of Project: Lower-limb muscle performance in diurnal variation conditions. 
 
Name of Researcher (Student):  Zulezwan Ab Malik 
 
Name of Research Supervisors: Dr Jatin Burniston, Dr Ben Edwards & Dr Jos 
Vanrenterghem. 
 
School:      Sport and Exercise Sciences 
Contact details:    Z.Ab-Malik@2011.ljmu.ac.uk 
 
For most people, physical activity should not pose any problem or hazard. The 
PAR-Q is designed to identify the small number of adults for whom physical 
activity might be inappropriate or those who should seek medical advice 
concerning the type of activity most suitable for them.  
 
1. Do you have a muscle, ligament bone or joint problem such as 
arthritis or previous injuries, which has been aggravated by exercise 
or might be made worse with exercise?  
YES  NO  
2. To your knowledge, do you have high blood pressure?  YES  NO  
3. To your knowledge, do you have low blood pressure?  YES  NO  
4 Do you have Diabetes mellitus or any other metabolic disorder?  YES  NO  
5. Has your doctor ever said that you have raised cholesterol (serum 
level above 6.2mmol/L)?  
YES  NO  
6. Do you have or ever suffered a heart condition?  YES  NO  
7 Have you ever felt pain in your chest when you do physical 
exercise?  
YES  NO  
8. Is your doctor currently prescribing you drugs or medication?  YES  NO  
9. Have you ever suffered from shortness of breath at rest or with 
mild exercise?  
YES  NO  
10. Is there any history of Coronary Heart Disease within your 
family?  
YES  NO  
11. Do you ever feel feint, have spells of dizziness or have ever lost 
consciousness?  
YES  NO  
12. Do you currently drink more than the average amount of alcohol 
per week (21units for men and 14 units for women (1 unit = 1⁄2 pint 
of beer/cider/larger or 1small glass of wine))  
YES  NO  
13. Do you currently smoke?  YES  NO  
14. Do you NOT currently exercise regularly (at least 3 times per 
week) and/or work in a job that is physically demanding.  
YES  NO  
15. Are you, or is there any possibility that you might be pregnant?  YES  NO  
16. Do you know of any other reason why you should not participate 
in a programme of physical activity?  
YES  NO  
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Participant Consent Form 
 
 
 
 
 
 
 
Project title: Lower-limb muscle performance in diurnal variation conditions. 
Researcher: Zulezwan Ab Malik 
        Sport and Exercise Sciences 
 
5. I confirm that I have read and understand the information provided for 
the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily 
 
6. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving a reason and that this will not 
affect my legal rights. 
 
7. I understand that any personal information collected during the study 
will be anonymised and remain confidential 
 
8. I agree to take part in the above study (if appropriate please specify the 
type of study or particular intervention you are seeking consent for – eg 
focus group, interview, training programme) 
 
 
 
 
 
 
Name of Participant    Date     Signature 
 
 
 
Name of Researcher         Date    Signature 
 
 
 
Name of Person taking consent  Date    Signature 
(if different from researcher) 
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Appendix 
Title of Project: Mechanisms underpinning diurnal variation in 
human muscle performance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dear potential participant,
My name is Zule, I’m a PhD student in the School of Sport and Exercise Sciences 
supervised by Dr. Jatin Burniston. I am currently recruiting participants to take part in a 
research study for my PhD thesis on muscle function and myofibre protein analysis.
I’m looking for males aged 18 – 39 who are physical active and have a background in 
resistance exercise/ strength training. If you would like to offer your time for this exciting 
and beneficial research project you will be asked to attend the laboratory on 2 main 
occasions, one in the morning (7-8 am) and one in the afternoon (5-6 pm) to:
• perform muscle performance tests
• have a muscle biopsy where a 1⁄4 pea-sized amount of muscle will be 
taken from your outer thigh muscle. 
After the data are analysed, each participant will be able to view their muscle performance 
results and myofibre profile.
If you are interested or would like to chat about further details of the project, please contact 
me using one of the options listed below. PLEASE NOTE THAT BY DISPLAYING AN 
INTEREST YOU ARE IN NO WAY OBLIGED TO PARTAKE IN THIS STUDY. 
Many thanks,
   Zulezwan Ab Malik.
Version: 1 ! Monday, 27 January 2014
Zulezwan Ab Malik, BSc, MSc
Research Institute for Sport & Exercise 
Sciences
Z.Ab-Malik@2011.ljmu.ac.uk
0779 939 6665
Recruitment letter/ email
Mechanisms underpinning diurnal 
variation in human muscle 
performance
Study Number: 14/WM/0065
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
Zulezw
an A
b M
alik. TRB Rm
 1.47
Z.A
b-M
alik@
2011.ljm
u.ac.uk
Tel: 0779 939 6665
The proposed work will examine The 
This work will examine whether the difference in muscle performance between morning 
and evening is due to differences that occur to contractile proteins within muscle. This 
specific question has not been investigated before and we hope to discover new 
information about how muscle force production might be regulated by the body-clock. We 
hypothesise the greater force output in the afternoon is due to short-term modifications to 
contractile proteins within muscle that enable it to work more efficiently. If we are able to 
discover which proteins correspond with optimal muscle performance in the afternoon, we 
will be able to use these as a research tool or ‘biomarker.’ Such a biomarker could be used 
to provide objective evidence that pharmacological treatments or exercise interventions 
are able to prevent the decrement in muscle performance that typically occurs in the 
morning.
In order to test our hypothesis we aim to recruit 10 active male participants aged between 
18 and 39 years. After consenting to take part in the study, these participants will be 
required to complete a protocol that consists of the following components:
•  2 x skin temperature recordings using adhesive skin thermistors
•  2 x core temperature recordings using a flexible rectal probe
•  4 x muscle temperature measurements using a 3 cm needle thermistor
•  2 x exercise tests, including general warm-up (5 min cyclergometry) and 
measurement of muscle function using isometric dynamometry (i.e. maximum 
voluntary contractions; MVC)
•  2 x needle biopsies (about the size of 1⁄4 of a pea) from the muscle on the outside 
of your thigh
The muscle samples obtained will be analysed using state-of-the-art techniques capable of 
identifying hundreds of different proteins within muscle and characterising their different 
states of modification. The protein data will be aligned with the muscle force 
measurements to discover which proteins or protein modifications might regulate diurnal 
variations in force production.
Please see overleaf for a detailed version of the protocol
Version: 1 ! Monday, 27 January 2014
Zulezwan Ab Malik, BSc, MSc
Research Institute for Sport & Exercise 
Sciences
Z.Ab-Malik@2011.ljmu.ac.uk
0779 939 6665
Basic and Detailed Protocol
Mechanisms underpinning diurnal 
variation in human muscle 
performance
Study Number: 14/WM/0065
Purpose – To examine whether the difference in muscle performance between morning 
and evening is due to post-translation modification of human myofibrillar proteins.
Sample Population – Young (aged 18-39) recreationally active males from Liverpool John 
Moores University or associated sports teams.
Design – Balanced cross-over design where the order of the measures (morning-evening 
or evening-morning) will be randomised.
Methodology.
Figure 1 – Schematic representation of the proposed experimental protocol
Scientific Justification.
The process of human ageing from maturation to senescence is associated with marked 
losses in skeletal muscle mass and function that negatively impact mobility, quality of life 
and independence. In particular, muscle weakness is associated with a greater risk of falls, 
which may require hospitalization. The World Health Organisation reports 1 in 3 adults 
over the age of 65 falls each year, and the incidence of falls increases further with 
advancing age and muscle frailty. Interventions aimed at maintaining muscle mass are key 
in the defense against age-associated muscle loss (Sarcopenia). However, indices of 
muscle performance such as force or power output often decline earlier and more 
precipitously than the measured changes in muscle volume. Moreover, approximately 
twice as many falls occur in the morning, when muscle strength is at its lowest, compared 
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to in the afternoon/ early evening, when muscle performance is optimal. Diurnal variation 
in muscle performance is also widely reported in young healthy individuals but the 
mechanisms underpinning this phenomenon are not yet understood. 
Day-to-day movements or sporting actives rely on the ability of skeletal muscle to produce 
force against varying external loads and at different speeds. Indeed, muscle output can be 
described along a continue from high-velocity low-force movements to low-velocity or 
stationary contractions. Recently we completed preliminary work using a battery of 
laboratory tests to determine which aspects of muscle performance show the greatest 
magnitude of diurnal variation. Twenty young healthy males completed measures 
spanning maximum force production through to maximum speed of contraction. Values 
were consistently greater in the evening compared to morning, and the magnitude of 
diurnal variation ranged from 7.6 % to 13.3 % across the 6 different measures. Rate of 
force development (RFD) and isometric force during maximal voluntary contraction (MVC) 
exhibited the greatest diurnal variation (2.89 ± 0.56 - 3.23 ± 0.52 Nm/s, P= 0.009 and 
634.98 ± 53.8 - 704.7 ± 73.2 Nm, P=0.002 respectively). The proposed work will use these 
robust measures of performance and attempt to discover changes within muscle that 
correlate with the differences in muscle output.
Fluctuations in force production co-occur alongside biological rhythms in core temperature 
but we have found diurnal variation in muscle performance is not entirely explained by 
differences in muscle temperature. For example, passive heating in the morning to 
simulate the warmer afternoon muscle temperature did not bring about a similar elevation 
in muscle performance. Similarly, passive cooling in the afternoon to replicate the cooler 
muscle temperature of the morning was not associated with a decrease in performance. 
Thus intrinsic differences occur in the ability of skeletal muscle to produce force during the 
course of the day. The parameters of muscle performance (i.e. maximum force or 
maximum speed) are determined by a collection of contractile proteins. Differences in 
genetic background, habitual activity or training status effect the relative amounts of each 
muscle protein and are one of the main reasons for broadly different physiques and 
physical performances, e.g. sprinters compared to marathon runners. The same 
contractile proteins can also be rapidly modified to cope with short-term changes in 
demand. This latter mechanism contributes to the positive effect of warming up prior to 
strenuous exercise, and similar mechanisms could also be responsible for the greater 
output of skeletal muscle in the afternoon compared to the morning.
The current study will use state-of-the-art proteomic techniques to simultaneously 
investigate modifications to numerous contractile proteins in human skeletal muscle. 
Information regarding changes at the protein level will be compared with measures of 
muscle performance to determine the level of association between muscle output and a 
particular protein modification. If successful, this work will provide candidate biomarkers 
that could be used to develop and optimise interventions aimed at forestalling morning 
decrements in muscle performance.
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Please either initial or tick each box to acknowledge that you consent/ agree with the 
individual statements. Please then sign and date the document.
1. I confirm that I have read and understand the information sheet dated 11/03/2014 for the 
above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights 
being affected. 
3. I understand that data collected during the study will be recorded and looked at 
by members of the research team listed above. I give permission for these 
individuals to have access to these records. 
4. I agree to take part in the above study 
Name of Participant ! ! ! Date ! ! ! Signature
Name of person taking consent! ! Date! ! ! Signature
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Zulezwan Ab Malik, BSc, MSc
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Research Institute for Sport & Exercise 
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Name:................................................................. 
Age:....................... 
Height:................... (cm) Weight:............... (kg) 
Telephone:......................................................... 
Email:................................................................. 
The following information is required in order for the principal investigator to 
determine whether you are eligible to take part in the trial. This is to ensure that 
there is minimal risk to you when taking part in the investigation. Please circle as 
appropriate when answering. 
Are you currently being treated for any medical condition or have been in the last year? If 
yes to either, please provide further information. 
YES / NO 
If yes __________________________________________________________________ 
When was your last medical check-up? (if not sure please skip the question) 
 
_______________________________________________________________________ 
Are you taking any medication, non-prescription drugs or herbal supplements?  
YES / NO 
If yes __________________________________________________________________ 
Are you currently taking any dietary supplements including multivitamins, protein 
supplements, creatine etc? If yes, state what and how frequently. 
YES / NO 
If yes __________________________________________________________________ 
Has there been any change in your health over the past year? If yes please explain.  
YES / NO / NOT SURE 
If yes __________________________________________________________________ 
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Do you have any allergies? If yes, please use the criteria below to tick the appropriate 
choice.  
YES / NO / NOT SURE 
(i)  Medications  
(ii) Rubber/latex products  
(iii)  Other (food, hayfever etc) please state ___________________________________ 
Have you ever had an adverse reaction to a needle injection?  
YES / NO 
Do you have or have ever had heart or blood pressure problems? If yes please state what.  
YES / NO 
If yes __________________________________________________________________ 
Have you ever been hospitalized for any illness or operation? If yes please state what. 
YES / NO 
If yes __________________________________________________________________ 
Are there any medical conditions not listed above that you have? If yes, please state what. 
YES / NO 
If yes __________________________________________________________________ 
Do you have or have ever had any of the following? Please tick the appropriate boxes. 
  
Chest pain, 
angina   
Rheumatic 
fever   Pacemaker   Steroid therapy   
Seizures 
(epilepsy)   
Osteoporosis 
medications 
(e.g. 
Fosamax, 
Actonel  
Heart attack   
Mitral valve 
prolapse   Lung disease   Diabetes   Kidney disease   
 Stroke   Heart murmur   Tuberculosis   Stomach ulcers   Thyroid disease   
 
Shortness of 
breath      Cancer   Arthritis   
Drug/alcohol 
dependency    
 
Are you currently unfit to perform physical activity? If yes, please state why.  
YES / NO 
If yes __________________________________________________________________ 
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Do you have a bleeding problem or bleeding disorder?  
YES / NO / NOT SURE 
Have you travelled across multiple time zones or undertaken shift work during the past 3 
months?  
YES / NO 
If yes, please provide details _______________________________________________ 
______________________________________________________________________ 
How many hours of physical activity (e.g. gym use, playing sport etc) do you engage in on 
average per week? Please tick the appropriate choice. 
(i)  0-1  
(ii) 1-3  
(iii)  3-5 
(iv)  More than 5 hours 
I confirm that the details that I have provided here are correct to the best of my 
knowledge and understand that withholding medical information can increase the 
risk of adverse events. I understand that the information that I have provided is 
confidential and that is for the attention of the principal investigator only. 
 
PRINT NAME: ___________________________________________________________ 
 
SIGNED: ___________________________________________ DATE: ____________ 
 
 
PI SIGNATURE: ______________________________________ DATE: ____________ 
